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Abstract 
The transcription factor Forkhead Box Protein M1 (FOXM1) regulates several genes 
involved in the cell cycle, DNA repair, and oxidative stress, and is frequently 
upregulated in cancer cells. Whilst targeting FOXM1 alone represents an attractive 
treatment strategy, emergence of drug resistance makes a combination treatment 
strategy more clinically relevant. 
 
To investigate novel combination treatments with FOXM1 inhibition, we aimed to 
exploit the role of FOXM1 in regulating genes involved in the DNA repair pathway, 
homologous recombination. We hypothesised that reduction of homologous 
recombination due to FOXM1 inhibition, would render cancer cells synthetically 
lethal to PARP inhibition. Our data showed the FOXM1 inhibitor Thiostrepton and 
the PARP inhibitor Olaparib in combination caused greater reduction in cell viability, 
compared to either agent alone, in breast cancer cells. Mechanistically, our data 
suggested that RAD51 and BRIP1 may play a role in mediating Olaparib 
sensitisation upon Thiostrepton treatment, due to increased DNA double-strand 
breaks in cells treated with our combination therapy. 
 
We also explored the possibility of exploiting the role of FOXM1 in regulating 
oxidative stress response genes as a combination therapeutic strategy. Our data 
suggested that FOXM1 and NQO1 may play a role in generating chemoresistance. 
Furthermore, cancer cells may have a threshold of expression of FOXM1 and 
NQO1 for viability, where loss of both resulted in the greatest reduction in viability in 
Ovcar4 ovarian cancer cells. Therapeutically, our data showed for the first time that 
the FOXM1 inhibitor Thiostrepton and the NQO1 inhibitor Diminutol in combination 
caused greater reduction in cell viability, compared to either agent alone, in ovarian 
cancer cells. Our data suggested that our combination therapy may act through 
different mechanisms, including increased DNA double-strand breaks and 
increased levels of reactive oxygen species. 
 
Overall, we showed that exploiting the role of FOXM1 as a transcription factor 
provides a means for therapeutically targeting FOXM1 in combination with drugs 
that are synthetically lethal with FOXM1 transcriptional target genes. 
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1.0 Introduction to breast cancer 
1.1 Breast cancer 
Breast cancer is the leading cause of cancer-related death among women 
worldwide, and it is the most frequently diagnosed cancer [1]. Of the 3.4 million new 
cases of cancer reported in Europe in 2012, breast cancer was the most common 
cancer site, accounting for 13.5% of cases [2]. In more recent data, it was 
suggested that 2.1 million cases worldwide of newly diagnosed female breast 
cancer cases would be recorded in 2018, accounting for nearly 1 in 4 cancer cases 
among women [3]. Notably, mammography is the only screening method to have 
shown reduced breast cancer mortality [4]. In a study that investigated a screening 
program in London, it was found that mortality risk was reduced by 35% for those 
attending breast screening at least once [5]. 
 
Developments in screening methods, and therefore early detection, have 
subsequently facilitated an improvement in breast cancer patient survival, in 
countries that are able to offer this medical support to patients [4]. This needs to be 
better-developed in low and middle income countries (LMICs) to help in alleviating 
the burden of breast cancer around the world [4]. These differences, with regard to 
medical support in LMICs, is further evidenced from the five-year survival rate which 
is around 85% in the United States and many European countries, while it is around 
60% in many LMICs [1, 6].  
 
There are models to assess risk of breast cancer, such as the Gail or Tyrer-Cuzick 
models [7]. The Gail model assesses multiple risk factors, including age and 
hormone factors, and it has been validated to be applicable to the general 
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population [7]. The Tyrer-Cuzick model also assesses classic risk factors, including 
menopause and body mass index [8]. This model had been suggested to identify 
few women in the general population at high risk, however the inclusion of 
mammographic density not only identified women at the extremes of risk 
distribution, and it may also be valid after evaluation for several years later for 
follow-up [8]. When considering individual risk factors such as age, it has been 
demonstrated that breast cancer incidence is low before the age of 30, and this is 
followed by a linear increase up to 80 years old [9].  
 
Cancers can occur either sporadically, or through an inherited predisposition [10]. 
Women with mutations in the breast cancer susceptibility genes, Brca1 and Brca2, 
which are tumour suppressor genes, have a significantly higher risk of developing 
breast and ovarian cancer, compared to women from the general population [10].  
 
Breast and ovarian cancer risk has been evaluated [10]. Specifically, the Ashkenazi 
Jewish women population harbors three ancient Brca1 and Brca2 mutant alleles, 
with very few rare family-specific mutations, and has Brca1 or Brca2 mutations [10]. 
Of the observations, by the age of 40 breast cancer risk to relatives with Brca1 or 
Brca2 mutations was 20%, rising to more than 80% by the age of 80 [10]. 
Furthermore, the lifetime risk of breast cancer among female mutation carriers was 
82% [10]. Interestingly, it was also noted that breast cancer onset was significantly 
delayed in those who had physical exercise and lack of obesity in adolescence [10]. 
 
Genetic counselling is routinely offered to individuals at high risk of carrying a Brca1 
or Brca2 mutation, for the purpose of receiving advice and making decisions 
regarding their health, such as screening and prevention strategies [11]. In a meta-
23 
 
analysis study, mean cumulative cancer risks for mutation carriers at age 70 years 
were determined [11]. For breast cancer risk, it was 57% for Brca1 and 49% for 
Brca2 mutation carriers [11]. Then for ovarian cancer risk it 40% for Brca1 and 18% 
for Brca2 mutation carriers [11]. This type of study was carried out to assist with 
clinical management and counselling of the at-risk population, to help better-advise 
patients [11]. Other types of inherited mutation include PTEN germline mutations, 
causing Cowden syndrome, as well as being characterised by a high risk of breast 
cancer [12]. The lifetime breast cancer risk, for female patients with Cowden 
syndrome, is 25-50% [12]. 
 
1.2 Breast cancer subtypes 
Ductal carcinoma in situ (DCIS) is a premalignant proliferation of neoplastic 
epithelial cells contained within the lumen of mammary ducts, and DCIS can 
become invasive [13]. It has been suggested that DCIS is a precursor to invasive 
ductal carcinoma (IDC), and this can culminate in metastatic disease [14]. Whilst 
IDC is the most common subtype of breast cancer, there is another form of breast 
cancer known as invasive lobular carcinoma, emphasising the importance of 
personalised treatment options [15].  
 
DCIS account for approximately 20% of mammographically detected breast cancers 
[16]. Furthermore, in patients who have had breast-conserving surgery and then 
experienced local recurrence, half of those have been found to be invasive [13]. 
Interestingly, it has also been shown that not all high‐grade DCIS lesions exhibit a 
potential for invasion [16]. 
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There are also more specific classifications based on markers, including: oestrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor 
receptor 2 (HER2), and an “intrinsic gene set” has also been identified [17, 18]. 
Therefore, the intrinsic subtypes that are defined by expression of these markers 
are luminal types A and B, basal-like and HER2-enriched [18]. Luminal A is ER 
positive, and/or PR positive, and HER2 negative; luminal B is ER positive, and/or 
PR positive, and HER2 positive; basal-like is ER negative, PR negative, and HER2 
negative; and, HER2-enriched is ER negative, PR negative, and HER2 positive [19]. 
 
In a study that investigated breast cancer molecular subtypes, luminal A subtype 
was identified as the most prevalent, at 34% [20]. This was followed by basal 
like/triple negative subtype, at 25% [20]. Luminal B and HER2 subtypes had same 
prevalence, which was 18% each, and there was also breast tissue like/unclassified 
subtype, which was 5% [20]. In another study, luminal A was also shown to be the 
most commonly diagnosed subtype, and this subtype had the greatest survival, 
whereas triple-negative had the poorest survival [21]. 
 
Of the classifications, HER2-enriched breast cancer has the highest risk of brain 
metastases compared to other subtypes, and has been generally identified as 
having a poor prognosis [22, 23]. There has been another study that showed how 
triple-negative breast cancer patients have an increased risk of distant recurrence 
and death, relative to other subtypes [24, 25]. That said, it was determined that 
triple-negative breast cancer patients who did not show progression after 8 years 
were then not going to have a recurrence [24]. This differed to other subtypes which 
could still have a distant recurrence up to 17 years after diagnosis [24].  
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The ability to determine the subtype of a breast cancer patient is important for 
guiding treatment option decisions [26]. Not only does it guide more personalised 
treatment decisions, it has also been shown to be important in deciding which 
patients would need to have preoperative breast magnetic resonance imaging [26]. 
Specifically, this magnetic resonance imaging can help to detect characteristics 
such as lymph node involvement in luminal B and HER2 molecular subtype breast 
cancers, where these patients are more likely to have clinically significant disease, 
thus changes in treatment strategies may affect clinical outcomes [26].  
 
1.3 Current treatment options for breast cancer 
patients 
1.3.1 Early treatments and targeted treatments  
The majority of breast cancers diagnosed in early stages are offered surgery, which 
can be as a mastectomy or lumpectomy [27]. Breast-conserving surgery comprises 
of a lumpectomy, and it is also important to have some normal tissue removed to 
indicate the cancer has been excised [27]. In a study where radical mastectomy 
was compared with less extensive surgery, it was found that there was no 
advantage to having radical mastectomy, and that less radical surgery seemed just 
as effective [28]. Furthermore, in another study of breast cancer patients who had 
undergone either radical mastectomy or breast-conserving surgery, the long-term 
survival rate among women was found to be the same regardless of their surgery 
type [29]. 
 
For early stage breast cancers, complete resection by surgery can remove the 
cancer, but there is a chance that over time there may be a recurrence [30]. 
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Therefore, surgery followed by adjuvant treatment offers patients a more effective 
treatment option, which could also be considered alongside neoadjuvant treatment 
[30]. Breast conservation is today’s intended surgical standard of care for most 
breast cancer patients, to avoid what would have previously been a primary 
mastectomy, and this is supported by advances in oncoplastic surgical techniques 
and successes of neoadjuvant tumour-shrinking drug therapies [31].   
As illustrated in Figure 1, there are a number of systemic ways to treat early-stage 
breast cancer. Once the breast cancer subtype has been determined, based on this 
information, the most appropriate treatment can be offered to the patient. To 
support an improved prediction of clinical outcome, the 70-gene signature was 
developed, alongside other gene-expression profiles, and this has proven to be 
particularly valuable in recognising which patients may benefit from adjuvant 
chemotherapy [32, 33]. The 70-gene signature classifies tumours into groups that 
are associated with a good prognosis or a poor prognosis, and this is on the basis 
of the risk of distant recurrence at 5- and 10-years [32, 33]. 
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Figure 1. Treating early breast cancer. 
There are a number of systemic ways to treat early breast cancer, depending upon 
the molecular breast cancer subtype of the patient (adapted from: [31]). 
 
Breast cancer patients are often over-treated and exposed to the toxicity of 
chemotherapy, without benefits, therefore this could be avoided by incorporating the 
70-gene signature into clinical decisions [33]. In fact, more than 30 different 
signatures have been reported [34]. As breast cancer is heterogeneous, it has been 
suggested that there may not be a one-size-fits-all signature; however these 
authors did report that better models could be built from common genes across 
different signatures [34]. 
 
The characteristics considered for treatment decisions is not an exhaustive list, 
however, such that tumour characteristics including tumour grade and size are also 
important [33, 35]. Furthermore, patient characteristics including age and 
menopausal status provide additional information in making an informed decision 
[33, 35]. Whilst not accounting for individual biologic characteristics of patient 
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tumours, tools like PREDICT Plus are also available to assist in treatment option 
choices [33].  
 
Tamoxifen is an ER antagonist that has been used to treat patients with ER-positive 
breast cancer [36, 37]. However, aromatase inhibitors such as Letrozole have been 
shown to be a more effective endocrine therapy in the treatment of breast cancer 
patients, than Tamoxifen [38]. Aromatase inhibitors work by indirectly affecting ER 
function, through blocking the conversion of adrenal androgens to oestrogen in the 
peripheral tissues of postmenopausal women, including the breast [38]. 
 
For patients with metastatic breast cancer and a germline Brca mutation, the FDA-
approved oral PARP inhibitor Olaparib has been shown to have promising activity, 
over standard therapy [39]. This comes after Olaparib has already been used to 
give notable clinical improvements in the treatment of patients with recurrent 
ovarian cancer and a Brca mutation [40, 41].  
 
HER2 overexpression and/or amplification have been shown in around 25% of 
breast cancer cases [42, 43]. The targeted therapy known as Trastuzumab, a 
humanised monoclonal antibody against the extracellular domain of HER2 has 
benefitted patients with HER2-positive breast cancer, alone and in combination with 
chemotherapy, as well as following adjuvant chemotherapy [43-45]. More recently, 
another humanised monoclonal antibody against HER2 known as Pertuzumab, 
which binds different domains of HER2 compared to Trastuzumab, has been shown 
to be effective in a treatment strategy which also includes Trastuzumab and 
chemotherapy in HER-positive breast cancer [46]. 
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2.0 Introduction to ovarian cancer 
2.1 Ovarian cancer 
Ovarian cancer is the seventh most commonly diagnosed cancer among women in 
the world [2, 47]. It is the second most frequent gynaecologic malignancy, after 
endometrial cancer, and about two thirds of tumours occur at reproductive age [48]. 
In comparison to other female genital cancers, ovarian cancer carries a higher 
mortality rate [48].  
 
No singular diagnosis exists for ovarian cancer, such that many of these tumours 
involve the ovary secondarily, thus originating from other gynaecological tissues 
[47]. A gene profiling study showed that there was a significant correlation between 
gene expression in, for example, the fallopian tube mucosa and in serous 
carcinomas [49]. The prevailing view for the origin of high-grade serous ovarian 
carcinoma (HGSOC) was that it developed from the ovarian surface epithelium, 
however this had never been shown to be reproducible [50]. A study was therefore 
carried out to investigate the origin of HGSOC, and it was found to originate in the 
fallopian tube [50]. In fact, <1.25% of HGSOC are confined to the ovary at 
diagnosis, so this type of study can help improve clinical practice to carry out 
systematic sectioning and examination of the fallopian tube [50].  
 
Many patients present with advanced-stage disease, and this is because it is 
asymptomatic at the early stages, making detection more difficult [51]. There is no 
bleeding or obvious lump, and the types of symptoms that could be expected 
include bloating and frequent urination [52]. The 5-year survival rate is usually less 
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than 20% because often dissemination has already occurred when a patient is 
diagnosed [53].  
 
Unfortunately, screening methods in ovarian cancer have not been very successful 
and, if screening was to be used, one screening test would not be effective at 
detecting all types of ovarian cancer. For Type I ovarian carcinomas, these could be 
potentially more easily detected by pelvic examination and/or transvaginal 
ultrasound [54]. Then for Type II ovarian cancers, these become more difficult to 
detect because these tumours are not always confined to the ovary at diagnosis 
[54]. This could be improved by determining more sensitive and specific biomarkers 
for detection [54]. Furthermore, clinical trials are being carried out to investigate the 
efficacy and cost-effectiveness of screening for ovarian cancer [55]. 
 
Specific biological causes of infertility, such as endometriosis, have been linked to 
increased risk of ovarian cancer [56]. Furthermore, accumulating evidence has 
linked the benign disease endometriosis as a precursor to endometriosis‐associated 
ovarian cancer, in particular the endometrioid and clear cell subtypes [53]. Women 
who have used oestrogen-only replacement therapy, especially those that have 
used it for 10 years plus, have also been shown to have an increased risk of ovarian 
cancer [57]. In another study, it was found that older women, as well as women who 
had never used oral contraceptives, had an increased risk of rapidly fatal disease 
[58]. In this study, for example, the authors account for certain limitations such as 
not knowing the grade of all women, and this highlights the continued need for 
further study in this area [58]. 
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As discussed in the introduction to breast cancer, Brca1 and Brca2 mutations not 
only increase the risk of breast cancer, but these mutations also increase the risk of 
ovarian cancer. An inherited mutation in Brca1 or Brca2 accounts for around 10% of 
invasive ovarian carcinomas, with an even greater prevalence in Ashkenazi Jewish 
women, which is closer to 50% [59]. In a study where the prevalence of homologous 
recombination (HR)-related gene mutations was investigated across multiple 
cancers, ovarian cancer featured among the most commonly mutated lineages, 
accounting for a frequency of 20% [60]. While it has been suggested that BRCA-
associated and sporadic ovarian carcinomas seem to have similar histopathologic 
characteristics, p53 mutations have a higher frequency in hereditary ovarian 
carcinomas [59]. Interestingly, a study showed that when comparing advanced-
stage BRCA-associated ovarian carcinoma patients with sporadic ovarian 
carcinoma patients, there was a significantly improved survival [59]. This type of 
study can help clinicians with decisions regarding patient treatment options, and it 
can also help in assessing patient suitability for clinical trials [59].  
 
2.2 Ovarian cancer subtypes 
There are two broad categories used to divide ovarian cancer, Type I and Type II, 
and these are subsequently made up of several subtypes [51]. They are 
characterised by individual genes as well as certain molecular signalling pathways 
[54].  
 
Type I carcinomas include endometrioid, clear cell, mucinous and low-grade serous, 
and these are slow-growing indolent neoplasms, with clearly described precursor 
lesions [51]. Type II carcinomas includes high-grade serous, and these are clinically 
aggressive neoplasms and may develop de novo from the tubal and/or ovarian 
32 
 
surface epithelium [51]. Serous carcinomas are the most common type and high-
grade makes up about 70% of ovarian carcinomas [61]. The genes that characterise 
the high-grade serous subtype, for example, are p53 mutation and Brca1/2 
inactivation [54]. Furthermore, constitutive activation of molecular signalling 
pathways, such as cellular proliferation, can occur through mutated gene products 
[54]. 
 
Type I ovarian cancers, accounting for 5-10% of all epithelial tumours, are typically 
KRAS, PIK3CA, PTEN, or BRAF mutated, and often diagnosed at the early stages 
[62]. Type II tumours account for 90% of deaths from ovarian cancer due to late 
diagnosis in the advanced stage and are frequently p53 mutated  [62]. A mutation in 
the tumour suppressor p53 is considered a hallmark of high-grade serous ovarian 
cancer, present in nearly 100% of cases, compared to Type I carcinomas, where 
p53 is rarely mutated [62]. 
 
Interestingly, in a study where p53 status was analysed in high-grade serous 
ovarian carcinomas, it was discovered that patients who had wild-type p53 were 
seemingly more chemoresistant and had a poorer survival, compared to patients 
who had mutated p53 [63]. Whilst the mechanism was not clear in this study, a 
mouse model had previously shown that wild-type p53 promoted ovarian cancer cell 
survival and invasion [63, 64]. 
 
Ovarian clear cell carcinoma accounts for <5% of all ovarian malignancies, and a 
study showed that complete surgical staging, which included pelvic and para-aortic 
lymphadenectomy and chemotherapy, Paclitaxel plus Carboplatin, was able to 
improve survival of patients with ovarian clear cell carcinoma, stage I [65, 66]. This 
33 
 
type of study can benefit a large amount of patients, as up to 60% of patients have 
stage I disease at the time of diagnosis [65]. 
 
Metastasis of ovarian carcinomas is rarely through the vasculature, and the most 
common sites of metastasis include the fallopian tube and contralateral ovary [67]. It 
has been suggested that metastasis is the cause of bilateral ovarian cancer, 
whereby the spreading to the contralateral ovary seems to be a late event in the 
clonal evolution of these cancers [68]. 
  
2.3 Current treatment options for ovarian cancer 
patients 
2.3.1 Early treatments and targeted treatments  
Over the last two decades, surgery and chemotherapy as a primary treatment have 
had minimally improved results, and progression-free survival has been maintained 
at around 18 months [69]. Around 30% of ovarian cancer patients are diagnosed at 
early-stage disease and receive surgery, however it has been suggested that 
recurrence will happen in 10-50% of these patients [70]. It has been shown that 
adjuvant chemotherapy used in patients with early-stage disease does cause a 
delay in disease recurrence [70]. 
 
Furthermore, patients with advanced ovarian cancer can also go on to tumour 
progression or recurrence, and the added risks associated with this include drug 
resistance [69]. In cases where there is a high chance of gross residual disease 
after primary debulking surgery, the use of neoadjuvant chemotherapy can help to 
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reduce tumour load [71]. It is also interesting to note that time interval between 
surgery and adjuvant chemotherapy can affect the growth of metastasis, and one 
study has shown that early initiation of chemotherapy is important to improve overall 
survival of ovarian cancer patients [72]. Then there was a 4% decrease in relative 
overall survival when adjuvant chemotherapy was delayed, each week [72]. 
 
Some of the early treatment options for patients with different subtypes of ovarian 
cancer are listed in Figure 2. When considering the subtype of mucinous ovarian 
cancer, one study has shown that the response to first-line platinum-based 
chemotherapy is worse compared to other subtypes, and it has been suggested that 
fluorouracil-based chemotherapy may be a better alternative because of its use in 
treating mucinous gastrointestinal carcinomas [73]. Another study has shown that 
recurrent mucinous ovarian cancer also has a low response to chemotherapy [74]. 
 
 
Figure 2. Treating early ovarian cancer. 
There are a number of systemic ways to treat early ovarian cancer, depending upon 
the molecular ovarian cancer subtype of the patient (adapted from: [75, 76]). 
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Cisplatin was the first FDA-approved platinum compound for cancer treatment in 
1978, and this chemotherapy acts through binding DNA to cause DNA damage 
which blocks cell division and leads to apoptosis [77]. Drug resistance and side 
effects are always important considerations in the treatment of cancer patients, so 
this led to the development of analogues of Cisplatin, and Carboplatin was 
subsequently identified and shown to have fewer side effects than Cisplatin [77-79]. 
That said hypersensitivity reactions have been found to be an issue in recurrent 
ovarian cancer patients who have been challenged again with Carboplatin, where a 
discontinued platinum-based therapy schedule could impact on a patient’s 
prognosis [80]. Therefore, a study was able to show that hypersensitive-related 
risks could be reduced, and the benefits of platinum could be maintained, by 
treating these patients with Cisplatin [80]. 
 
Paclitaxel is another chemotherapeutic compound introduced in the 1990s, and it 
showed less toxicity and was easier to administer when used to treat patients in 
combination with Carboplatin, rather than in combination with Cisplatin [79, 81]. A 
study was carried out to investigate the schedule of treatment for patients with 
ovarian cancer, and whether patients would benefit from weekly Paclitaxel, 
compared to every-3-weeks Paclitaxel [82]. Interestingly, the weekly schedule did 
not prolong progression-free survival among patients with ovarian cancer, in 
comparison to having Paclitaxel administered every 3 weeks [82]. These types of 
studies are important to gain a more in-depth understanding of managing the costs 
associated with different treatment regimens for ovarian cancer patients [82]. 
 
The PARP inhibitor Olaparib is recognised as being the first compound to be 
approved for ovarian cancer treatment since 1996, illustrating the challenges in 
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developing novel treatments for these patients [40]. This treatment is offered to 
patients with deleterious or suspected deleterious germline Brca-mutated advanced 
ovarian cancer, and it has been shown to be effective as a monotherapy option in 
patients who have received three or more prior lines of therapy [40, 41]. Another 
study has shown that there may be other clinically relevant populations who can 
derive benefit from Olaparib, similar to patients with Brca-mutated ovarian cancer, 
where the tumours in these patients have loss-of-function mutations in other HR 
genes [83]. Genes involved in more than one patient included Brip1 [83]. 
 
3.0 FOXM1 plays a role in normal cellular events and 
cancer 
3.1 Introduction to FOXM1 
3.1.1 FOXM1 is a transcription factor 
Forkhead Box Protein M1 (FOXM1) (also known as Trident, MPP2, WIN, or HFH-
11) is a transcription factor that belongs to the Forkhead box family of proteins [84, 
85]. This family of transcription factors, one of the largest classes of transcription 
factors in humans, are defined by a conserved winged helix DNA binding domain, 
and spans a wide range of species [85, 86]. Expression of FOXM1 is found in all 
proliferating cells and it is required for cell division, however expression is absent in 
quiescent and terminally differentiated cells [85, 87]. 
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3.1.2 Structure and isoforms of FOXM1  
Outside of their conserved DNA binding domain, the structure of the Forkhead box 
proteins differ, such that FOXM1 also contains an N-terminal repressor domain and 
a transactivation domain [88]. FOXM1 is made up of 10 exons, and three distinct 
variants are formed through alternative splicing: FOXM1a, -b, and -c [84, 89] (Figure 
3). More recently, a fourth isoform has also been identified, known as FOXM1d [90]. 
 
 
Figure 3. Structure of FOXM1. 
The N-terminal repressor domain (NRD), the Forkhead (FKH) domain, and the 
transactivation domain (TAD) can be alternatively spliced to give rise to three 
isoforms: FOXM1a, -b, and -c (adapted from: [88, 91]). 
 
The FOXM1a isoform is transcriptionally inactive because of disruption to its 
transactivation domain, while the FOXM1b and FOXM1c isoforms are both 
identified as being transcriptionally active, without this disruption [87, 92]. FOXM1a 
is not conserved in mouse, which makes it more difficult to determine the 
physiological significance of this isoform [93]. Interestingly, the FOXM1a variant 
may act as a dominant-negative variant because of retaining normal DNA binding 
activity, without a functional transactivation domain [94]. FOXM1a could compete 
with other splice variants to bind FOXM1-responsive elements, and inducing this 
variant could reduce cell proliferation caused by FOXM1b and FOXM1c [94]. 
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Transcriptional activity of FOXM1 is prevented by an association of the N-terminal 
domain of FOXM1 with the C-terminal activation domain [95]. It was also shown that 
when the N-terminal domain was deleted, a constitutively active transcription factor 
was generated and functioned independently of phosphorylation events [95]. 
Furthermore, these cells exhibited increased transforming activity [95]. 
 
3.1.3 Localisation and regulation of FOXM1 
Localisation of FOXM1 appears to be cell cycle-dependent, such that FOXM1 is 
localised mainly to the cytoplasm in cells at late-G1- and S- phases [93]. Just before 
entering G2-/M- phase, FOXM1 is then translocated to the nucleus, and this is when 
FOXM1 is phosphorylated, such that activated Raf/MEK/MAPK signalling was found 
to promote FOXM1 phosphorylation [93]. Importantly, this group also provided the 
first evidence that Raf/MEK/MAPK signalling and FOXM1c mediate cell cycle 
progression through G2/M [93]. Further evidence supports that FOXM1c is in fact a 
greatly attenuated form of FOXM1, and it requires Raf/MEK/MAPK signalling for 
activation [96]. Whilst the b isoform represents a more active form of FOXM1, and 
has been frequently associated with overexpression in cancer cells [96]. Indeed, 
FOXM1b has been suggested to be a potent activator of tumour metastasis [97]. 
 
During the cell cycle, FOXM1 itself undergoes regulation through post-translational 
modifications, including the direct phosphorylation by PLK1 which leads to 
activation of FOXM1’s transcriptional activity [98]. It is these phosphorylation events 
that have been suggested to relieve the repressive function of the N-terminal 
domain in FOXM1 [99]. That said, more recent evidence has suggested that 
SUMOylation is more likely blocking FOXM1 dimer formation, to alleviate 
autorepression of FOXM1 [100]. This modification has been shown to peak in G2- 
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and M-phase, and this Small Ubiquitin-Like Modifier-2 (SUMO-2) protein has been 
suggested to control FOXM1 transcriptional activity [100].  
 
It was observed that there is a progressive decrease in FOXM1 mobility when cells 
were released from G0/G1 arrest, and that there is an initial phosphorylation of 
FOXM1 in S-phase which leads to hyperphosphorylation in G2/M, when PLK1 
activity is at its highest [98]. So FOXM1 has been shown to be phosphorylated in 
the carboxy-terminal domain by Cdk1 initially, and this acts as a priming 
phosphorylation, ready for subsequent PLK1 phosphorylation [98]. Furthermore, it is 
FOXM1’s hyperphosphorylation during G2/M phase that correlates with its 
transcriptional activity being cell-cycle-restricted [98].  
 
To understand why phosphorylation and activation of FOXM1 are prevented at 
earlier stages, and restricted to G2, there was additional investigation of interactors 
with FOXM1. B55α, a regulatory subunit of the protein phosphatase 2A (PP2A), was 
subsequently identified as a novel interactor of FOXM1 [101]. The phosphatase 
PP2A/B55α has been shown to counteract phosphorylation of FOXM1, and 
negatively regulate the activity of FOXM1 [101]. It was suggested that PP2A/B55α 
might counteract indirectly the activation of FOXM1 by PLK1 [101]. 
 
FOXM1 is also regulated by the E3 ubiquitin ligase, with its substrate specificity 
subunit, APC/C-Cdh1, a complex that participates in proteolysis [102, 103]. This 
happens in late M-/early G-phase of the cell cycle and it is involved in regulating 
entry into S-phase [102, 103]. It has been suggested that Cdh1 recognises FOXM1 
as a target, by the degradation motifs that are present in FOXM1’s N-terminal 
domain [102]. As previously mentioned, the N-terminal domain acts as a 
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transcriptional repressor through intramolecular interaction with the C-terminal 
domain [95], therefore the role of this domain in degradation further emphasises its 
importance in tight control over the activity of FOXM1 to the G2-phase in G2-
specific gene expression [102]. Furthermore, another study showed how FOXM1 is 
downregulated by p53 after DNA damage, to lead to a stable G2 arrest and 
maintenance of genomic integrity [104]. 
 
3.2 Role of FOXM1 in the cell 
3.2.1 Cell cycle 
From S-phase, FOXM1 expression levels become increased and these levels 
persist until the end of mitosis, where the function of FOXM1 is important for proper 
mitotic progression [105]. This has been illustrated by FOXM1’s role in regulating a 
large number of G2-/M-specific genes, as well as FOXM1-mediated transactivation 
of cyclin B for timely mitotic entry [105, 106]. In another study, FOXM1 was found to 
be a requirement for cells to avoid mitotic catastrophe [106]. As FOXM1 plays a 
diverse role in cell cycle regulation, this has been summarised in Figure 4, 
indicating where FOXM1 is acting on the cell cycle.  
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Figure 4. FOXM1 plays a role in the cell cycle. 
A number of proteins involved in the cell cycle are either directly or indirectly 
transcriptionally regulated by FOXM1 (adapted from: [88, 107]). 
 
Briefly, one of the roles of FOXM1 is to regulate Skp2 and Cks1, to then target 
cyclin-dependent kinase inhibitors for degradation during G1-/S- phase transition 
[108]. The SKP2 and CKS1 proteins are specificity subunits of the SCF ubiquitin 
ligase complex, and these are essential for the recognition of the phosphorylated 
p27KIP1 and p21Cip1 proteins [108]. The degradation of cyclin-dependent kinase 
inhibitors subsequently prevents Cdk2-cyclin E complex inhibition so that RB protein 
is phosphorylated and ultimately stimulates genes for S-phase progression [108]. 
Another role of FOXM1 is to activate the transcription of Cdc25b, which is essential 
for the activation of the Cdk1-cyclin-B complex, during the G2/M transition [109]. 
Cdc25b is a phosphatase that dephosphorylates Cdk1 to promote M-phase 
progression, thus providing a mitotic checkpoint through regulating Cdk1/cyclin B 
kinase activity [109]. 
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3.2.2 Differentiation, migration and metabolism 
Functions of FOXM1 are not limited to cell cycle regulation. In one study, Foxm1-/- 
embryos were shown to survive until late gestation, with numerous well-developed 
embryonic tissues [110]. These tissues showed no proliferation defects [110]. 
During embryonic lung development, the role of FOXM1 in differentiation has been 
further explored, such that FOXM1-deficient mesenchyme has been shown to be 
unable to differentiate into capillary endothelial cells [111]. 
 
Other roles of FOXM1 have been investigated using different models, including 
cancer cells. In one study using U2OS osteosarcoma cells, FOXM1 was shown to 
directly activate JNK1 transcription [112]. This protein was not only shown to 
contribute to FOXM1-regulated G1/S transition, but also tumour cell migration, 
invasion, and anchorage-independent growth [112]. Furthermore, in a study using 
pancreatic cells, the authors were able to show differences between isoforms of 
FOXM1, such that FOXM1b and FOXM1c overexpression promoted pancreatic 
cancer cell migration and invasion, but not FOXM1a [92]. Additionally, FOXM1c was 
found to be the predominant isoform in pancreatic cancer cells, suggesting more of 
a role for this isoform in pancreatic cancer development and progression [92]. While 
FOXM1b, along with FOXM1c, may play more of a role in pancreatic cancer cell 
biology [92]. 
 
In another study using pancreatic cells, FOXM1 was implicated in regulating 
glucose metabolism via transactivation of LDHA expression [113]. Then, in a later 
study using epithelial ovarian cancer cells, FOXM1 was again shown to regulate 
glucose metabolism, this time through direct activation of the glycolytic genes 
glucose transporter 1 (GLUT1) and hexokinase 2 (HK2) [114]. FOXM1 expression 
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was positively correlated with GLUT1 and HK2 expression in epithelial ovarian 
cancer cells [114]. This group also found that inhibition of FOXM1 expression by 
shRNA did not affect expression of LDHA in epithelial ovarian cancer cells, and 
therefore different mechanisms may be acting across different cancer types [114]. 
 
3.2.3 DNA damage response 
In FOXM1-deficient cells, it was observed that there are increased DNA breaks, 
illustrating an integral role for FOXM1 in the regulation of genes involved in DNA 
repair [115]. Beyond avoiding the accumulation of DNA breaks, FOXM1 has been 
recognised to be instrumental in the transcriptional regulation of a number of DNA 
repair genes, including Brca2 and Xrcc1 [115]. This study also demonstrates how 
FOXM1 is involved in regulating different DNA repair pathways, including 
homologous recombination (BRCA2) and base excision repair (XRCC1) [115]. In 
addition, DNA damage in p53-depleted cells was shown to increase FOXM1 
expression levels, therefore supporting this data that DNA damage positively 
regulates FOXM1 protein stability [104, 115]. 
 
Further studies of homologous recombination have identified FOXM1 as a 
transcriptional regulator of the genes Rad51, Brip1 and Nbs1 [116-118]. When a 
microarray analysis was performed on FOXM1-depleted cells, Rad51 was noted as 
a potential downstream target of FOXM1 [116]. This was confirmed in stable cell 
lines of FOXM1-depletion, and it was subsequently found that FOXM1 directly binds 
to the promoter of Rad51 to regulate its activity [116]. This study also suggested 
that the FOXM1-RAD51 axis is involved in chemotherapy resistance [116]. 
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A link was also found between FOXM1 and BRIP1 [117]. In their model, the authors 
were able to demonstrate that Foxm1 silencing resulted in decreased expression of 
BRIP1 [117]. Consistently, Foxm1−/− mouse embryonic fibroblasts (MEFs) showed 
lower BRIP1 expression levels compared to WT MEFs [117]. The authors also 
established Brip1 as a direct transcriptional target of FOXM1 [117]. In addition, 
FOXM1’s role in regulating the expression of DNA repair genes, as in this instance 
with Brip1, has also been implicated in playing a role in drug resistance [117]. 
 
In the study of NBS1, whilst FOXM1 was shown to directly regulate Nbs1 
expression, other components of the MRN complex, MRE11 and RAD50, were 
found not to be under direct regulation of FOXM1 [118]. They were instead 
suggested to have their protein levels stabilised through forming an active MRN 
complex [118]. This also indicates that NBS1 may be limiting for the formation of the 
MRN complex and that its level could set the threshold for DNA repair activity [118]. 
Furthermore, upon FOXM1 overexpression and NBS1-depletion, HR activity was 
not increased, so NBS1 is essential to FOXM1’s HR function [118]. It was also 
suggested that the regulation of NBS1 by FOXM1 contributes to the DNA damage 
response, genotoxic drug resistance and DNA damage-induced senescence [118]. 
 
3.2.4 Oxidative stress response 
One of the main studies that investigated FOXM1 and oxidative stress showed how 
FOXM1 plays a role in regulating oxidative stress in the context of oncogenesis 
[119]. FOXM1 has also been shown to counteract oxidative stress-induced 
premature senescence, through regulating Bmi-1 expression [120].  
 
45 
 
It was shown that cells deficient in FOXM1 showed increased levels of ROS 
compared to normal cells, thus FOXM1 was shown to be an important regulator of 
the levels of intracellular ROS [119]. FOXM1 was also shown to bind to MnSOD and 
catalase promoter regions, further emphasising the role of FOXM1 in regulating 
oxidative stress through the regulation of anti-oxidant genes [119]. The authors then 
went on to speculate a possible role for FOXM1 in attenuating apoptosis, where 
mitochondrial ROS is involved, by upregulating detoxifying enzymes such as 
MnSOD [119]. Overall, it could be that tumour cells use FOXM1 to control oxidative 
stress and this is how premature senescence and apoptosis can be escaped [119].  
 
In a later study, normal cells and cancer cells were both identified to use FOXM1 as 
a key regulator of ROS levels and oxidative stress [121]. Normal keratinocytes and 
head and neck squamous carcinoma cells were sensitised to apoptosis when 
depleted of FOXM1 [121]. Again, as inferred by Park et al., these authors suggest 
that cancer cells expressing high levels of FOXM1 could be exploiting the anti-
oxidant activity of FOXM1 so that cancer cells escape premature senescence and 
apoptosis [121]. Furthermore, in a study of human embryonic stem cells, expression 
of FOXM1 was shown to be enriched and regulated in a cell cycle-dependent 
manner, and when FOXM1 was depleted in these cells they were sensitised to 
oxidative stress [122]. Interestingly, when the authors investigated the previously 
reported transcriptional targets of FOXM1, MnSOD and catalase, in FOXM1-
depleted human embryonic stem cells, they only observed a decrease in the 
expression of catalase and not MnSOD [122]. Therefore, FOXM1-depleted human 
embryonic stem cells may be sensitised to oxidative stress through reduced 
catalase expression [122]. 
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3.2.4.1 Oxidative stress in cancer  
Reactive oxygen species, at the right concentrations, play an important role in 
signalling processes [123]. For instance, an ‘oxidative burst’ has been described to 
occur in the first line of defence against pathogens, where ROS is produced by 
phagocytic NADPH oxidase [123]. Indeed, mice deficient in the gp91 protein of 
reduced nicotinamide adenine dinucleotide phosphate oxidase have been shown to 
have increased susceptibility to Listeria infection, for example [124].  
 
It is only when these concentrations of ROS become even higher than required, and 
this can be excessive and/or a sustained increase, then damage to the cell can lead 
to disease such as cancer [123]. Oxidative stress contributes to cancer in a number 
of ways; impacting on redox state, driving tumour progression, and adapting to 
hypoxic conditions [123, 125, 126].  
 
In patients with advanced malignancies a pro-oxidative shift in the plasma 
thiol/disulfide redox state has been observed, termed “mitochondrial oxidative 
stress”, suggested to be linked to uncontrolled availability of mitochondrial energy 
substrate [123]. Furthermore, higher levels of H2O2 and NADPH oxidases (NOXs) 
have been shown to play a role in increased tumourigenicity and angiogenesis in 
various cancers, including prostate cancer [125].  
 
Cancer cells also promote HIF-1α and HIF-2α accumulation, leading to 
transactivation of their target genes involved in processes like angiogenesis and 
metabolic adaptation to hypoxia, where ROS has been shown to stabilise HIF-1α 
protein in an AMPK-dependent manner [126]. AMPK plays a critical role as an 
energy sensor in response to stresses, such as hypoxia and ROS, and this study 
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showed that AMPK was required for ROS-induced HIF-1α induction, stabilisation, 
and transcriptional activation [126]. Whilst, under hypoxic conditions, AMPK activity 
was only involved in HIF-1 transcriptional activation, identifying AMPK as a key 
determinant of HIF-1 functions in response to ROS [126]. 
 
Activation of oncogenes is a key step in cellular transformation and maintenance of 
cancer, where an increase in ROS accumulation has also been reported in these 
cells [127]. Oncogenes, including Ras and Myc, give rise to compromised genome 
integrity through processes such as deregulated redox homeostasis and DNA 
replication stress, and these changes may differ depending upon which oncogene is 
involved [128].  
 
Ras-induced increases in ROS levels in immortalised cells have been suggested to 
lead to transformation, in response to DNA damage, instead of growth arrest [127]. 
Furthermore, oxidative-modified DNA may not be correctly sensed, or repaired 
[127]. Whereas, in normal cells, Ras-induced increases in ROS levels, 
accompanied by high oxidative stress, may lead to upregulation of p53 and p21, 
and ultimately senescence [127]. Overall, it has been suggested that oncogenic Ras 
causes ROS accumulation, and ROS scavenging plays a role in reducing cellular 
senescence [127]. 
 
How oncogenes such as Ras increase ROS has been investigated in a study which 
determined a model for oxidase function in cell transformation [129]. NADPH 
oxidases were the first systems identified to produce ROS in a targeted manner, not 
as a by-product [130]. It was therefore shown that Ras upregulated the expression 
of one of the NOX family of proteins, NOX1 [129]. Subsequently, it is the ROS 
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produced by NOX1 that plays a role in cell transformation and tumourigenicity by 
the Ras oncogene [129]. 
 
In later study, which compared the cellular responses of the oncogenes Ras and 
Myc, the DNA damage response was shown to be engaged early on in Myc-
overexpressed cells, and the speed of fork progression quickly reduced [128]. Then, 
in Ras-overexpressed cells, DNA replication stress resulted in later engagement of 
the DNA damage response, taking longer to slow fork progression [128]. This study 
also showed that mitochondria are not the source of ROS detected by the oxidative 
damage marker, 8‐oxoguanine, after Ras or Myc induction [128]. Therefore, a 
model has been proposed suggesting that oncogenes induce DNA replication 
stress, which may be associated with ROS‐induced signalling or damage, but that 
occurs independently of mitochondrial ROS production [128]. 
 
Cancer stem cells have been suggested to survive radiation, while the remaining 
tumour is removed, through enhanced ROS defences and reduced ROS levels 
[131]. The increased expression of free radical scavenging systems may be 
involved in lowering ROS in some cancer stem cells [131]. In further consideration 
of how cancer cells may compensate for increased ROS, the role of NRF2, a 
transcription factor involved in the defence against oxidative stress, is contentious. 
In one study, oncogene-induced NRF2 activation has been implicated in promoting 
ROS detoxification and tumourigenesis [132]. Then, in another study, NRF2-
deficiency was shown to play a role in metastasis [133]. Consequently, a model of 
human mesenchymal stem cell stepwise transformation was employed for ROS 
changes during tumourigenesis [134]. This study showed that NRF2 repression by 
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oncogenes acted as an adaptive response in some cancer cells for the acquisition 
of a pro-oxidant state, favouring cell survival and tumour growth [134]. 
 
As discussed, a controlled intracellular ROS level ultimately contributes to cell 
proliferation and survival.  Another study has shown that cancer cell antioxidant 
responses are enhanced through inhibition of the glycolytic enzyme pyruvate kinase 
M2 by ROS [135]. Specifically, glucose flux was found to divert into the pentose 
phosphate pathway, to enable sufficient reducing potential for ROS detoxification 
[135]. This study therefore indicates a role for metabolic alterations in both 
proliferation, and protecting against oxidative stress [135]. 
 
3.2.5 Antioxidant repair pathways 
3.2.5.1 NRF2 pathway 
Cells are protected against free radical damage by enzymatic and non-enzymatic 
antioxidant systems, and these systems can work synergistically [136]. Antioxidants 
can be endogenous or obtained exogenously, in the diet or as dietary supplements 
[136]. Glutathione peroxidase, catalase and superoxide dismutase are said to be 
contained in the most efficient enzymatic antioxidants [136]. Non-enzymatic 
antioxidants include Vitamin E and C, and thiol antioxidants such as glutathione and 
thioredoxin [136]. 
 
The NRF2-antioxidant response element signalling pathway is a major mechanism 
involved in the defence against oxidative stress [137], and its pathway is 
summarised in Figure 5. Briefly, under basal conditions NRF2 activity is repressed 
through its cytoplasmic tethering and ubiquitination, mediated by the redox-sensitive 
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Kelch-like ECH-associated protein 1 (KEAP1) [138, 139]. Changes in local redox 
conditions will affect KEAP1 because it is cysteine-rich, and it is therefore sensitive 
to deviations from basal conditions [138, 139]. There are two proposed mechanisms 
by how NRF2 becomes activated by KEAP1, through the imposed conformational 
change mediated by the cysteine residues [138]. The “hinge and latch” model 
suggests that the KEAP1 interaction is disrupted with NRF2, and the second model 
suggests Cul3, which is usually involved in repressing NRF2 by promoting its 
ubiquitination and proteasomal degradation, is dissociated from KEAP1 [138, 140]. 
Subsequently, KEAP1 becomes inactivated so that newly synthesised NRF2 can 
bypass repression and translocate to the nucleus [138]. Once translocated, the 
transcription factor NRF2 binds to the antioxidant response element (ARE) in the 
regulatory regions of antioxidant target genes, such as NAD(P)H:quinone 
oxidoreductase 1 (Nqo1), to coordinate an adaptive response to oxidative stress 
[138]. One study has shown that NQO1 can act as a direct ROS scavenger, and it 
can also play an antioxidant role [141]. 
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Figure 5. The NRF2 pathway. 
Under basal conditions, the NRF2 protein undergoes proteasomal degradation, 
while under oxidative stress conditions, the NRF2 protein acts as a transcription 
factor for drug metabolising enzymes, antioxidant proteins and stress response 
proteins (adapted from: [138-140, 142]). 
 
3.2.5.2 NQO1 plays a role in the oxidative stress response and cancer 
NAD(P)H:quinone acceptor oxidoreductases are present as two major forms in 
mammalian systems, NQO1 and NQO2 [143]. Under normal and oxidative stress 
conditions, Nqo1 gene expression is regulated by the antioxidant response element 
(ARE) [144]. 
 
NQO1 is a widely distributed FAD-dependent flavoprotein and it has greatly 
increased gene expression when there is stress on the cell, including oxidative 
stress and toxicity [145]. It also has increased gene expression in response to 
ionising radiation, heat shock, electrophiles, hypoxia, and heavy metals [146]. 
Quinone reduction and antioxidant activity, either indirectly through ubiquinone and 
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Vitamin E derivatives or directly through superoxide scavenging, are roles employed 
by NQO1 to protect cells against these stresses [141, 147]. 
Quinones are reduced to hydroquinones by the obligate two-electron reductase 
NQO1, where NADH or NADPH are used as reducing cofactors, stopping redox 
cycling of xenobiotics [147, 148]. Therefore, NQO1 acts as a detoxification and 
antioxidant enzyme to protect cells against toxicity and free radical generation from 
xenobiotic containing quinone moieties [147]. Through this mechanism, NQO1 
diverts quinone electrophiles from participating in reactions that could lead to 
sulfhydryl depletion, as well as bypasses the unstable and highly reactive 
semiquinone intermediate [145, 147]. It is also possible for the hydroquinone 
products to be further metabolised to glucuronide and sulfate conjugates, allowing 
excretion to be facilitated [145].  
It must also be noted that NQO1 can act as either a detoxification enzyme or an 
activating enzyme, and this can be based on how stable the hydroquinone is after 
reduction [148]. In the case of Menadione, this quinone can be reduced to a stable 
hydroquinone by NQO1, and subsequently conjugated and excreted, or it can form 
a semiquinone and give rise to ROS generation through one-electron reductases 
[148]. These one-electron reductases compete with the beneficial two-electron 
reduction by NQO1, for Menadione [148].  
Up- or down-regulation of ARE-mediated gene expression is through a balance of 
NRF2 and another transcription factor, BACH1, inside the nucleus [144]. 
Overexpression of BACH1 was shown to repress Nqo1 gene expression and 
induction in response to antioxidant treatment [144]. Furthermore, NRF2 and 
53 
 
BACH1 were shown to compete with each other to regulate ARE-mediated gene 
expression [144]. In response to antioxidant treatment, NRF2 and BACH1 have 
both been shown to translocate to the nucleus, where BACH1 accumulated more 
slowly than NRF2 [144]. This antioxidant-induced delayed accumulation of BACH1 
could subsequently downregulate ARE-mediated gene expression, and could 
therefore allow antioxidant enzymes to return to normal levels [144]. 
 
High expression of NQO1 has been associated with poor prognosis in cancers, 
such as breast cancer and ovarian cancer [149, 150]. NQO1 bioactivatable drugs, 
such as the quinone known as β-lapachone, could be used to deliver tumour-
selective DNA damage and cell death [151]. NQO1 catalyses the two-electron 
oxidoreduction of β-lapachone to generate an unstable hydroquinone, and this then 
spontaneously reacts in a two-step back-reaction with oxygen to regenerate the 
original compound [151]. Significantly, around 60 moles of NAD(P)H can be 
oxidised by NQO1-dependent futile redox cycling, and this can generate around 120 
moles of ROS in about 2 minutes [151]. This can ultimately cause increased DNA 
lesions and hyperactivation of PARP [151]. Therefore, this study showed that a 
combination of β-lapachone and PARP inhibitors is synergistic at nontoxic doses of 
both drugs in NQO1-overexpressing cancers, including breast cancers [151]. 
 
3.3 Targeting NQO1 overexpression 
3.3.1 Diminutol 
An affinity chromatography experiment with Diminutol identified NQO1 as a possible 
target, when the role of NQO1 in microtubule polymerisation was also been 
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investigated in Xenopus egg extracts [152]. It was discovered that Diminutol is a 
competitive inhibitor of NQO1 with respect to NAD(P)H, with a Ki of 1.72M [152].  
As previously discussed, NQO1 catalyses the two-electron reduction of quinones to 
hydroquinones, using NAD(P)H as an electron donor, thus preventing other 
enzymes from catalysing a one-electron reduction and potential free radical 
production [147, 148, 152]. When this was tested in Xenopus egg extracts, 
Diminutol was not shown to increase free radical production when microtubules 
were depolymerised, therefore this effect was independent of oxidative stress [152]. 
Based on the limited investigations of Diminutol, this makes it an ideal compound to 
carry out further studies, and there is also potential for application as a therapy in 
the treatment of cancer patients. 
3.3.2 Dicoumarol 
Derived from Coumarin, the chemically named 3,3′-methylenebis[4-
hydroxycoumarin], also known as Dicoumarol, is a natural anticoagulant drug that 
has been used extensively in research [153, 154]. Dicoumarol is considered to be a 
potent NQO1 inhibitor, and it has also been suggested to play a role in interfering 
with mitotic spindle microtubule function and therefore inhibiting cell proliferation 
[153, 154]. 
As an NQO1 inhibitor, Dicoumarol acts as a competitive inhibitor by competing with 
NAD(P)H for binding to NQO1 and thus preventing electron transfer to FAD [155, 
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156]. Its potency relative to other NQO1 inhibitors, such as ES936, is indicated by 
its Ki value of 1-10nM, compared to 450nM, respectively [155, 156]. 
Dicoumarol has been used to target NQO1 in cancer cells, and it has shown to be 
effective at sensitising different cancer cells to Cisplatin, Doxorubicin and 
Gemcitabine [157-159]. In urogenital cancer cell lines, cytotoxicity of Dicoumarol 
was dependent upon NQO1 expression status [157]. Then, when investigating the 
role of NQO1 in Dicoumarol-mediated modulation of Cisplatin cytotoxicity, NQO1-
depleted cells did not show enhanced sensitivity to Cisplatin by Dicoumarol [157]. 
This result therefore suggested that NQO1 is required for Dicoumarol-mediated 
modulation of Cisplatin cytotoxicity [157]. 
3.3.3 Other Coumarin-based compounds 
Despite Dicoumarol being recognised as the most commonly used NQO1 inhibitor, 
it is not without its limitations. This has been shown in a study of the MTT assay, 
where it is normally included in the assay, the authors concluded on a 
recommendation that it should not be added [160]. This is because cell lines 
showed different sensitivities to the compound, and this may skew cell viability data 
when evaluating cytotoxins [160]. In a study of ovarian cancer, Dicoumarol was 
found to inhibit an overexpressed protein pyruvate dehydrogenase kinase 1, and 
the authors also acknowledged other anticancer effects of Dicoumarol through 
NQO1 inhibition [161]. These studies therefore illustrate how Dicoumarol may effect 
cell viability data and how there are potentially multiple cellular targets in cancer 
cells, so the effects may not always be mediated by NQO1 inhibition [160, 161]. 
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Based on these limitations, there was a subsequent need to achieve both greater 
potency and greater selectivity for inhibiting NQO1, than that of Dicoumarol [162]. 
To investigate this, two sets of novel NQO1 inhibitors that were analogues and 
hybrid compounds, were firstly identified [163, 164]. From this, further studies 
showed that these compounds could lower toxicity and have fewer off-target effects, 
in addition to increased potency [162, 164, 165]. When testing the 
chemotherapeutic agent EO9, which is normally activated by NQO1 to generate 
highly cytotoxic species, it was observed that some of their compounds were more 
efficient than Dicoumarol at inhibiting NQO1, and that they had greater protection 
against EO9 toxicity [162]. Additionally, the authors commented on Dicoumarol as 
being one of the most toxic compounds in all cell lines, and it is unclear whether 
factors such as NQO1 status play a role in determining the level of toxicity [165]. It 
was then suggested that the toxicity of Coumarin analogues may be related to 
superoxide generation, however exceptions would exist [165]. 
 
3.3.4 Irreversible inhibitors  
Even the Coumarin analogues are not without limitations, and this is based on the 
competitive inhibition nature of these compounds, as with Dicoumarol [155, 156]. 
This property actually impedes their use in the evaluation of the activating or 
detoxifying properties of NQO1 [155, 156]. To overcome this, mechanism-based 
inhibitors such as ES936 have also been investigated [166]. In this instance, rather 
than identifying a potential therapeutic treatment option, this study has identified a 
compound that can be used as a tool to further define the role of NQO1 [166]. 
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3.4 FOXM1 in cancer  
3.4.1 Overexpression of FOXM1 in different cancer types 
FOXM1 has been shown to be overexpressed in early and later stages of breast 
cancer development [167]. It has also been shown that FOXM1 expression 
correlated with HER2 status, suggesting FOXM1 may represent an important target 
in treating HER2-resistant breast cancer tumours [168]. In another study, this time 
in the oestrogen receptor-positive subtype of breast cancer, FOXM1 overexpression 
was found to be associated with poor disease free and overall survival [169]. 
Furthermore, Tamoxifen resistance had been linked to increased expression of 
FOXM1 and an increase in cancer stem cells, in oestrogen receptor-positive breast 
cancers [170]. In a very recent study of breast cancer, the overall assessment of 
FOXM1 and different breast cancer subtypes suggested that triple-negative breast 
cancer cells had the highest expression of FOXM1, compared to other subtypes 
[171]. 
 
Integrated genomic analyses of ovarian carcinoma were used to show pathway 
alterations in high-grade serous ovarian cancer, using clinically annotated samples 
[172]. Notably, the FOXM1 transcription factor network was found to be activated in 
84% of cases [172]. As previously discussed, p53 represents a repressor of FOXM1 
after DNA damage, so the high rate of p53 mutation in high-grade serous ovarian 
cancer could contribute to overexpression of FOXM1 [104, 172]. When the 
expression status of FOXM1 was investigated in ovarian cancer, it was observed 
that high FOXM1 expression correlated with high-grade tumours [173]. FOXM1 
overexpression was found in 73% of Grade 3 tumours, while 68% of Grade 1 and 
Grade 2 tumours had low FOXM1 expression [173]. It has also been shown that 
overexpression of FOXM1 correlates with poor patient survival [174]. 
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In a comparison of bladder tumour samples to normal tissue, FOXM1 was among a 
list of five genes that were identified to be overexpressed in tumour samples, which 
were involved in promoting cell proliferation and growth [175]. When invasively 
growing T24 bladder cancer cells and poorly invasive bladder cancer cells, BIU-87, 
were investigated it was determined that FOXM1 expression was higher in T24 
bladder cancer cells [176]. When investigating FOXM1 with clinicopathologic 
parameters, of the 63 bladder cancer patients to experience recurrence, 60 also 
had high FOXM1 expression levels [176]. This was in contrast to the 37 patients 
who did not experience recurrence, and only 18 also had high FOXM1 expression 
levels [176]. In addition, FOXM1 was shown to be increased from low- to high-grade 
bladder cancers [177]. 
 
High levels of FOXM1 were observed in 85% of colorectal cancer tissue samples, 
compared to only 20% in adjacent non-cancerous tissue samples [178]. The 
colorectal cancer cell line LOVO was used as a model because of having high 
FOXM1 expression, and it was subsequently found that when FOXM1 was depleted 
in these cells this caused suppression of cell growth, invasion, and metastasis 
[178]. Therefore, FOXM1 may be involved in initiation and progression of colorectal 
cancer [178]. It was also found that poor patient survival was associated with high 
FOXM1 expression in colorectal cancer patients [179]. 
 
3.4.2 FOXM1 as a novel candidate for cancer therapy 
FOXM1 was identified to be overexpressed in several types of solid tumours, 
including breast, ovarian, bladder, lung and colon [180]. A correlation of FOXM1 
and human cancer was shown with high expression levels of FOXM1 in human 
basal cell carcinomas, and that this was a target of the glioma transcription factor-1, 
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Gli1 [181]. In a study of UVB and FOXM1 in skin cancer initiation, aberrant 
upregulation of FOXM1 was described as a “first hit” in cells, causing genomic 
instability [182]. UVB-activation of FOXM1B was shown to be dose-dependent 
[182]. The “second hit” has been suggested to occur when the DNA-damage 
checkpoint response ceases to exist, such as inactivation of p53, subsequently 
leading to cancer initiation [182]. In breast cancer, FOXM1 was identified as one of 
seven early molecular markers [167]. Furthermore, FOXM1 was found to be 
significantly overexpressed in ductal carcinoma in situ, and it was even more highly 
expressed in invasive ductal carcinoma [167]. In this instance, FOXM1 as a 
molecular marker may assist in earlier detection of breast cancer [167]. In continued 
consideration of other breast cancer studies, it was found that Thiostrepton could be 
used to selectively target FOXM1, and that cell proliferation and tumour growth are 
suppressed when FOXM1 is depleted, in breast cancer cells [183, 184]. Therefore, 
FOXM1 represents a molecular marker and a novel candidate for cancer therapy 
[167, 180, 183, 184].  
 
Significantly, the previously discussed roles of FOXM1, such as regulating the DNA 
damage response and oxidative stress response, make targeting FOXM1 even 
more of an attractive therapeutic option [185]. In one investigation, it was observed 
that cancer cells were sensitised upon FOXM1 suppression, by RNA interference or 
FOXM1 inhibition, to DNA-damaging agent-induced apoptosis [186]. In another 
investigation, FOXM1 inhibition and ROS inducers in combination were shown to 
induce apoptosis in cancer cells [187]. Therefore, these studies show evidence that 
a combinatorial anticancer therapy may also be considered as an effective way to 
treat patients [186, 187]. 
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3.4.3 FOXM1 and chemoresistance 
As previously mentioned, the role of FOXM1 in regulating members of DNA repair 
pathways has been linked to chemoresistance. Briefly, RAD51 re-expression was 
shown to partially rescue Temozolomide resistance in FOXM1-depleted recurrent 
glioblastoma cells [116]. FOXM1- or BRIP1-depleted Epirubicin-resistant cells could 
be resensitised to Epirubicin [117]. In breast cancer cells treated with Epirubicin, 
overexpression of FOXM1 led to increased NBS1 expression and ATM 
phosphorylation, while in FOXM1-depleted breast cancer cells this resulted in 
reduced NBS1 expression and ATM phosphorylation [118]. As with FOXM1, NBS1 
was also overexpressed in Epirubicin-resistant cells, and the parental cells showed 
low but Epirubicin-inducible levels [118].  
 
In other studies of breast cancer, acquired resistance to Cisplatin has been 
suggested to be mediated by FOXM1 and enhanced DNA-damage repair pathways 
[188]. FOXM1 has also been shown to mediate resistance to Herceptin and 
Paclitaxel in breast cancer, and in this instance it is suggested to be through altered 
microtubule dynamics [189]. In both studies, targeting FOXM1 enabled cells to be 
resensitised to therapy, and this could subsequently be applied in other cancer 
types [188, 189]. Additionally, FOXM1 has been shown to mediate resistance to 
Paclitaxel in ovarian cancer, and KIF2C, a novel transcriptional target of FOXM1, 
may also be implicated in Paclitaxel resistance [174]. The roles of KIF2C include 
maintenance of spindle assembly during mitosis and meiosis, and this protein has 
already been shown to be involved in carcinogenesis [174]. Inhibition of FOXM1 has 
resulted in increased sensitivity to Cisplatin, Carboplatin, Doxorubicin 
Hydrochloride, and Olaparib, in ovarian cancer, again illustrating the role of FOXM1 
in driving chemosensitvity [190]. 
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FOXM1 and FOXM1 targets have also been considered in relation to evasion of 
apoptosis [191]. In this case, FOXM1 was shown to be a transcriptional activator of 
the anti-apoptotic genes XIAP and Survivin [191]. Furthermore, overexpression of 
FOXM1, XIAP, and Survivin has been suggested to contribute to the development 
of resistance to Docetaxel and Doxorubicin [191]. 
 
4.0 Targeting FOXM1 overexpression 
It is widely discussed that transcription factors are deemed to be less “druggable” 
than, for example, enzymes [192, 193]. This is because when developing drugs that 
target transcription factors, they must be able to specifically disrupt or recruit DNA-
protein or protein-protein interactions, to directly modulate protein function [192]. To 
overcome these limitations, several approaches have been investigated, including 
the use of screens to identify FOXM1 inhibitors [194].  
 
4.1 Thiazole antibiotics and proteasome inhibitors  
4.1.1 Siomycin A 
In a cell-based screening system of compound libraries from the National Cancer 
Institute, the antibiotic thiazole Siomycin A was identified as a potent inhibitor of 
FOXM1 transcriptional activity [194]. It was also found that Siomycin A was able to 
inhibit anchorage-independent growth and induce apoptosis in transformed cells, 
whilst sparing normal cells [194]. In further mechanistic studies, it was shown that 
Siomycin A inhibits FOXM1 expression, but not the expression of other members of 
the Forkhead box family, indicating that this is a FOXM1-specific inhibitor [195]. 
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Downregulation of FOXM1 with Siomycin A was shown to sensitise glioblastoma 
cells to irradiation, and these cells showed significantly increased DNA double-
strand breaks as well as enhanced radiation induced mitotic catastrophe [196]. This 
may not be effective in all cancer types, as when this strategy was applied to 
radioresistant melanoma cells, these cells were not resensitised [197]. That said 
Siomycin A was proven to be effective as a single agent, inducing cell death in 
metastatic melanoma cells with constitutive FOXM1 expression [197]. 
 
4.1.2 Thiostrepton 
Following the identification of Siomycin A, another thiazole antibiotic with small 
structural differences to Siomycin A was discovered to inhibit FOXM1, known as 
Thiostrepton [183, 198]. As described for the specificity of Siomycin A, treatment 
with Thiostrepton causes FOXM1 expression to be specifically inhibited in cells 
[198]. Therefore, not only do thiozole antibiotics downregulate transcriptional 
activity, but they also downregulate the expression of FOXM1 at the protein and 
mRNA levels [198]. This decrease in protein expression of FOXM1 that is detected 
after Thiostrepton treatment is suggested to be attributed to the positive auto-
regulatory loop of FOXM1 [199].  
 
In a study where Thiostrepton was identified as a potential anticancer agent, its 
selectivity for inducing cell death only in breast cancer cells and not in 
nontransformed breast epithelial cells was shown to be through downregulation of 
FOXM1 expression [183]. The authors also suggested that the reason for 
nontransformed cells not being sensitive to Thiostrepton is related to a tolerable 
toxicity of the compound, which may not be the case for cancer cells with much 
higher FOXM1 expression [183]. Furthermore, Thiostrepton was shown to inhibit 
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migration and invasion in addition to inhibiting tumour growth, in ovarian cancer 
cells [200]. Thus targeting signalling pathways which involve FOXM1, with 
Thiostrepton, could be used as a way of combating aberrant activation of such 
pathways in ovarian cancer [200]. Targeting FOXM1 with Thiostrepton has also 
been shown to induce apoptosis, as well as exhibit chemosensitising activity, in 
medulloblastoma cells [201]. When investigating the role of FOXM1 in 5-
Flourouracil resistance, a synergistic effect was subsequently observed when 
FOXM1 was targeted in cells treated with Thiostrepton, in combination with 5-
Flourouracil [202]. It was suggested that FOXM1 partially mediates resistance 
through regulating the main target of 5-Flourouracil, thymidylate synthase enzyme 
[202]. 
 
Interestingly, in an investigation of the thiopeptides Siomycin A and Thiostrepton, 
these compounds were reported to also act as proteasome inhibitors [195]. The 
stabilisation of proteins, such as p21, that are usually upregulated during 
proteasome inhibition, facilitated the discovery of the proteasome inhibitor activity of 
Siomycin A and Thiostrepton [195]. The authors investigated some well-known 
proteasome inhibitors, including Bortezomib, and these were also found to inhibit 
FOXM1 transcriptional activity and expression [195]. Therefore, this property of 
negative regulation of FOXM1 by proteasome inhibitors could be exploited for their 
anticancer properties [195].  
 
When considering the mechanism of action of Thiostrepton, different concepts have 
been proposed in the literature [203, 204]. One suggested mechanism is that 
FOXM1 is bound directly by Thiostrepton [203]. The authors state that this 
interaction prevents the interaction of the transcription factor with several gene 
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promoters, but not necessarily to its own [203]. Another mechanism relates to 
Thiostrepton as an inhibitor of transcriptional activity and FOXM1 expression, via 
proteasome inhibition [204]. It suggests that proteasome inhibitors increase the 
expression of a putative negative regulator of FOXM1, and this binds to the 
promoter of FOXM1 to interrupt the autoregulation of transcription of FOXM1 [204]. 
Furthermore, this may explain how a number of proteasome inhibitors can block 
transcriptional activity and expression independently of their structure [204]. HSP70 
was later identified as the negative regulator of FOXM1, after proteotoxic stress, 
through binding FOXM1 and interfering with its DNA binding action [205]. The 
authors also discussed how targeting HSP70 as a therapeutic strategy in cancer is 
becoming more prominent and that this should be developed in combination with 
FOXM1 inhibitors, because of their work showing that HSP70 inhibition leads to 
upregulation of FOXM1 [205]. 
 
4.1.3 Bortezomib 
As previously discussed, the thizole antibiotics Siomycin A and Thiostrepton act as 
proteasome inhibitors, and that inhibition of FOXM1 by these compounds can also 
be achieved by well-known proteasome inhibitors, such as Bortezomib [195]. 
Notably, Bortezomib was the first proteasome inhibitor to enter clinical practice 
[206]. However, restrictions on Bortezomib use have been identified, and these 
include dose limiting toxicity [206]. For this reason, second generation proteasome 
inhibitors are now in clinical development [206]. 
 
One group investigated the potential for a combination therapy of Thiostrepton and 
Bortezomib, to allow for a decreased chance of drug resistance emergence, and to 
use subtoxic concentrations [207]. As thiopeptides have been shown to cause 
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suppressed FOXM1 expression and induction of apoptosis in cancer cells, it has 
been suggested, and subsequently shown, that Bortezomib could act synergistically 
with these compounds [198, 207, 208]. It was observed that Thiostrepton and 
Bortezomib in combination caused apoptosis and inhibition of long-term colony 
formation in different cancer cell lines, and that the relative level of FOXM1 may 
affect the sensitivity of cells to this combination treatment [207]. Importantly, when a 
modified form of Thiostrepton, without proteasome activity, was used in combination 
with Bortezomib, the synergy was lost, and therefore suggests that proteasome 
activity of these compounds is required for a synergistic action [207].   
 
4.2 Small molecules and other FOXM1 inhibitors  
Despite the previously discussed promising investigations of thiazole antibiotics and 
proteasome inhibitors in targeting FOXM1, these compounds are not without 
limitations, such as off-target effects [209]. To identify inhibitors of FOXM1 that 
block DNA binding, a high-throughput screening assay of just over 50,000 small 
molecules was carried out and novel inhibitors were discovered [209]. The lead 
inhibitor, NCGC00099374 (FDI-6), was further investigated and it was found to 
target FOXM1 and displace it from chromatin to reduce its transcriptional activity 
[209]. This study therefore offers the chance to explore other opportunities to target 
FOXM1 overexpression in cancer [209, 210]. 
 
In another high-throughput screening approach, the novel small-molecule 
compound RCM-1 was identified, and it was found to inhibit FOXM1 activity [211]. 
As opposed to inhibiting FOXM1 and its binding to its target DNA, FOXM1 targeting 
was through inhibition of its nuclear localisation [211]. Therefore, because of the 
auto-regulatory function of FOXM1 [199], the reduced Foxm1 mRNA that was 
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observed in this study where mice had been treated with RCM-1, was seemingly as 
a consequence of the reduction in FOXM1 protein abundance caused by RCM-1 
[211]. 
 
The small molecule Honokiol has been previously shown to be effective in cancer 
cells at suppressing Ras activation [212], and more recently it has also been shown 
to bind and inhibit FOXM1 [213]. The authors demonstrated that inhibition of 
FOXM1 with Honokiol induced apoptosis, and that structural analogues of this 
compound were not able to reproduce the same effect, therefore suggesting that 
there is a required structural specificity to inhibit FOXM1 [213]. 
 
Another FOXM1 inhibitor, known as an ARF peptide inhibitor, has shown to be 
effective at limiting proliferation and inducing apoptosis of liver cancer cells in vivo 
[214]. Despite the promising results of studies like this, it has also been discussed 
that there may be unwanted immunological responses to the peptide structure, 
associated with long-term administration of the peptide [215]. This could therefore 
render a decreased effectiveness of this treatment in cancer patients [215]. 
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5.0 DNA damage response and oxidative stress, and 
their roles in cancer 
5.1 DNA damage 
5.1.1 Endogenous and exogenous DNA damage 
Hydrolysis, exposure to reactive oxygen substances and other reactive metabolites 
are some of the chemical events that happen inside the cell that lead to DNA 
damage [216]. Reactive oxygen species (ROS) production from normal cellular 
metabolism is the major source of endogenous DNA damage, and this will be 
discussed in more detail in the next section [217]. Environmental agents that are 
known exogenous sources of DNA damage include ultraviolet light, ionising 
radiation, chemicals, toxins and pollutants [217]. Cancer treatments are also forms 
of exogenous DNA damage, such as chemotherapy and ionising radiation, and they 
exert their cytotoxic effects by inducing DNA damage through various mechanisms, 
including DNA double-strand breaks [218].  
 
In the case of hydrolysis, this can occur in the form of DNA hydrolysis where the 
glycosidic bond between bases and deoxyribose can be labile under conditions 
such as alkylation of bases, and this can lead to an abasic site once cleaved [216]. 
Notably, abasic sites are estimated to occur at a rate of 10000 lesions/human 
cell/day, and these are considered to be one of the most frequent endogenous 
lesions [216]. If abasic sites are bypassed and subsequently left unrepaired, they 
may become mutagenic [216, 219].  
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Other examples of endogenous DNA damage include hydrolytic deamination of 
cytosine to generate uracil, an aberrant base [220]. To overcome this potential for 
mutations to occur, base excision repair may be initiated in the cell [220]. 
 
5.1.2 Reactive oxygen species and oxidative stress 
ROS is endogenously and exogenously produced by sources such as oxidative 
metabolism in the mitochondria and ionising radiation, respectively [217]. In normal 
cells, ROS generation is highly regulated, where ROS are required as signalling 
molecules and for cellular homeostasis [221, 222]. To maintain a healthy status, 
equilibrium between oxidants and antioxidants must be achieved, and an imbalance 
is what leads to oxidative stress and consequently oxidative damage. Therefore, 
when generation of ROS becomes uncontrolled and exceeds levels of antioxidants, 
the result is oxidative stress and damage to lipids, proteins, and nucleic acids, 
because ROS will react with these macromolecules [217]. This can subsequently 
lead to the pathogenesis of age-related and chronic diseases, such as cancer [217].  
 
Free radicals of ROS have unpaired electrons that are highly unstable and active 
towards chemical reactions with other molecules [223]. There is another group of 
ROS known as nonradicals, formed when two free radicals share their unpaired 
electrons [223]. The superoxide anion, hydroxyl radical, and hydrogen peroxide are 
three major ROS that are of physiological relevance [223]. Superoxide anion, for 
example, is formed by the addition of one electron to molecular oxygen [223]. 
Usually, electrons are transferred down the electron transport chain, however some 
electrons will leak and this is what allows superoxide to form [223]. 
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Cancer cells have been said to be characterised by high levels of ROS and 
persistent oxidative stress, to further promote cancer growth and metastasis of the 
cell clones [217]. Increased ROS may lead to the activation of oncogenes and 
oncogenic signals, resulting in processes including cell proliferation and inactivation 
of tumour suppressor genes [222]. These conditions of oxidative stress have 
caused neoplastic cells to develop powerful antioxidant mechanisms [224]. Hence 
ROS represent a double-edged sword in cancer treatment, and whether clinically 
therapeutic benefits can be achieved through antioxidant supplementation or 
inhibition [222]. 
 
The oxidised DNA base, 8-hydroxy-2-deoxyguanosine, has been recognised as a 
potential marker of target organ damage from ROS, and it is one of the most 
abundant oxidative-modified lesions in DNA [225, 226]. 8-hydroxy-2-
deoxyguanosine is a mutagenic lesion which can be mispaired with adenine, and 
during the next replication this wrongly paired adenine will cause a transversion by 
pairing with thymidine [226]. Its level correlates well with cancer incidence, and it 
has also been shown to be increased in breast tumours compared to noncancerous 
controls [225]. Another study has shown that there are significant differences 
between the control group and group with advanced disease, when investigating the 
involvement of oxidative stress during the progression of cervical carcinoma [226]. 
 
5.2 DNA repair pathways 
5.2.1 Repairing DNA single-strand breaks 
The DNA damage response is a collective term used to describe the mechanisms 
that cells have evolved to respond to and ultimately protect themselves against 
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DNA damage, so that they can detect, signal and repair any DNA lesions [227]. 
There are a number of DNA repair pathways that cells use to repair DNA lesions, 
and this can be for the repair of single- or double-strand breaks [227]. 
 
Single-strand breaks (SSBs) can be introduced into DNA through a variety of ways, 
including ROS and even erroneous activity of enzymes, such as DNA 
topoisomerase 1 where a transient nick in the DNA can sometimes become a lesion 
[228]. Importantly, unrepaired SSBs can block or collapse DNA replication forks and 
lead to double-strand breaks (DSBs), and whilst DSB-repair pathways exist in the 
cell, acute increases in cellular SSB levels may cause pathway saturation, leading 
to genetic instability and/or cell death [228]. 
 
As SSBs represent the most frequent form of genomic damage, PARP-1 plays a 
vital role as a stress sensor for this type of DNA lesion [229]. In a structural study of 
PARP-1, it was revealed that there is a tight spatio-temporal control of catalytic 
activity, as well as subtle degrees of regulation, alongside its rapid response to 
SSBs [229].  
 
The mismatch repair (MMR) pathway is required for the removal of base-base 
mismatches that can give rise to point mutations and insertion/deletion loops 
leading to frameshift mutations. Briefly, MutSα/MutSβ recognises the mismatch and 
subsequent binding of MutLα/MutLβ to MutSα starts the process of mismatch 
excision which is followed by EXO1 recruitment to enable removal of nucleotides 
[230]. Once removed, DNA polymerase δ is involved in the DNA resynthesis step 
and DNA ligase seals the nick [230]. 
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The base excision repair (BER) pathway is required for the removal of non-bulky 
base damages. Abasic sites are created in BER, and these are recognised by 
endonuclease 1 so that the DNA backbone is then cleaved to allow for repair to be 
initiated by DNA polymerase β [230]. 
   
The nucleotide excision repair (NER) pathway is for the removal of bulky DNA 
lesions. The XPA protein and the XPC–HR23B complex are suggested to detect a 
lesion in NER [231]. The next steps involve DNA melting and opening of the repair 
section by the XPB and XPD helicases of TFIIH, and then the XPF and XPG 
endonucleases excise the damaged DNA so that the re-synthesise step can be 
carried out by the DNA polymerases α and δ [231]. These pathways all involve the 
repair of SSBs, and they also have SSB transients during the processing of DNA 
damage [230-232]. 
 
5.2.1.1 Role of PARP 
Poly(ADP-ribose) polymerase (PARP-1) is an abundant nuclear protein, belonging 
to a family of at least 17 members [233]. Within the family, PARP-1 and PARP-2 are 
known to play a role in DNA repair, and they are localised to the nucleus [233]. 
PARP family members are also known to have other functions in the cell, including 
gene regulation, chromatin remodelling, and apoptosis [234]. All PARP proteins 
have a conserved catalytic domain, as well as other domains, such as zinc finger, 
BRCT, SAM, SAP, and ankyrin [235]. 
 
A nomenclature system has been used to classify PARP proteins, according to their 
motifs and functions: (1) PARP 1‐5, have a conserved glutamate residue that 
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defines PARP catalytic activity; (2) PARP 6‐8, 10‐12, and 14‐16, are putative mono‐
(ADP‐ribose) polymerases; and, (3) PARP 9 and 13 which do not have PARP 
signature motif that binds NAD+ nor do they have the catalytic glutamate, implying 
that they are inactive [236]. 
 
The PARP-2 catalytic domain has the strongest resemblance to that of PARP-1 with 
69% similarity [237]. PARP-3 has been identified as a core component of the 
centrosome [237]. PARP-4 is the largest member of the family, and it was 
discovered associated with vault particles [237]. The function of these particles is 
unknown; however, they could be associated with multidrug resistance in some cell 
lines [237]. Tankyrase 1 (TRF1-interacting, ankyrin-related ADP-ribose 
polymerase), (PARP-5a), which is involved in telomere maintenance, contains the 
smallest domain homologous to PARP-1 that still displays PARP enzymatic activity 
[237]. Furthermore, a second tankyrase (PARP-5b or tankyrase-2) encoded by a 
distinct gene has also been discovered [237]. The catalytic residue E988 of PARP-1 
is conserved among PARP-1s from various species, in PARP-2, PARP-3, PARP-4 
and in Tankyrases [237]. This Glu residue is also conserved in other members: 
PARP-5c, PARP-11, PARP-12 and PARP-14 [237]. 
 
There has been evidence suggesting a role for PARP-3 in the cellular response to 
DSBs, potentially acting with PARP-1 [238]. This study also found that PARP-3 may 
be functioning in a network linked to mitosis, with the mitotic factor NuMA and 
Tankyrase 1, linked to spindle microtubule dynamics and telomere integrity [238]. 
Furthermore, other studies have shown that PARP family members contain a group 
of IFN-inducible inhibitors of virus replication [239]. Specifically, PARP-7, PARP-10, 
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and the long isoform of PARP-12 have been demonstrated to be potent regulators 
of cellular translation and virus replication [239]. 
 
The catalytic ability of PARP-1 allows long polymers of ADP-ribose to be produced 
on it, and other proteins, by a process known as PARylation [240]. This 
polymerisation is stimulated by the binding of PARP-1 to a single-strand break in 
the DNA, and PARP-1 has been found to be required for the recruitment of 
essential factors in single-strand break repair, including the molecular scaffold 
protein XRCC1 [241]. This study determined that mutation of the XRCC1 BRCT I 
domain, which interacts with poly (ADP-ribose) polymer, reduced or prevented the 
appearance of XRCC1 foci [241]. Therefore, PARP-1 is indicated to be required for 
XRCC1 recruitment to single-strand break sites [241]. 
 
PARylation is a transient, reversible modification, and it is counteracted by the 
activity of PARglycohydrolase (PARG), which degrades PAR [242]. This study 
showed, for the first time, that PARG is critical for rapid rates of chromosomal SSB 
repair [242]. Then, PARP-1 and PARG deficiency together did not slow SSB repair 
any more effectively than reduction of either protein alone, such that an increased 
rate of SSB repair may be due to the proteins acting together [242]. The authors 
also suggested that the accumulation of XRCC1 protein scaffold at sites of damage 
may be regulated [242]. A later study subsequently showed a dynamic regulation of 
XRCC1, in response to damage, such that XRCC1 dissociates from PAR, and 
locates to sites of SSBs dependent on its BRCTII domain and PARG function [243]. 
The authors suggest a model where XRCC1 is recruited to PAR at the damage site 
through its BRCT I domain, while XRCC1 is kept at the site once PARG degrades 
PAR through its BRCT II domain [243]. 
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PARP-1 has been suggested to essential to efficient base excision repair, where 
efficiency was reduced in PARP1-deficient cells [244]. In a study where PARP-2 
was characterised, it was discovered that the PARP-1 and PARP-2 proteins homo- 
and hetero-dimerise and poly(ADP-ribosyl)ate each other [245]. Furthermore, 
PARP-2 was shown to interact with the base excision repair proteins XRCC1, DNA 
polβ, and DNA ligase III, which are all PARP-1 partners [245]. The authors noted 
that despite a low capacity to synthesise ADP-ribose polymers, PARP-2 is also an 
active player in base excision repair [245]. 
 
Another study has proposed that PARP inhibition causes PARP-1 trapping on the 
single-strand break intermediate formed during base excision repair, rather than 
there being an immediate role for PARP-1 in base excision repair [246]. The authors 
suggested that PARP-1 may have a role in recognising single-strand breaks, or 
other DNA ends in the DNA, and to increase the repair [246]. A later study then 
suggested that PARP-1 is involved in base excision repair of a subset of lesions, 
such that PARP-dependent and –independent pathways exist in the cell [247]. The 
authors described a role for XRCC1 and PARP-1 in the repair of single-strand 
breaks and purine lesions, whilst PARP-1 activity was suggested to not be required 
for the repair of pyrimidine lesions [247]. 
 
Other functions of PARP-1 in the DNA damage response include its suggested role 
in protecting the homologous recombination pathway from interference with the 
non-homologous end-joining pathway protein, Ku70 [248]. Therefore, PARP-1 could 
be playing a role in regulating the balance between these two repair pathways 
[248]. A later study consistent with these findings, that PARP-1 and Ku compete 
with each other to recognise double-strand breaks, showed how these proteins may 
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be acting at the damage site [249]. PARP-1 and the Ku complex are suggested to 
compete with each other for the double-strand break repair because, once PARP-1 
has been loaded to the double-strand break, the Ku complex was removed via 
PARylation [249]. 
 
To maintain accurate replication and genomic stability, it is important that stalled 
replication forks become reactivated, and PARP-1 has been shown to play an active 
role in replication restart [250]. Mechanistic investigations found that PARP-1 is 
involved in the recruitment of MRE11; promoting resection of the DNA and restart 
replication forks [250]. Therefore, PARP-1 is suggested to have a role in the 
detection and repair of single-strand breaks [241], repair pathway regulation [248, 
249], as well as detecting stalled or collapsed replication forks and replication 
restart [250]. 
 
5.2.2 Repairing DNA double-strand breaks 
There are several ways that DSBs arise in the DNA, such as replication across a 
nick, giving rise to chromatid breaks during S-phase, ideally repaired by HR using 
the nearby sister chromatid [251]. Other DSBs caused by ROS or ionising radiation, 
for example, are often repaired by non-homologous end joining (NHEJ) because 
they usually occur when there is no nearby homology donor, or because they occur 
outside of S-phase [251]. SSBs are generated first, and when two closely spaced 
lesions of this type on anti-parallel strands occur, this is what causes a DSB [251]. 
Furthermore, a physical dissociation of the two DNA ends that are generated by a 
DSB can make repair difficult, and this can also cause inappropriate recombination 
with other genomic sites [252]. Generation of DSBs can induce mutations and 
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chromosomal translocations, and such genome changes may have tumourigenic 
potential [252].  
5.2.2.1 Double-strand break repair and pathway choice  
There are a number of ways the cell can repair a DNA double-strand break. The 
major conservative repair pathways are non-homologous end-joining and 
homologous recombination [253]. Whilst other competing repair pathways, including 
single-strand annealing and alternative end-joining also exist, for when free DNA 
ends arise in the cell [253]. The competing pathways often take place 
opportunistically, where vulnerable repair intermediates may divert along one of 
those pathways [253]. 
In non-homologous end-joining, the core machinery is composed of DNA-
dependent protein kinase (DNA-PK) complex and ligase IV/XRCC4 [254]. The DNA 
end-binding Ku70/80 heterodimer and the DNA-PK catalytic subunit (DNA-PKCS) are 
involved in phosphorylation events after a double-strand break has been induced 
[254]. DNA-PKCS autophosphorylation enable DNA ends to be accessible for 
processing factors and DNA ligase, where ligase IV/XRCC4 is responsible for 
joining DNA ends [254]. Ku70/80 and XRCC4 have been proposed to interact, 
where XRCC4 may serve as a flexible tether between Ku70/80 and ligase IV [254]. 
The steps involved in HR are illustrated in Figure 6. Briefly, once ATM and ATR 
kinases have recognised the DSB, downstream proteins are then phosphorylated 
which include CHEK2, P53, BRCA1 and H2AX, and it is BRCA1, along with BARD1 
and BRIP1, that provide a scaffold for other proteins to be organised at the repair 
site [255]. MRE11, RAD50 and NBS1 form the MRN complex which is involved in 
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DNA resection, and then BRCA2 is recruited to load RAD51 onto the DNA, assisted 
by RAD51B, RAD51C and RAD51D [255]. Strand invasion is then initiated by the 
RAD51 nucleoprotein filament, where the sister chromatid is used as a template to 
enable error-free repair to take place [255]. Therefore, RAD51 forms the central 
enzymatic component of HR. 
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Figure 6. The homologous recombination pathway. 
ATM and ATR kinases involved in step (1) recognise and initiate homologous 
recombination, and facilitate downstream phosphorylation of proteins such as 
CHK2, p53, BRCA1 and H2AX. BRCA1 scaffolds and organises DNA repair 
proteins like BARD1 and BRIP1, involved at step (1). The MRN complex which 
plays a role in DNA end resection in step (2) comprises of Mre11, RAD50 and 
NBS1. Then, it is during the unwinding of the double-stranded DNA that the proteins 
RPA, EXO1 and BLM can access, cleave and remove damaged sections, as shown 
in step (3). As illustrated, the central enzymatic protein, RAD51, can then be loaded 
onto the DNA by BRCA2. Finally, RAD51 nucleoprotein filament invades 
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homologous DNA in step (4) and accurate repair is completed in step (5). (Adapted 
from: [255-257]). 
 
Single-strand annealing, another type of double-strand break repair pathway, 
involves annealing between DNA repeats that become single-stranded following 
resection of broken DNA ends, leading to deletions or changes to DNA structure 
[258]. This pathway is dependent on the key end resection factor, CtIP, and after 
end resection there is annealing of the flanking repeats, followed by removal of the 
non-homologous 3′ single-strand DNA tails, which are mediated by RAD52 and 
ERCC1 [259]. Gaps are then filled by DNA polymerases to allow DNA ligase to 
complete single-strand annealing [259]. Single-strand annealing may be important 
to restore a broken chromosome with double-strand break ends that have 
undergone extensive end resection, but are unable to be resolved other pathways, 
such as alternative end-joining pathway [259]. 
 
The alternative end-joining pathway is also initiated by end resection [259]. It is 
similar to single-strand annealing in that it involves annealing of flanking repeats to 
bridge the double-strand break [259]. While RAD52 plays a conserved mediator role 
in single-strand annealing, it appears dispensable for alternative end-joining [259]. 
Then, alternative end-joining seems to specifically require PARP and DNA 
polymerase theta [259]. 
 
Despite the mutagenicity of non-homologous end-joining, by blunt end ligation 
independently of sequence homology, its fast kinetics has a clear role in protecting 
genome integrity, particularly by Ku80 in the suppression of chromosomal 
translocations [260]. Then, if NHEJ cannot be completed, there are other pathways 
including homologous recombination, single-strand annealing, and alternative end-
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joining, that can be used when DNA has been resected, leaving 3′ single-stranded 
DNA overhangs, demonstrating that the choice of repair mechanism is regulated 
throughout the cell cycle [261]. NHEJ is dominant in G1 and G2, even when both 
repair pathways are functional, and the highest proportion of breaks repaired by HR 
is mid-S-phase [261]. Furthermore, the absence of a sister chromatid for HR in G1 
may support the use of alternative end-joining and single-strand annealing to repair 
resected double-strand breaks in this phase [262]. 
 
Further to the previously discussed PARP family members, PARP-3 has been 
suggested to limit end resection subsequently helping to decide between HR and 
end-joining pathways, partly in cooperation with the Ku70–Ku80 heterodimer [263]. 
This study found that PARP-3 PARsylates Ku70–Ku80, when recruited to DNA 
damage sites, caused limited DNA end resection during HR, while stimulated NHEJ. 
Then, when PARP-3 was deficient, they showed nevertheless that HR is 
significantly reduced, while enhanced end resection causes mutagenic deletions 
during alternative non-homologous end-joining [263]. 
 
HR and alternative non-homologous end joining both occur mostly in S- and G2-
phases, and the mechanism of choice between these pathways has been 
investigated in a study linked to the roles of Polθ and RPA during DSB repair [264]. 
The authors suggest Polθ–helicase helps with the removal of RPA from resected 
DSBs to allow their annealing and subsequent polymerase joining by alternative 
non-homologous end-joining, making Polθ a potential novel cancer drug target 
[264]. 
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5.2.3 RAD51 plays a role in DNA repair and cancer 
Upon exposure to a variety of DNA-damaging treatments, subnuclear foci 
containing RAD51 form, and other recombination proteins including RAD52, BRCA1 
and BRCA2, co-localise with RAD51 [265]. In fact, formation of these foci after DNA 
damage is dependent upon BRCA2 and RAD51 paralogues, indicating an ordered 
assembly is required, and to enable subsequent repair of damage [265]. RAD51 foci 
also appear during S-phase, and these are required to initiate stalled or broken 
DNA replication forks [266]. BRCA2 and RAD51C have both been implicated in 
facilitating nuclear transport of RAD51 [267]. 
 
Alongside its role in regulating nuclear transport and intracellular localisation of 
RAD51, BRCA2 has also been shown to regulate the DNA binding ability of RAD51 
[268]. So, in cells that have BRCA2 inactivation, impairment in these controls may 
be involved in causing genomic instability, and tumourigenesis [268]. This study 
showed that the peptides corresponding to the BRC3 or BRC4 repeats of BRCA2 
bind RAD51 protein and inactivate it with respect to its ability to bind DNA [268]. It 
was suggested that this inactivation was through an inability for RAD51 to self-
associate, and therefore prevent nucleofilament formation, when there is no DNA 
damage [268].  
 
Furthermore, when there is DNA damage, this interaction may also be involved in 
sequestering RAD51 in a ready-state to be brought to damaged sites, upon 
activation of the complex, to then play its role in DNA repair [268]. In Brca2-mutant 
cells, RAD51 may bind damaged DNA in a less productive manner, which may also 
affect RAD51’s state of readiness as well as proper assembly of repair proteins at 
the damaged site, thus causing inefficient HR and genomic instability [268]. 
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Importantly, increased nuclear RAD51 foci number and size represent a hallmark 
for early response to genomic damage [267]. Overexpression of RAD51 also 
increases nuclear RAD51 foci and then formation of higher order RAD51-chromatin 
complexes in the absence of DNA damage, and this has been shown to correlate 
with elevated HR, genomic instability and even increased radiation and drug-
treatment resistance in cancer cells [267]. Hence nuclear RAD51 availability 
requires careful regulation to allow for the right amount of recombination, before and 
after DNA damage [267]. 
 
The role of RAD51 in breast cancer tumourigenesis has not consistently shown the 
same effects, such that in sporadic breast cancers the absence of the tumour 
suppressor protein BRCA1 and overexpression of wild‐type RAD51 has been 
shown to contribute to pathogenesis, whilst another report showed reduced RAD51 
in analysis of breast carcinomas [269, 270].  
 
The functional observations from a study of pancreatic cancer indicated that RAD51 
overexpression enhanced survival of cells after induction of DNA double strand 
breaks [271]. Furthermore, it was suggested that changes in RAD51 may contribute 
to the malignant phenotype for pancreatic cancer [271]. In another study, RAD51 
overexpression was also identified in aggressive prostate cancer [266]. Therefore, 
elevated expression of RAD51 might have diagnostic value in identifying patients 
requiring more immediate treatment, and could be useful when analysing the 
biological basis of aggressive prostate cancer [266]. 
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6.0 Synthetic lethality 
The term synthetic lethality can be described as a type of genetic interaction in 
which occurrence of a specific genetic effect alone does not influence cell survival, 
whilst the co-occurrence of two specific genetic events results in cell death [272]. It 
is probably best known in the context of loss-of-function mutants, but other 
combinations of perturbations also cause synthetic lethality, such as the action of 
chemical compounds [272]. Therefore, the opportunity to exploit this mechanism 
offers the potential for the identification of novel cancer therapies [272]. 
6.1 Identification of synthetic lethal interactions using 
screening approaches 
Compared to standard agents, synthetic lethal targeting of cancer cells is 
therapeutically advantageous in that this approach selectively kills cancer cells with 
a specific genetic mutation [273]. It also offers an increased therapeutic index, 
because of its selectivity for tumour cells, and therefore sparing of normal cells 
[273]. Another advantage of synthetic lethality in cancer treatment is that there is an 
opportunity to target loss-of-function mutations in tumour suppressor genes, which 
may have been previously more difficult to modulate with other strategies, because 
unlike oncogenes there is often no protein to inhibit [273]. 
Synthetic lethal interactions can be identified using screening approaches. In a 
genome-wide RNAi screen which investigated synthetic lethal interactions with the 
frequently mutated Ras gene in cancer cells, a number of genes were found, and 
subsequent inhibition of these proteins was shown to impair Ras mutant cell viability 
[274]. Not only does the screen offer therapeutic options, it also accounts for the 
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gene network supporting the RAS oncogene which can provide further insight into 
tumourigenesis [274]. In another study, genetic and chemical screening were 
integrated to identify E-cadherin synthetic lethal interactions for breast cancer 
patients, as these patients frequently have defects in E-cadherin, a tumour 
suppressor cell adhesion glycoprotein [275]. A drug-sensitivity screen, with drugs 
for clinical use for the treatment of cancer or in late-stage clinical development, and 
a parallel siRNA sensitivity screen were used, and a ROS1 receptor tyrosine 
kinase/E-cadherin synthetic lethal effect was discovered [275]. The synthetic 
lethality observed with ROS1 siRNA was statistically significant and ROS1 
inhibitors, Foretinib and Crizotinib, were identified as candidate synthetic lethal 
drugs, suggesting that the ROS1 effect might be clinically tractable [275]. 
 
The implications of such approaches give rise to advantages and disadvantages, 
regarding therapeutic potential and translational benefits. As such, the advantages 
of RNAi screening include the ability to target any gene within the genome, whilst 
disadvantages include an inability to get a complete gene knockdown [276]. Then 
the advantages of drug screening include easier translation into clinical practice, 
whilst disadvantages include variability in drug specificity [276].  
 
6.2 PARP inhibitors and beyond 
Individuals who have with deleterious heterozygous germline mutations in Brca1/2 
tumour suppressor genes have significantly increased risks of developing breast, 
ovarian and other cancers, because this mutation can cause reduced function and 
less effective DNA repair mechanisms, which would normally act to prevent cancer 
[277]. Loss of the remaining wild-type BRCA allele through a somatic loss-of-
function aberration occurs during tumourigenesis [277]. In HR-deficient cells, other 
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DNA repair pathways can become more predominant, and this can cause 
alterations to the DNA and could contribute to cancer initiation and progression 
[277]. Thus, HR-deficient cells require PARP activity, and PARP inhibitors offer a 
tumour-selective approach in cancer treatment [278] (Figure 7). 
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Figure 7. Synthetic lethality occurs in Brca1/2-deficient cells treated with a 
PARP inhibitor. 
Normal cells (a) have fully functioning DNA repair pathways.  When normal cells are 
treated with a PARP inhibitor (b), causing inefficient single-strand break repair, 
these cells are not susceptible to cell death because the DNA double-strand break 
repair pathways of these cells remain intact. While, in Brca1/2-deficient cancer cells 
(c), these cells have inefficient double-strand break repair mechanisms, and 
therefore have genomic instability. When Brca1/2-deficient cancer cells are treated 
with PARP inhibitor (d), causing inefficient single-strand break repair, these cells are 
susceptible to cell death because DNA double-strand break repair pathways of 
these cells are not intact. (Adapted from: [279, 280]). 
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The first synthetic lethal therapy has been approved for clinical use, and these 
include Olaparib and Rucaparib, which are collectively known as PARP inhibitors 
[40, 278, 281]. These are for patients with Brca1-mutant or Brca2-mutant ovarian 
and breast cancers, and the concept has been illustrated in Figure 7 [39, 40, 278]. 
An increase in DSBs or collapsed replication forks, initiated by PARP inhibition or 
PARP trapping, is said to be the cause of the synthetic lethal interaction between 
harbouring loss of BRCA function and PARP inhibition [277]. 
 
Olaparib represents the first PARP inhibitor to become available in clinical practice, 
where the greatest clinical benefit of this compound has been demonstrated for 
Brca-mutated patients, in clinical trials of patients with ovarian cancer [282]. It has 
also been considered to be well-tolerated by patients, where reported adverse 
effects have included fatigue and anaemia [282]. Furthermore, in proof of concept 
trials, Brca-mutated advanced ovarian cancer and Brca-deficient breast cancers 
showed favourable therapeutic index when treated with Olaparib [283, 284]. 
Response to PARP inhibition has also been shown to correlate with platinum 
sensitivity in ovarian cancer patients, however patients with platinum-resistant 
disease still had potential benefit, but these patients had a lower response rate 
[285]. In breast cancer patients, it was those who had HER2-negative metastatic 
breast cancer and a germline Brca mutation, where Olaparib monotherapy was 
shown to have a significant benefit over standard therapy [39]. 
 
In other studies, a tolerated dose of Olaparib in combination with Cisplatin was 
identified for patients with advanced solid tumours [286]. Antitumour activity was 
observed, and this was more evident in patients with germline Brca1/2 mutations 
[286]. Furthermore, Olaparib in combination with Paclitaxel and Carboplatin, 
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followed by Olaparib maintenance monotherapy, was investigated in recurrent 
platinum-sensitive ovarian cancer patients [287]. This was shown to significantly 
improve progression-free survival, when compared to Paclitaxel with Carboplatin 
alone [287]. The greatest benefit was again for Brca-mutated patients, and there 
was an acceptable and manageable tolerability profile [287].  
 
Furthermore, whilst the role of PARP inhibitors in relapsed ovarian cancer has been 
well-established, less was known about Olaparib as a maintenance therapy in newly 
diagnosed ovarian cancer, and so a trial was conducted to investigate this in these 
patients [288]. The findings of this study showed that Olaparib maintenance therapy 
benefitted patients with newly diagnosed advanced ovarian cancer and a Brca1/2 
mutation, for progression-free survival, and it was also shown that there was a 70% 
lower risk of disease progression or death with Olaparib compared to the placebo 
[288].  
 
A catalytic mechanism of PARP inhibition has been proposed, as well as a PARP1-
trapping model [289]. Since PARP inhibition was shown to delay SSB repair more 
than PARP deletion, this indicated that catalytic inhibition would not be the only 
mechanism of action of PARP inhibitors [289]. PARP1-trapping by PARP inhibitors 
is explained by PARP1 being trapped on DNA, forming PARP1-DNA complexes 
that interfere with DNA replication, and differing potencies have been described for 
different PARP inhibitors [289]. These potency differences may be important when 
designing combination therapies that include PARP inhibitors, to not exceed toxicity 
levels with other therapies such as chemotherapy when given in combination [277].   
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Rucaparib is another FDA-approved PARP inhibitor, and offers a new therapeutic 
option for patients with ovarian cancer [281]. As illustrated when Rucaparib was 
used in a trial of recurrent ovarian cancer patients following platinum therapy 
response, whilst maintenance therapies do offer improved progression-free survival, 
these effects may be transient so there is always a need to develop new therapies 
and optimise treatment strategies [290]. In this study, Rucaparib maintenance 
treatment improved progression-free survival compared with the placebo [290]. As 
observed in patients receiving Olaparib treatment, adverse effects of Rucaparib 
included fatigue [290]. 
 
Further studies of Rucaparib and ovarian cancer have suggested that quantitative 
BRCA1 methylation analysis could provide insight into PARP inhibitor response 
[291]. Near to the BRCA1 transcription start site, methylation of CpG sites is 
associated with reduced BRCA1 mRNA and protein, and when combined with loss 
of heterozygosity in the other allele, loss of functional BRCA1 results [291]. 
Methylation loss has been shown to occur after exposure to chemotherapy and can 
therefore be used as a predictor of response to Rucaparib, as well as emphasising 
that earlier introduction of PARP inhibitor therapy may also benefit patients [291]. 
 
Talazoparib is another FDA-approved PARP inhibitor, and can be used to treat 
patients with deleterious or suspected deleterious germline Brca-mutated, HER2-
negative, locally advanced or metastatic breast cancer [292]. As with the other 
PARP inhibitors, there are adverse effects association with Talazoparib, and the 
most frequent of these is anaemia [292]. In a study of advanced disease breast 
cancer patients with a germline Brca1/2 mutation, the outcome showed that 
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progression-free survival was favoured after single-agent Talazoparib, compared to 
standard chemotherapy [293]. 
 
As previously discussed, PARP inhibitors exert their mechanism by catalytic 
inhibition and PARP1-trapping [289]. Furthermore, it has been suggested that 
PARP1-trapping is more effective at causing cancer-cell death, rather than catalytic 
inhibition alone [293]. Interestingly, studies have shown Talazoparib to be a potent 
PARP inhibitor, not only because of its strong catalytic inhibition, but it also exhibits 
a PARP-trapping potential that is around 100 times greater than other PARP 
inhibitors under current investigation [293]. 
 
In one study, the DNA DSB response proteins ATM and DNA-dependent protein 
kinase (DNA-PK) were knocked out or inhibited to determine the role of these 
proteins in cellular survival, following PARP inhibition [294]. ATM was found to be 
required for PARP inhibitor-induced HR repair, where ATM was shown to be 
activated upon PARP inhibition [294]. Inhibition of DNA-PK was shown to make no 
difference to PARP inhibitor-induced HR, suggesting that PARP inhibition causes 
ATM to have additional functions in the pathway but not DNA-PK [294]. 
 
Use of PARP inhibitors may also be beneficial to more patients characterised by 
other mutations that lead to HR defects, rather than Brca mutations alone [295]. 
Patients with mutations in the tumour suppressor gene PTEN could be responsive 
to PARP inhibitors, where a study has shown synthetic lethal targeting of PTEN 
mutant cells with PARP inhibitors [295]. This is because besides its role as a 
phosphatase in the control of the phosphoinositide 3 kinase signalling pathway, 
PTEN has also been shown to have a role in genome stability, and PTEN-deficiency 
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gives rise to a HR defect which was shown to sensitise cells to PARP inhibitors 
[295].  
 
Another study has shown a functional link between androgen receptor signalling 
and HR in prostate cancer [296]. The study showed that androgen receptor 
signalling regulates HR and promotes MRN foci formation, leading to ATM 
activation [296]. Therefore, inhibition of androgen receptor function is synthetically 
lethal with PARP inhibition [296]. 
 
Studies have also indicated how patient resistance can develop to PARP inhibitors, 
such as secondary mutations in Brca2 [297, 298]. It was shown that resistance to 
therapy could be caused by intragenic deletion in BRCA2 [297]. By understanding 
the implications of these observations, this could not only provide insight into the 
mechanisms of drug resistance in Brca mutation carriers, it may also help in 
defining functionally important domains in BRCA2 [297]. Therefore, a screening 
approach could be adopted to assess for secondary mutations and response to 
PARP inhibitors, and therefore support the guidance of treatment decisions for 
patients [298].  
 
Beyond PARP inhibition and BRCA deficiency, other DNA repair deficiencies have 
been exploited using a synthetic lethal approach. Tumour cells with the defective 
MMR gene MSH2, a tumour suppressor which forms the MutSα complex with 
MSH6, were shown to be selectively sensitive to Methotrexate [299]. In this study, a 
drug screen identified Methotrexate, which caused oxidative DNA damage in all 
cells [299]. This damage was repaired in MSH2-proficient cells but persisted in 
MSH2-deficient cells, indicative of the selectivity offered by this synthetic lethal 
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approach [299]. In a later study, tumour cells defective in MSH2 or another MMR 
gene MLH1, a tumour suppressor which forms the MutLα complex with PMS2, were 
shown to be selectively sensitive to inhibition of particular DNA polymerases [300]. 
It was suggested that accumulation of the DNA base lesion 8-oxoguanine may have 
been responsible for the formation of lethal DNA breaks [300]. Another novel 
candidate therapeutic target for cancers deficient in the MMR pathway was 
identified, using parallel siRNA screens with tumour cell models either proficient or 
deficient in MSH2 or MLH1 [301]. The results showed that silencing of PTEN-
induced putative kinase 1 (PINK1) was synthetically lethal in cells with MSH2, 
MLH1, or MSH6 dysfunction [301]. 
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Aims 
The transcription factor Forkhead Box Protein M1 (FOXM1) has been identified to 
be overexpressed in several types of solid tumours, including breast, ovarian, 
bladder, lung and colon [180]. Therefore, FOXM1 represents an attractive 
therapeutic target in the treatment of cancer patients. However, a number of studies 
have also implicated FOXM1 in chemoresistance, suggesting that targeting FOXM1 
alone may not translate into the clinic as a potential treatment strategy [116-118, 
174, 190]. Our aim was to investigate novel combination therapy strategies, using a 
two-pronged approach, by targeting FOXM1 and exploiting the role of FOXM1 in 
regulating DNA repair genes and oxidative stress genes as a second target [116-
119, 302, 303]. To this end, we aimed to: 
 
Investigate Thiostrepton and Olaparib as a combination therapy and its mechanistic 
implications 
 
Investigate the role of FOXM1 in the oxidative stress response and its therapeutic 
implications 
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Materials and 
Methods   
Chapter 2 
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1.0 Cell culture 
1.1 Cell lines and reagents 
The non-tumourigenic breast epithelial cell line MCF10A was kindly provided by the 
Bianchi lab, Barts Cancer Institute (BCI). The human breast cancer cell lines 
BT474, HCC1954, HS578T, MCF7 and MDA-MB-453 were kindly provided by the 
Schmid lab, BCI. The human breast cancer cell line SKBR3 was kindly provided by 
the Kermorgant lab, BCI. The human ovarian cancer cell lines Ovcar4, Ov4cis and 
Ov4carbo were kindly provided by the Lockley lab, BCI. Medium requirements for 
each cell line are detailed in Table 1. Dulbecco’s Modified Eagles medium (DMEM) 
(REF 41966-029), Roswell Park Memorial Institute medium (RPMI) (REF 21875-
034), Fetal Bovine Serum (FBS) (REF 10500-064) and penicillin-streptomycin (REF 
15140-122) were all purchased from Gibco. For the MCF10A cell line additional 
supplements, purchases were as follows: horse serum (Sigma H1138), EGF 
(Peprotech AF-100-15-1000), hydrocortisone (Sigma H4001-1G), cholera toxin 
(Sigma C8052) and insulin (Gibco 12585-014). 
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Table 1. List of cell lines used in project, including cell type and medium 
requirements. 
 
 
 
 
Cell line Cell type Medium requirements 
MCF10A Normal breast  DMEM/F12 +5% horse serum 
+20ng/mL EGF +0.5ug/mL 
hydrocortisone +100ng/mL cholera 
toxin +10ug/mL insulin +1% penicillin-
streptomycin 
BT474 Breast cancer  RPMI +10% FBS +1% penicillin-
streptomycin 
HCC1954 Breast cancer  RPMI +10% FBS +1% penicillin-
streptomycin 
HS578T Breast cancer  DMEM +10% FBS +1% penicillin-
streptomycin 
MCF7 Breast cancer  RPMI +10% FBS +1% penicillin-
streptomycin 
MDA-MB-
453 
Breast cancer  DMEM +10% FBS +1% penicillin-
streptomycin 
SKBR3 Breast cancer  DMEM +10% FBS +1% penicillin-
streptomycin 
Ovcar4 Ovarian cancer, parental DMEM +10% FBS +1% penicillin-
streptomycin 
Ov4cis Ovarian cancer, Cisplatin-
resistant 
DMEM +10% FBS +1% penicillin-
streptomycin 
Ov4carbo Ovarian cancer, Carboplatin-
resistant 
DMEM +10% FBS +1% penicillin-
streptomycin 
97 
 
1.2 Growing and seeding conditions 
All cell lines were grown in T75 flasks, at 37°C, 5% CO2. Cell lines were passaged 
at 70% confluency and medium was refreshed every 3-4 days. Cell lines were kept 
up to and including passage 12, from thawing. Stocks of each cell line were made 
up in FBS + 10% dimethyl sulfoxide (DMSO) (Fisher Chemical D/4121/PB08) and 
subsequently stored at -80°C or liquid nitrogen. Cells were visually monitored and 
regularly tested for mycoplasma. 
 
To passage cell lines, old medium was aspirated from the flask and cells were 
washed with 1x phosphate buffered saline (PBS). Next, 3mL 1x trypsin (Gibco R-
001-100) was added to the flask and cells were incubated at 37°C for 3-5min, or 
until cells detached. 7mL of medium was then added to neutralise the trypsin and 
cell suspension was centrifuged (1200rpm, 3min). Medium was aspirated from cell 
pellet and cell pellet was resuspended in 10mL of fresh medium. The required 
volume of cell suspension was aliquoted into a new flask to grow until the next 
passage. 
 
For experimental setup, cells were passaged as described. Before cell suspension 
was returned to a new flask, cells were counted and seeded depending upon 
required seeding density. A cell counter slide (Invitrogen Countess) was used to 
count cells, where 10µL of cell suspension was added to the slide to calculate the 
number of cells in the cell counter (Invitrogen Countess II). An average was 
calculated based on counts, and cells were seeded for the experiment.  
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2.0 Protein expression analysis 
2.1 Protein extraction 
All steps involving protein isolation were carried out on ice. Cells were washed with 
1x PBS and lysed using RIPA buffer (150mM NaCl, 1%(v/v) IGEPAL-630 (Sigma 
I8896-100mL), 0.5%(w/v) sodium deoxycholate (Sigma D6750-25G), 0.1%(w/v) 
SDS (10% solution Severn Biotech 20-4000-10), 50mM Tris, Protease inhibitor 
(Roche 11836170001) (1 tablet in 50mL); dissolved in H2O; pH 8). Cells were 
immediately scraped in the RIPA buffer and the entire well contents was transferred 
to a microcentrifuge tube, and incubated on ice for a further 5-10min. Samples were 
then vortexed and centrifuged (12000rpm, 5min, 4°C). The supernatant was 
transferred to a new microcentrifuge tube and isolated protein was stored at -80°C. 
 
For protein quantification, Bradford reagent (Sigma B6916-500mL) was used to 
generate a standard curve of bovine serum albumin (BSA) (Sigma A9647-100G) 
and to subsequently determine the concentration of our protein sample. Absorbance 
630 was measured on the plate reader (Fluostar Omega BMG Labtech). 
 
2.2 Western blotting 
To prepare samples to load on the gel, 30µg of protein lysate was combined with 
10% dithiothreitol (DTT) (Thermo Scientific R0862) and 4x NuPage LDS sample 
buffer (Invitrogen NP0007) to a final volume of less than 40µL per well. This mix 
was incubated (5min, 95°C) prior to gel loading. Samples were then pulse 
centrifuged and electrophoresed following the NuPAGE system (4-12% Bis-Tris 
protein gels, Invitrogen NP0335BOX) (20x Running buffer, Invitrogen NP0001-02) 
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for 80min at 130V. A protein ladder (Amersham RPN800E) was run alongside our 
samples. Gels were transferred onto nitrocellulose membrane (Thermo Scientific 
88018), using a wet-transfer method for 2hr at 25V. 
 
Membranes were then blocked with either 5% BSA-TBS-T or 5% milk-TBS-T (1 
hour, room temperature) (milk powder, Sigma 70166-500G; 10x TBS, Severn 
Biotech 20-7301-10; Tween, Fluka P1379-500mL). Next, the membranes were 
probed with the desired primary antibody (overnight, 4°C), following the dilutions 
listed in Table 2. The membranes were then incubated in their respective secondary 
antibody (1:4000, anti-rabbit or anti-mouse), diluted in 5% milk-TBS-T or 5% BSA-
TBS-T (1 hour, room temperature). Protein levels were detected by 
chemiluminescence (SuperSignal West Pico PLUS Chemiluminescent Substrate, 
Thermo Scientific 34578) on x-ray films. Immunoblotting for β-actin or β-tubulin 
served as loading controls.  
 
Quantification of Western blots was carried out using ImageJ software for three 
independent experiments. 
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Table 2. List of antibodies used in project, including standard dilution. 
 
 
 
 
 
 
 
Antibody name Company and code Standard dilution 
FOXM1 Abcam ab58675 1:500 
FOXM1 (D12D5) XP Cell Signaling #5436 1:1000 
Gpx1 Cell Signaling #C8C4 1:1000 
Phospho-NRF2, phospho 
S40 
Abcam ab76026 1:1000 
Total NRF2 Abcam ab137550 1:1000 
NQO1 Cell Signaling #3187S 1:3000 
RAD51 Abcam ab63801 1:1000 
SOD1 Cell Signaling #71G8 1:1000 
β-actin Cell Signaling #4970L 1:10000 
β-tubulin Cell Signaling #2146S 1:10000 
β-tubulin Cell Signaling #86298S 1:10000 
Secondary rabbit Dako P0448 1:4000 
Secondary mouse Dako P0447 1:4000 
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3.0 mRNA expression analysis  
3.1 RNA extraction 
Cells were lysed with RLT buffer from the RNeasy Mini Kit (Qiagen 74106), and 
subsequent steps were followed according to the manufacturer’s instructions for the 
kit. To summarise, cells were scraped in the RLT buffer and transferred to a 
microcentrifuge tube, for each well, and debris was centrifuged (12000rpm, 3min). 
The supernatant was transferred to a new tube and 70% ethanol was added to 
lysate. After mixing, the contents were then transferred to an RNeasy Mini spin 
column with collection tube. The column was centrifuged (8000rpm, 15sec) and the 
flow-through was discarded. Next, RW1 was added to the column and centrifuged 
(8000rpm, 15sec). There were then two RPE wash steps at (8000rpm, 15sec) and 
(8000rpm, 2min), respectively. The columns were then placed into new collection 
tubes and 50µL RNase-free water was added to each column and left to incubate 
(10min, room temperature). Once incubated, columns were spun (8000rpm, 1min) 
and RNA was eluted and collected.  
 
For RNA quantification, the Nanodrop 2000 Spectrophotometer (Thermo Scientific) 
was used and a blank sample was always measured first before our RNA sample. 
 
3.2 RT-qPCR 
The High capacity cDNA reverse transcription kit (Applied Biosystems) was used to 
prepare cDNA from our total RNA samples. A total of 20µL was made up for each 
reaction mix, with fixed volumes of 10x buffer (2µL), dNTPS (0.8µL), RT random 
primers (2µL) and reverse transcriptase (1µL). Upon RNA quantification, 500ng of 
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RNA was added to each reaction mix, and the final volume of 20µL was made up 
with RNase-free water. The following Thermocycler reverse transcription settings 
were used to generate cDNA for each reaction mix: Stage 1 25°C 10min; Stage 2 
37°C 60min, 37°C 60min (machine maximum time is 60min so x2 60min set); Stage 
3 85°C 5min; and, End 4°C (Applied Biosystems, Veriti 96 well Thermocycler). 
 
For real-time quantitative PCR (RT-qPCR), cDNA (0.5µL) and desired Taqman 
probe (0.5µL) was added to Taqman Universal PCR Master Mix (Applied 
Biosystems) (5µL) and H2O (4µL), for number of wells required. Each sample was 
assayed in duplicate, where relative mRNA levels were determined according to the 
ΔΔCt method and subsequently normalised to the level of beta-actin mRNA. RT-
qPCR plates were run in QuantStudio 5 (Applied Biosystems). The Taqman probes 
used are listed in Table 3. 
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Table 3. List of Taqman probes used in project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.0 Gene silencing 
4.1 6-well plate siRNA transfection 
4.1.1 Single siRNA transfection 
To obtain protein and RNA from siRNA-transfected cells, cells were seeded in 6-
well plates at optimal density on day 1 and transfected with 50nM siRNA (20µM 
stocks), according to the manufacturer’s guide, on day 2. In summary, 250µL 
optiMEM (Gibco 31985-062) was incubated with 5µL transfection reagent for 5min 
at room temperature. Then 5µL of required siRNA was added and incubated for 
Probe name Code 
BRCA2 Hs00609073_m1 
BRIP1 Hs00908143_m1 
FOXM1 Hs01073586_m1 
MTCO1 Hs02596864_g1 
NBS1 Hs01039845_m1 
NRF1 Hs01031046_m1 
NRF2 Hs00975961_g1 
PPARGC1 Hs01016719_m1 
RAD51 Hs00947967_m1 
β-actin Hs01060665_g1 
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20min at room temperature, per well. Lipofectamine RNAiMAX (Invitrogen 13778-
150) was used for siRNA transfection of all cell lines. Medium was aspirated and 
replaced with fresh medium, in each well. The transfection mix of optiMEM + 
RNAiMAX + siRNA was added dropwise to each respective well. Medium was 
refreshed 5-hours post-transfection, in each well. The control siRNA solutions 
AllStars negative control siRNA (siCon) and positive control Hs_PLK1 siRNA 
(siPLK1) were used in each experiment. The FOXM1-targeting siRNAs used were: 
siFOXM1(5) (Qiagen), siFOXM1(6) (Qiagen), and siFOXM1(pool) (Dharmacon). 
The NQO1-targeting siRNA used was siNQO1(pool) (Dharmacon). Silencing was 
observed across different time-points (mainly at 48-hours, 72-hours and 96-hours 
post-transfection for 6- and/or 96-well plate setup). 
 
4.1.2 Double siRNA transfection 
The protocol used was similar to single siRNA transfection (section 4.1.1). The 
difference in this protocol was the amount of siRNA used for each condition in each 
well. In double siRNA-transfected wells, 5µL of siRNA (50nM final concentration) 
were used of each siRNA. For wells that contained controls and single siRNA 
transfections, an additional 5µL of AllStars negative control siRNA was added to 
account for the two siRNAs used in the double siRNA-transfected well. Besides the 
amount of siRNA used, the protocol remained the same as Section 4.1.1. 
 
4.2 96-well plate siRNA transfection  
4.2.1 Single siRNA transfection 
To assess the effect of specific siRNA transfection on cell viability, cells were 
seeded in 96-well plates at optimal density on day 1 and transfected with 50nM 
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siRNA (2µM stocks), according to the manufacturer’s guidelines, on day 2. In 
summary, 24.75µL optiMEM was incubated with 0.25µL transfection reagent for 
5min at room temperature. Then 2.5µL of required siRNA was added and incubated 
for 20min at room temperature, per well. The transfection reagent used is as listed 
in 4.1. Medium was aspirated and replaced with fresh medium, in each well. The 
transfection mix of optiMEM + RNAiMAX + siRNA was added to each respective 
well. Medium was refreshed 5-hours post-transfection, in each well. The control 
siRNA solutions and FOXM1-/NQO1-targeting siRNAs used are as listed in Section 
4.1. Silencing was observed across different time-points (mainly at 48-hours, 72-
hours and 96-hours post-transfection for 6- and/or 96-well plate setup).  
 
4.2.2 Double siRNA transfection 
The protocol used was similar to single siRNA transfection (Section 4.2.1). The 
difference in this protocol was the amount of siRNA used for each condition in each 
well. In double siRNA-transfected wells, 2.5µL of siRNA (50nM final concentration) 
were used of each siRNA. For wells that contained controls and single siRNA 
transfections, an additional 2.5µL of AllStars negative control siRNA was added to 
account for the two siRNAs used in the double siRNA-transfected well. Besides the 
amount of siRNA used, the protocol remained the same as Section 4.2.1. 
 
5.0 Compounds used 
All compounds were diluted and stored according to the manufacturer’s instructions 
(Table 4).  
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Table 4. List of compounds used in project. 
 
 
 
6.0 Cell viability analysis 
6.1 Cell-Titer Glo assay 
The Cell-Titer Glo reagent (Promega G7573) was diluted 1 in 4 with 1x PBS. 
Medium was aspirated from each well and 100µL Cell-Titer Glo + PBS mix was 
added to each well. Next, the plate was put on the plate shaker for 2min at a low 
speed and then incubated for 10min at room temperature. Luminescence was 
measured on the plate reader as a measure of cell viability in each well. 
Compound name Reconstituted in, stock Company and code 
Thiostrepton DMSO, 50mM Chemcruz sc-203412A 
Olaparib DMSO, 10mM Cambridge Bioscience 
CAY10621 
Menadione DMSO, 10mM Sigma M9429 
Podophyllotoxin Ethanol, 10mM Sigma P4405 
Diminutol DMSO, 10mM Santa Cruz Biotechnology 
sc-203923 
Cisplatin H2O, 1mg/mL Adooq Bioscience 15663-
27-1 
Carboplatin H2O, 10mg/mL Cambridge Bioscience 
CAY13112 
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7.0 Colony formation analysis 
7.1 Sulforhodamine B assay 
To assess the colony formation ability of cells upon drug treatment, cells were 
seeded in 6-well plates at optimal density on day 1, and treated with single agents, 
combination agents or vehicle control on day 2. The cells were subsequently 
retreated every 2-3 days, where old medium was removed and fresh drug was 
added to each well. Colony formation was measured by the sulforhodamine B 
(SRB) (Sigma S1402-5G) assay, once distinct colonies had formed, on day 10-14. 
 
For the SRB assay, old medium was aspirated and 1x PBS was used to gently 
wash each well. Next, 1mL of methanol (stored at -20°C) (Fisher M/3950/17) was 
added to each well to fix the cells, and incubated for 10min at room temperature, 
and then aspirated off. The wells were then left at room temperature to air dry. 
Plates could be stored at this step, or proceed directly to SRB staining. For SRB 
staining, 1mL of SRB stain was added to each well and incubated for 30min at room 
temperature, and then aspirated off. To wash away excess SRB, 1% acetic acid 
(Fluka 607-002-00-6) was used to wash each well four times and the plates were 
finally left to air dry overnight at room temperature. Colonies were either counted by 
eye or they were dissolved. In the case of counting by eye, a pen was used to mark 
the bottom of the plate to count each colony. Alternatively, colonies were dissolved 
in 2mL Tris pH 10.5 and absorbance was read at 490nm on a plate reader. 
108 
 
8.0 Confocal microscopy 
8.1 γH2AX staining 
To assess the levels of DNA double-strand breaks in our cells upon drug treatment, 
cells were seeded onto poly-L-lysine-coated coverslips (Corning 354085) in 24-well 
plates at optimal density on day 1, and treated with agents alone, agents in 
combination or vehicle control on day 2. Differences in γH2AX foci, a marker of 
DNA double-strand breaks, which formed upon treatment with agents alone and 
agents in combination were measured in cancer cells.  
 
At the selected time-point post-treatment, cells were fixed in 4% paraformaldehyde 
(PFA) (Sigma Aldrich P6148-1KG) 2% sucrose in 1x PBS and incubated for 15min 
at room temperature. Cells were then washed twice in 1x PBS. Next, 500µL of 
blocking buffer (1% BSA, 0.1% Tween in 1x PBS) was added to each coverslip. 
Plates were wrapped in cling film and stored at 4°C until two days before confocal 
microscopy.  
 
The blocking buffer was then aspirated off the cells, and coverslips were washed 
twice in 1xPBS. Then 400µL 0.5% Triton (BDH 306324N) in 1x PBS was added to 
each coverslip and incubated for 10min at room temperature, followed by two 1x 
PBS washes. The coverslips had blocking with 400µL blocking buffer for 1 hour at 
room temperature. After blocking, 400µL of primary antibody (γH2AX, 1:800) 
(Millipore 05-636) in 2% BSA PBS was added. Plates were wrapped in cling film 
and incubated at 4°C overnight.  
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The primary antibody was aspirated off the cells, and coverslips were washed three 
times in 1x PBS at low speed on the plate shaker. Following the washes, 400µL of 
secondary antibody (anti-mouse ALEXA 488 (green), 1:1000) (Invitrogen A11001) 
in 2% BSA PBS was added and coverslips were incubated for 1hr, protected from 
light, at room temperature. Coverslips were then washed three times in 1x PBS. 
Following the washes, cells were stained with DAPI (1:10000, 1mg/mL) in 1x PBS 
and incubated for 1min at room temperature. Coverslips were washed twice in 1x 
PBS and the slides were mounted with Mowiol (5µL/slide) (Calbiochem 475904). 
 
The coverslips were imaged using the confocal LSM 710 microscope (Zeiss), where 
the 63x oil objective was used to capture images of cells for each condition tested. 
ImageJ was used to quantify the images and percentages were calculated 
comparing to the total number of cells (quantified by γH2AX and DAPI staining). 
Approximately 150 cells were analysed per condition and cells containing more than 
5 γH2AX foci were considered positive for DNA double-strand breaks. Previous 
studies have shown that more than 5 foci per cell are considered positive for DSBs 
[278, 300, 304, 305], so we selected this to be the cut off in our experiments. 
 
9.0 Reactive oxygen species assay 
9.1 DCFDA cellular ROS detection 
DCFDA Cellular ROS Detection Assay Kit (Abcam, ab113851) uses 2’,7’ –
dichlorofluorescin diacetate (DCFDA), a fluorogenic dye that enters the cell and 
measures hydroxyl, peroxyl and other reactive oxygen species activity. DCFDA is 
first deacetylated by cellular esterases, and this is a non-fluorescent compound. 
ROS then oxidise this into 2’, 7’ –dichlorofluorescein (DCF), a highly fluorescent 
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compound. Fluorescence spectroscopy can be used to detect this fluorescence, 
with excitation / emission at 485 nm / 535 nm. 
 
To evaluate the generation of ROS upon drug treatment, cells were seeded in two 
96-well plates at optimal density on day 1. To measure ROS, a dark, clear bottom 
96-well plate was used. The second 96-well plate was used to measure cell viability, 
in parallel. Cells were treated the same in both 96-well plates, for ROS and cell 
viability, with the agents alone, the agents in combination or vehicle control on day 
2. At our selected treatment end-point, cells in the ROS plate were stained with the 
cell permeant reagent 2’,7’ –dichlorofluorescin diacetate (DCFDA), based on the 
manufacturer’s guidelines (Abcam, ab113851, DCFDA Cellular ROS Detection 
Assay Kit). The cell viability plate was kept in the incubator until measuring the 
luminescence end-point. In order to assess the level of ROS in the cells, medium 
was removed from the cells, and cells were then washed with 1x PBS. Cells were 
then stained with 25M DCFDA solution and incubated for 45min at 37C, in the 
dark. After this incubation, DCFDA solution was removed and this was followed by a 
1x PBS wash. After the 1x PBS was aspirated, 1x buffer was added to the cells and 
incubated for 4 hours at 37C. Fluorescence was measured on the plate reader 
Ex/Em = 485/535nm in the ROS plate, and luminescence was measured on the 
plate reader in the cell viability plate using the CTG assay (Section 6.1). Tert-Butyl 
Hydrogen Peroxide (TBHP) solution was used as the positive control for ROS, and 
1x buffer alone was used as the negative control. 
 
Once the ROS data and CTG data had been normalised to their respective vehicle-
treated controls, the ROS data was subsequently normalised to its equivalent CTG 
data to ensure that reduction in ROS levels was not due to a reduced cell number. 
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10.0 Drug dose response curves 
10.1 Cell viability  
Cells were seeded in 96-well plates at optimal density on day 1, and treated with 
increasing concentrations of the indicated compounds (Table 4) or relevant vehicle 
control on day 2. Cell viability was measured using Cell-Titer Glo (Section 6.1) on 
day 5. 
 
11.0 Drug combination analyses 
11.1 Cell viability 
Cells were seeded in 96-well plates at optimal density on day 1, and treated with 
agents alone, agents in combination or vehicle control on day 2. For Thiostrepton 
and Olaparib drug combination analyses, cells were subsequently retreated on day 
7, where medium was removed and fresh drug in medium was added to each well. 
CTG was measured on day 10 (Section 6.1). For Thiostrepton and Diminutol drug 
combination analyses, cells were not retreated and CTG was measured on day 6 
(Section 6.1). For Thiostrepton and Menadione drug combination analyses, cells 
were retreated on day 7 and CTG was measured on day 10 (Section 6.1). 
 
11.2 Colony formation  
Cells were seeded in 6-well plates at optimal density on day 1, and treated with 
agents alone, agents in combination or vehicle control on day 2. The cells were 
subsequently retreated on day 5 and day 8, where medium was removed and fresh 
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drug in medium was added to each well at each retreatment. Colony formation was 
measured on day 11 (Section 7.1). Colonies were counted by eye or dissolved.  
 
11.3 γH2AX staining  
Cells were seeded in 24-well plates at optimal density on day 1, and treated with 
agents alone, agents in combination or vehicle control on day 2. For Thiostrepton 
and Olaparib drug combination analyses, coverslips were fixed on day 3, 24-hours 
post-treatment. For Thiostrepton and Diminutol drug combination analyses, 
coverslips were fixed on day 4, 48-hours post-treatment (Section 8.1). 
 
11.4 DCFDA cellular ROS detection  
Cells were seeded in a cell viability 96-well plate and a ROS dark, clear bottom 96-
well plate, at optimal density on day 1, and treated with agents alone, agents in 
combination or vehicle control on day 2. For Thiostrepton and Diminutol drug 
combination analyses, cells were DCFDA-stained on day 2, 3-hours post-treatment 
(Section 9.1). 
 
12.0 Bioinformatics  
Using the TCGA-BRCA database, breast cancer RNA-seq data was used to 
generate “survival: median dichotomisation” graphs, where tumour samples was 
represented as n=1,092. These analyses were performed independently for low 
expression and high expression of FOXM1, and also for RAD51.  
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13.0 Data analysis and representation  
All graphs were generated using Prism software. In graphs where multiple repeats 
were represented, error bars were plotted as standard error of the mean (SEM). In 
graphs where a single repeat was represented, standard deviation (SD) was plotted 
for error bars.  
 
As a t-test is used to determine if there is a significant difference between the 
means of two groups, which may be related in certain features, we considered this 
test to be the most appropriate to be used in our data analyses. Therefore, a t-test 
was used for analysis between two sets of data, where two-sided, unpaired tests 
were carried out. When a t-test showed statistical significance, the p-value was 
listed as <0.05*, <0.01**, <0.001***, or <0.0001****, depending upon the level of 
significance. 
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Results 
Chapter 3 – Investigating Thiostrepton and Olaparib as a 
combination therapy and its mechanistic implications 
 
Chapter 4 – Investigating the role of FOXM1 in the oxidative 
stress response and its therapeutic implications  
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Chapter 3 - Investigating Thiostrepton and Olaparib 
as a combination therapy and its mechanistic 
implications 
 
 
1.0 Basal FOXM1 and RAD51 expression levels in 
cancer 
1.1 Expression levels of FOXM1 and the homologous 
recombination protein RAD51 vary in different cancer 
cell lines 
Previous studies have indicated Foxm1 as a candidate gene for targeted therapy 
and diagnostics in cancer, and it was found to be highly overexpressed in almost 
every tumour analysed [180]. FOXM1 overexpression has been strongly correlated 
with poor prognosis in breast cancer [168]. As FOXM1 is known to play a role in 
regulating DNA repair genes [115], this may offer a target for a combined therapy in 
cancer cells. The potential of exploiting synthetic lethality in cancer cells with 
FOXM1 overexpression has already been shown in a similar premise, where drug-
resistant glioblastoma cells were sensitised to Temozolomide through FOXM1 
inhibition, and a subsequent downregulation of the homologous recombination 
protein, RAD51 [116]. Furthermore, Rad51 was identified to be under the 
transcriptional regulation of FOXM1, where re-expression of RAD51 in FOXM1-
depleted cells gave partial rescuing of Temozolomide resistance [116]. In this study, 
we aimed to develop a combination therapy, to target FOXM1 and a reduced 
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homologous recombination pathway, as well as to understand the mechanistic basis 
for this potential combination treatment. 
 
We first determined whether basal FOXM1 levels varied in our cell line panels which 
included breast cancer, ovarian cancer, mesothelioma, bladder cancer and 
colorectal cancer. In recurrent glioblastoma multiforme tumour samples, FOXM1 
expression has previously been directly correlated with RAD51 expression [116]. 
Therefore, we next assessed basal expression levels of RAD51 in each of our cell 
line panels, so that we could identify if FOXM1 levels correlated with RAD51 levels 
in other cancer types. The non-tumourigenic breast epithelial cell line MCF10A was 
also included in the breast cell line panel to compare against the breast cancer cell 
lines. Expression levels of MCF10A cells is therefore important to consider when 
developing therapeutic options for cancer patients, in order to spare their normal 
cells. 
 
For the breast cancer cell line panel, upon quantification of the Western blots 
(Figure 8A(i)), MDA-MB-453 and BT474 showed that when FOXM1 expression level 
was high, RAD51 expression level was also high. The opposite was observed for 
MCF7 and HS578T, such that when FOXM1 expression level was low, RAD51 
expression level was also low. MCF10A and HCC1954 had variation in the different 
isoforms of FOXM1, but both cell lines had high RAD51 expression levels. 
 
For the ovarian cancer cell line panel, upon quantification of the Western blots 
(Figure 8B(i)), one FOXM1 isoform (bottom band) was more greatly expressed than 
the other (top band) across all cell lines. The lowest expression of FOXM1 (top 
band) also correlated with the lowest expression of RAD51 in PEO4. 
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For the mesothelioma and bladder cancer cell line panel, upon quantification of the 
Western blots (Figure 8C(i)), the FOXM1 isoform (bottom band) was expressed 
lower in Ju77S, compared to other mesothelioma cell lines. Whilst the other FOXM1 
isoform (top band) was expressed higher in MSTO compared to other 
mesothelioma cell lines. FOXM1 expression levels do not seem to correlate with 
RAD51 expression levels in mesothelioma or bladder cancer cell lines. 
 
For the colorectal cancer cell line panel, upon quantification of the Western blot 
(Figure 8D(i)), both of the FOXM1 isoforms were expressed higher in SW48 and 
SW620, compared to the other cell lines. FOXM1 expression levels do not seem to 
correlate with RAD51 expression levels in colorectal cancer cell lines. 
 
As this experiment is not N=3 this is a caveat, and must be taken into consideration 
when making conclusions. This also applies to later experiments that are not N=3. 
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Figure 8. FOXM1 and RAD51 expression in cancer cell line panels. 
Whole cell lysates were isolated for a panel of (A) (Ai) breast cancer cell lines, (B) 
(Bi) ovarian cancer cell lines, (C) (Ci) mesothelioma and bladder cancer cell lines, 
and (D) (Di) colorectal cancer cell lines, and analysed on a Western blot and probed 
with FOXM1 and RAD51 antibodies. β-tubulin was used as a loading control. N=1. 
Image J was used to quantify Western blots. 
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We used our breast cancer cell lines as a model for the rest of our study on 
targeting FOXM1 and homologous recombination. This is because FOXM1 and 
RAD51 expression showed correlation in some breast cancer cell lines (Figure 8A), 
and these differences may reflect the effectiveness of a therapy for treating cancer 
patients. 
 
We selected a range of breast cancer cell lines in this project, to have a 
representative cell line from a number of different breast molecular subtypes. The 
breast cancer cell lines HCC1954, BT474, and SKBR3, are all in the HER+ subtype. 
The HS578T breast cancer cell line is Triple Negative Breast Cancer (TNBC) 
subtype, Basal B subgroup. While, the MDA-MB-453 breast cancer cell line is 
TNBC subtype, Basal A subgroup. The MCF7 breast cancer cell line is the only ER+ 
subtype, Luminal A subgroup. Finally, the MCF10A human breast epithelial cell line 
was selected as the model of “normal”, as one of the most commonly used normal 
breast cell models [306]. The MCF10A cell line was ultimately, upon our 
investigation, not an optimal model of normal in terms of FOXM1 expression, 
because FOXM1 is highly expressed in this cell line. Then, normal cells in a cancer 
patient may need low expression levels of FOXM1 to have a tolerable toxicity to 
FOXM1 inhibition [183]. Furthermore, when the MCF10A cell line was previously 
evaluated as a reliable model for normal human mammary epithelial cells, the 
results did challenge the model [306]. This study showed that there are differences 
in marker expression profiles between MCF10A cells in 2D culture as well as 3D 
culture, compared to normal mammary tissue [306]. Therefore, the MCF10A cell 
line may not be a suitable model for normal breast epithelial cells, in general. 
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Figure 9. High expression of FOXM1 and high expression of RAD51 correlate 
with reduced survival probability. 
Using The Cancer Genome Atlas (TCGA) database, patients were compared for 
low and high expression of FOXM1 and RAD51, independently (P>0.05 for 
multivariate analysis).  
 
We also investigated whether this relationship between FOXM1 and RAD51 
translated beyond our initial in vitro studies, and we carried out bioinformatics 
analysis using breast cancer patient data from the TCGA database. From this broad 
analysis, we established that there was a significant correlation between patients 
that had either high FOXM1 expression or high RAD51 expression, and a reduced 
survival probability (Figure 9). Further investigation is required to determine whether 
those patients with high FOXM1 expression levels also have high RAD51 
expression levels. 
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2.0 Analysing the sensitivity of breast cancer cells to 
Thiostrepton and to Olaparib 
2.1 Treatment with the FOXM1 inhibitor Thiostrepton 
and the PARP inhibitor Olaparib reduced cell viability  
Based on our data demonstrating FOXM1 and RAD51 correlate in breast cancer 
cells (Figure 8A), and that this also seems to be evident in breast cancer patients 
(Figure 9), we subsequently explored the therapeutic strategy of targeting FOXM1 
and a reduced homologous recombination pathway. To this end, we used the FDA-
approved FOXM1 inhibitor, Thiostrepton, and the FDA-approved PARP inhibitor, 
Olaparib, in our breast cancer cells.  
 
The PARP inhibitor Olaparib is FDA-approved for clinical treatment of patients with 
mutations in HR genes, Brca1 and Brca2, in ovarian cancer and, more recently, 
breast cancer [39, 40]. Olaparib is a targeted treatment that causes cell death of 
cancer cells only, sparing normal cells, through synthetic lethality [307]. Inhibition of 
PARP, by Olaparib, combined with a mutation in the cancer cell such as Brca1-
deficiency, will together cause cancer cell death [307]. Based on these current uses 
of Olaparib, this is what made it the ideal compound to be used in combination with 
Thiostrepton in our study. Thus, on the basis of the role of FOXM1 in the DNA 
damage response and the mechanism of action of Olaparib, we hypothesised that 
inhibiting FOXM1 will then reduce the levels of essential DNA repair HR proteins, 
including RAD51, and sensitise these cells to Olaparib.   
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We first determined whether treatment with Thiostrepton and Olaparib alone caused 
any effect on cell viability in our breast cancer cells. We treated cells with either 
increasing concentrations of the FOXM1 inhibitor Thiostrepton (Figure 10A-D) or the 
PARP inhibitor Olaparib (Figure 11A-F) for 72-hours, and analysed cell viability.  
 
Initially, a range of Thiostrepton and Olaparib concentrations were tested and this 
was modified according to cell sensitivity. For subsequent experiments, these 
ranges also helped selection of concentrations that would not be too toxic to the cell 
for the type of experiment. 
 
 
Figure 10. Sensitivity of a panel of breast cancer cell lines, and MCF10A, to 
Thiostrepton treatment. 
A panel of breast cancer cells A) HCC1954 and MCF7, B) MDA-MB-453 and 
BT474, C) MCF10A, and D) HS578T, were plated in a 96-well plate and treated with 
increasing concentrations of Thiostrepton, as indicated. Cell viability was analysed 
using an ATP-luminescent assay 72-hours post-treatment. Data was normalised to 
vehicle (DMSO) control. N=2 (HCC1954 and MCF7) and error bars represent SEM. 
N=1 (MDA-MB-453, BT474, MCF10A, HS578T) and error bars represent SD. 
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Table 5. IC50 values for breast cancer cell lines, and MCF10A, treated with 
Thiostrepton. 
 
Our results suggested that our breast cancer cell lines and our non-tumourigenic 
breast epithelial cell line MCF10A responded in a similar therapeutic window to the 
FOXM1 inhibitor, Thiostrepton, up to around 5µM (Figure 10A-D). The breast 
cancer cell lines HS578T (IC50 4.3µM, Table 5), MDA-MB-453 (IC50 out of range, 
Table 5) and BT474 (IC50 2.5µM, Table 5) were the least sensitive to Thiostrepton, 
compared to the other breast cancer cell lines. Interestingly, MDA-MB-453 and 
BT474 cells showed some of the highest expression levels of FOXM1 (Figure 8A), 
so it could be that these cells are still able to resist Thiostrepton at this particular 
concentration. In contrast, our non-tumourigenic breast epithelial MCF10A cells and 
our HCC1954 breast cancer cells were the most sensitive cell lines to Thiostrepton 
(Table 5). These cell lines also showed some of the higher expression levels of 
FOXM1 (Figure 8A), so it could be that these cells are more dependent on FOXM1 
for cell viability.  
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Figure 11. Sensitivity of a panel of breast cancer cell lines to Olaparib 
treatment. 
A panel of breast cancer cells A) MCF7, B) HS578T, C) BT474, D) MDA-MB-453, E) 
Ei) HCC1954, and F) Fi) SKBR3, were plated in a 96-well plate and treated with 
increasing concentrations of Olaparib, as indicated. Cell viability was analysed 
using an ATP-luminescent assay 72-hours post-treatment. Data was normalised to 
vehicle (DMSO) control. A-D N=3, E-F N=2 (including a third repeat, Ei and Fi, 
across a different concentration range). 
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Table 6. IC50 values for breast cancer cell lines treated with Olaparib. 
 
As with Thiostrepton, our results suggested that our breast cancer cell lines seemed 
to respond across a similar therapeutic window to the PARP inhibitor, Olaparib 
(Figure 11A-F). The breast cancer cell lines MCF7, SKBR3 and HCC1954 (IC50 
values all out of range, Table 6) were the least sensitive Olaparib, compared to the 
other breast cancer cell lines. The SKBR3 and HCC1954 cell lines had higher 
expression levels of RAD51, compared to MCF7 (Figure 8A). Therefore, with less 
basal RAD51 expression MCF7 cells may respond to Olaparib through a different 
mechanism, compared to SKBR3 and HCC1954 cells.  Whereas, SKBR3 and 
HCC1954 cells may resist Olaparib because of their existing higher basal 
expression levels of RAD51 and this may already compensate for the PARP 
inhibition that is exerted on these cells. Conversely, HS578T and BT474 cells were 
the most sensitive to Olaparib (Table 6). These cell lines showed some of the lower 
expression levels of RAD51 (Figure 8A), so this could be the reason that these cells 
are more sensitive to PARP inhibition. Therefore, lower RAD51 expression levels 
combined with PARP inhibition may be what causes these cells to exhibit reduced 
cell viability. 
 
Taken together, our results suggested that FOXM1 status and RAD51 status of our 
breast cancer cell lines did not necessarily influence the response to the FOXM1 
inhibitor Thiostrepton and the PARP inhibitor Olaparib. This may also suggest that a 
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combined therapy of Thiostrepton and Olaparib could be used to treat a broader 
group of cancer patients, independent of their expression levels of FOXM1 and/or 
RAD51. 
 
3.0 A combined treatment of Thiostrepton and 
Olaparib show they more greatly reduce viability in 
breast cancer cells 
3.1 Thiostrepton and Olaparib treatment in 
combination cause significantly reduced cell viability, 
compared to either agent alone 
The concept of targeting FOXM1 as part of a combination therapy has been 
investigated using a number of approaches. A previous study has indicated that 
targeting FOXM1 provides a strategy for sensitising ovarian cancer cells to 
Cisplatin, and it was suggested that this is partially mediated by changes in a 
downstream target of FOXM1, the DNA repair gene EXO1 [308]. During the time 
that we were conducting our study, other groups published data showing how they 
had been working on similar strategies to us. One study demonstrated that the 
addition of Thiostrepton to Paclitaxel and Cisplatin showed synergistic effects in 
chemoresistant ovarian cancer cells [309]. Another group also showed that 
silencing Foxm1, followed by treatment with a number of chemotherapeutic agents, 
including Carboplatin and Olaparib, significantly enhanced the response to these 
chemotherapeutic agents in ovarian cancer cells [190]. An even more recent study 
has shown that Thiostrepton enhances sensitivity to Olaparib, through a suggested 
mechanism of decreased Brca1 and Brca2 that the authors described as 
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“BRCAness”, in ovarian cancer cells [310]. Collectively, these studies provide 
evidence that the combination therapy of Thiostrepton and Olaparib could be a 
promising treatment option to offer ovarian cancer patients. We therefore tested this 
combination therapy in our breast cancer cells, to determine whether Thiostrepton 
and Olaparib could also be used in the treatment of breast cancer patients. 
 
To investigate this, we treated HCC1954, MCF7, MDA-MB-453 and HS578T breast 
cancer cells, on day 2 and day 7, with Thiostrepton alone, Olaparib alone, 
Thiostrepton and Olaparib in combination, or vehicle control, and analysed cell 
viability on day 10.  
 
Thiostrepton and Olaparib concentrations used were from the lower end of the 
range in Figure 10 and Figure 11 to ensure low toxicity for these experiments. 
These concentrations were also selected based on a study which showed that 
Thiostrepton inhibits FOXM1 expression, 10µmol/L Thiostrepton was used to 
reduce FOXM1 expression over a 24-hour period in MCF7 breast cancer cells [183]. 
In a more recent study, 24-hour treatment with 3.75µM of Thiostrepton was shown 
to reduce FOXM1 expression levels in MCF7 breast cancer cells [311]. Based on 
these studies of MCF7 breast cancer cells treated with Thiostrepton, there seems to 
be a range of concentrations that can be selected to ensure the target, FOXM1, is 
inhibited in breast cancer cell lines. For Olaparib, IC50 values of 5 nM, 1 nM and 4 
nM for PARP1, PARP2 and PARP3 respectively have been reported, and a study 
has shown that 1μM Olaparib inhibited PARP [312]. Moreover, following on from 
this, we optimised the cell viability assays based on the toxicity of drugs. 
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For this figure, and all successive figures with statistical analyses, the standard 
error of the mean of three biological repeats was calculated, performed in triplicate. 
Where triplicate was not carried out, this is noted in the figure legend. 
 
 
   
Figure 12. Treatment with Thiostrepton and Olaparib in combination cause a 
greater reduction in cell viability, compared to either agent alone, in breast 
cancer cells. 
A panel of breast cancer cells A) HCC1954, B) MCF7, C) MDA-MB-453, and D) 
HS578T, were plated in a 96-well plate and treated with Thiostrepton alone (white), 
Olaparib alone (white), Thiostrepton and Olaparib in combination (red), or DMSO-
vehicle control (grey), as indicated. Cell viability was analysed using an ATP-
luminescent assay on day 10 post-treatment. The treatments used were: HCC1954, 
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50nM Thiostrepton alone, 5µM Olaparib alone, 50nM Thiostrepton + 5µM Olaparib 
and vehicle control, DMSO; MCF7, 500nM Thiostrepton alone, 1µM Olaparib alone, 
500nM Thiostrepton + 1µM Olaparib and vehicle control, DMSO; MDA-MB-453, 
3µM Thiostrepton alone, 3µM Olaparib alone, 3µM Thiostrepton + 3µM Olaparib 
and vehicle control, DMSO; and, HS578T, 3µM Thiostrepton alone, 2µM Olaparib 
alone, 3µM Thiostrepton + 2µM Olaparib and vehicle control, DMSO. Data was 
normalised to its vehicle (DMSO) control. N=3 and error bars represent SEM. T-
tests were used (p-value of: <0.01**, <0.001***, <0.0001****). 
 
Our results were consistent with what has been shown previously in ovarian cancer 
cells [310], and suggest that treatment with Thiostrepton and Olaparib in 
combination caused a greater reduction in cell viability, compared to either agent 
alone, for the first time in breast cancer cells (Figure 12A-D). Furthermore, all breast 
cancer cell lines showed that Thiostrepton and Olaparib in combination caused a 
greater reduction in cell viability, compared to either agent alone, indicating that this 
response was not FOXM1- or RAD51-expression level dependent.   
 
There was no measurement of drug potency in cell lines in this particular 
experiment, which limits full interpretation (Figure 12). This applies to later 
experiments, also lacking this measurement. 
 
3.2 Thiostrepton and Olaparib treatment in 
combination cause significantly reduced colony 
formation, compared to either agent alone 
To corroborate our findings suggesting that Thiostrepton and Olaparib in 
combination cause a greater reduction in cell viability, compared to either agent 
alone, in breast cancer cells, we also analysed treatment with Thiostrepton and 
Olaparib in combination by clonogenic assay. To this end, we treated HCC1954, 
MCF7, MDA-MB-453 and HS578T breast cancer cells on day 2, day 5, and day 8 
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with Thiostrepton alone, Olaparib alone, Thiostrepton and Olaparib in combination, 
or vehicle control.  
 
 
     
Figure 13. Treatment with Thiostrepton and Olaparib in combination cause a 
greater reduction in colony formation, compared to either agent alone, in 
breast cancer cells. 
A panel of breast cancer cells A) MCF7, B) HCC1954, C) HS578T, and D) MDA-
MB-453, were plated in a 6-well plate and treated with Thiostrepton alone (white), 
Olaparib alone (white), Thiostrepton and Olaparib in combination (red), or DMSO-
vehicle control (grey), as indicated. Colony formation was analysed using SRB 
staining and counting colonies, on day 11 post-treatment. The treatments used 
were: MCF7, 50nM Thiostrepton alone, 100nM Olaparib alone, 50nM Thiostrepton + 
100nM Olaparib and vehicle control, DMSO; HCC1954, 40nM Thiostrepton alone, 
1µM Olaparib alone, 40nM Thiostrepton + 1µM Olaparib and vehicle control, 
DMSO; HS578T, 200nM Thiostrepton alone, 500nM Olaparib alone, 200nM 
Thiostrepton + 500nM Olaparib and vehicle control, DMSO; and, MDA-MB-453, 
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1µM Thiostrepton alone, 1µM Olaparib alone, 1µM Thiostrepton + 1µM Olaparib 
and vehicle control, DMSO. Data was normalised to its vehicle (DMSO) control 
sample. N=3 and error bars represent SEM. T-tests were used (p-value of: <0.05*, 
<0.01**, <0.001***, <0.0001****). 
 
We analysed colony formation on day 11, confirming our cell viability analysis that 
Thiostrepton and Olaparib in combination caused a more significantly reduced 
colony formation, compared to either agent alone, in breast cancer cells (Figure 
13A-D). Again, all breast cancer cell lines showed a significantly greater reduction in 
colony formation when treated with Thiostrepton and Olaparib in combination, 
indicating that this response was not FOXM1- or RAD51-expression level 
dependent. 
 
Having observed that Thiostrepton and Olaparib in combination more greatly 
reduced cell viability and colony formation in breast cancer cells, compared to either 
agent alone, we have therefore provided significant evidence that this combination 
therapy can be more widely exploited than what has been currently suggested for 
ovarian cancer patients [310]. We have therefore shown that Thiostrepton and 
Olaparib could also have important therapeutic implications in the treatment of 
breast cancer patients, independent of molecular subtype. 
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4.0 Depletion of FOXM1 alters expression levels of 
homologous recombination proteins  
4.1 Cell viability is reduced upon Foxm1 silencing in 
breast cancer cells 
To understand the mechanistic basis for Thiostrepton and Olaparib as a 
combination therapy in breast cancer cells, we next investigated the levels of the 
range of HR genes using siRNA targeting Foxm1 and FOXM1 inhibition using 
Thiostrepton. Prior to investigating the effect of Foxm1 silencing on members of the 
homologous recombination pathway, we first determined the effect of Foxm1 
silencing on cell viability in our breast cancer cells. We transfected HCC1954 and 
MCF7 cells with either siRNA against FOXM1 (siFoxm1(6); siFoxm1(pool)) and a 
non-targeting siRNA control (siCon) for 72- and 96-hours, and then measured cell 
viability.  
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Figure 14. Foxm1 silencing causes reduced cell viability in breast cancer 
cells. 
Cell viability of the breast cancer cell lines HCC1954 and MCF7, plated in a 96-well 
plate, was analysed A) B) 72- and C) D) 96-hours post-transfection with the 
FOXM1-targeting siRNAs, siFoxm1(6) and siFoxm1(pool), using an ATP-
luminescent assay. The controls used for this transfection were siCon (negative 
control) and siPLK1 (positive control). N=3 and error bars represent SEM. T-tests 
were used (p-value of: <0.05*, <0.01**, <0.001***, <0.0001****). 
 
Our results showed that depletion of FOXM1 resulted in a significant reduction in 
cell viability in our cell lines, and this was to a greater extent at 96-hours post-
transfection (Figure 14A-D). Breast cancer cells may therefore have a threshold of 
expression of FOXM1 that is required for viability, in particular when FOXM1 is 
depleted for a greater amount of time. Our Foxm1 silencing data (Figure 14A-D) 
therefore correlated with our Thiostrepton sensitivity data (Figure 10A), for the 
HCC1954 and MCF7 cells, where FOXM1 inhibition also reduced cell viability. It 
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must also be noted that, there was no measurement of efficiency of siRNA in this 
experiment, which limits full interpretation. 
 
4.2 FOXM1 regulates the expression levels of a 
number of genes involved in homologous 
recombination in breast cancer cells 
We next explored the extent at which a number of genes involved in homologous 
recombination may be regulated by changes in FOXM1 expression, and could 
therefore be involved in mediating Olaparib sensitisation upon Thiostrepton 
treatment, in our breast cancer cells. We performed RT-qPCR on the breast cancer 
cell lines MCF7, HCC1954 and HS578T that were transfected with two different 
siRNAs targeting FOXM1 (siFoxm1(5) and siFoxm1(pool)) or a non-targeting siRNA 
control (siCon; Figure 15A-C). We measured the expression levels of a range of 
genes shown to be involved in homologous recombination. These included BRCA2; 
mediates the recruitment of the recombinase RAD51 to DNA double-strand breaks, 
BRIP1; acts with BARD1 to interact with BRCA1 to organise repair proteins on this 
BRCA1 scaffold, NBS1; part of the MRN complex, which resects the DNA to form 3′ 
overhangs that are bound by RPA, and RAD51; the RAD51 nucleoprotein filament 
is involved in strand invasion, allowing the remaining DNA repair to occur with the 
use of the sister chromatid as a template for error-free repair.  
 
siFoxm1(6) and siFoxm1(pool) were initially tested in cell viability assays (Figure 
14). siFoxm1(5) was later tested in RT-qPCR assays (Figure 15). When compared, 
siFoxm1(5) and siFoxm1(pool) showed the most consistent reduction in Foxm1 
135 
 
expression across numerous experiments and therefore were used in subsequent 
experiments in this project. 
 
Our results showed that, upon Foxm1 silencing (Figure 15A-D), we observed 
significant changes in the expression of Brca2, Brip1, Nbs1, and Rad51. 
Furthermore, we validated previous findings that show FOXM1 as a transcriptional 
regulator of Brca2, Brip1, and Nbs1, in breast cancer cells [115, 117, 118]. We also 
validated previous findings that show FOXM1 as a transcriptional regulator of 
Rad51, in glioblastoma cells [116]. Significantly, we have shown for the first time 
that FOXM1 regulates Rad51 expression in breast cancer cells. Furthermore, the 
expression of Rad51 and Brip1 were the most consistently reduced in all three 
breast cancer cell lines, compared to Brca2 and Nbs1 expression, upon Foxm1 
silencing. This data suggests that RAD51 and BRIP1 may be playing a more direct 
role in mediating Olaparib sensitisation upon Thiostrepton treatment, in breast 
cancer cells. If this is the case, this mechanism differs to what has been suggested 
for ovarian cancer cells, where “BRCAness” is described, through decreased 
expression of Brca1 and Brca2 [310]. 
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Figure 15. FOXM1 regulates the expression levels of a number of genes 
involved in homologous recombination in breast cancer cells. 
RNA was collected from the breast cancer cell lines A) MCF7, B) HCC1954, and C) 
HS578T, 48-hours post-transfection with siFoxm1(5) and siFoxm1(pool) and RT-
qPCR performed. β-actin was used as a control and mRNA levels of BRCA2, 
BRIP1, NBS1, FOXM1 and RAD51 were normalised to siCon. N=3 and error bars 
represent SEM. T-tests were used (p-value of: <0.05*, <0.01**, <0.001***, 
<0.0001****). Whole cell lysates were isolated for the breast cancer cell line (D) (Di) 
HCC1954, 48- and 72-hours post-transfection with siFoxm1(6) and siFoxm1(pool) 
were analysed on Western blot and probed with FOXM1 and RAD51 antibodies. β-
tubulin was used as a loading control. N=1. Image J was used to quantify Western 
blots. (E) (F) HCC1954 and MCF7 were also transfected with siFoxm1(6) to 
compare siRNAs. The controls used for these transfections were siCon (negative 
control) and siPLK1 (positive control). 
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As there is already published data on FOXM1 regulating Brip1 in breast cancer cells 
[117], but not for Rad51 in breast cancer cells, we decided to focus on the FOXM1-
mediated regulation of RAD51 in breast cancer. To this end, we next determined 
whether the change in Rad51 mRNA expression upon Foxm1 silencing was also 
translated into changes in protein expression. We immunoblotted protein lysates 
that had been isolated from HCC1954 cells that had been transfected with either 
siRNA against FOXM1 (siFoxm1(6) and siFoxm1(pool)) or a non-targeting siRNA 
control (siCon). Our data confirmed our RT-qPCR data, and showed a significant 
reduction in RAD51 protein expression, upon Foxm1 silencing (Figure 15D). This 
data further corroborates a role for FOXM1 in regulating Rad51 expression, in 
breast cancer cells. It also indicates that this reduction in RAD51 protein expression 
levels, caused by silencing Foxm1, may contribute to Olaparib sensitisation in 
Thiostrepton-treated breast cancer cells. 
 
5.0 Inhibition of FOXM1 by Thiostrepton alters 
expression levels of homologous recombination 
proteins 
5.1 Thiostrepton treatment changes expression levels 
of FOXM1 and homologous recombination proteins 
over time in breast cancer cells 
To validate our results suggesting that FOXM1 regulates Rad51 in breast cancer 
cells, and that this regulation may play a role in mediating Olaparib sensitisation in 
Thiostrepton-treated breast cancer cells, we next treated HCC1954 cells with 
Thiostrepton and determined changes in FOXM1 and HR gene expression over 
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time. We first performed RT-qPCR on HCC1954 cells that had been treated with 
Thiostrepton over time (Figure 16A).  
 
50nM Thiostrepton was selected because this concentration was used for HCC1954 
in Figure 12. Then, the MCF10A cell line was treated the same, with 50nM 
Thiostrepton, as shown in Figure 16 and Figure 17.  
 
 
 
 
Figure 16. FOXM1 inhibition reduces expression levels of homologous 
recombination proteins and mRNA which is rescued over time, in breast 
cancer cells. 
A) Ai) RNA collected at various time-points post-treatment with 50nM Thiostrepton 
and RT-qPCR performed. β-actin was used as a control and mRNA levels of 
BRCA2, BRIP1, NBS1, FOXM1 and RAD51 were normalised to vehicle control, 
DMSO. Two repeats are shown, at different time-points, with a similar trend. B) C) 
Whole cell lysates collected 24-, 72- and 120-hours post-treatment with 50nM 
Thiostrepton were analysed on Western blot and probed with FOXM1 and RAD51 
antibodies. β-tubulin was used as a loading control. N=3 and error bars represent 
SEM. T-tests were used (p-value of: <0.05*, <0.01**, <0.001***). 
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Figure 16A shows a trend that Foxm1 mRNA levels were reduced after 4-hours 
Thiostrepton treatment. In addition, we observed a corresponding decrease in the 
HR genes Brac2, Nbs1, Brip1 and Rad51, which may be attributed to the role of 
FOXM1 in regulating the expression of these genes. Interestingly, Brip1 is the least 
reduced HR gene at this time-point. The expression of Brip1 may be maintained at 
a higher level, independently of FOXM1 regulation, so that cells can continue to 
repair any basal DNA damage, and any additional DNA damage caused by 
Thiostrepton treatment.  
 
We also investigated the expression of Foxm1 and HR genes at 24- and 120-hours 
post-treatment with Thiostrepton, to determine the effect of FOXM1 inhibition after 
longer exposure to the compound. After 24-hours of Thiostrepton treatment, 
expression levels of Foxm1 and HR genes have recovered compared to 4-hours of 
Thiostrepton treatment (Figure 16A). The mechanism of action of Thiostrepton is 
suggested to be through binding FOXM1 and preventing the regulation of other 
gene promoters, but not necessarily its own promoter [203]. With this in mind, this 
could potentially explain why levels of Foxm1 have increased at this time-point, 
because of its suggested auto-regulatory function [199]. Therefore, at 24-hour 
exposure to Thiostrepton, cells may be responding to the compound through up-
regulating HR genes, and this could be part-mediated by the increased Foxm1 
expression levels, as well as any additional compensatory action of the cells. 
 
By 120-hours of Thiostrepton treatment, expression levels of Foxm1 and HR genes 
had recovered even more, compared to 4- and 24-hours of Thiostrepton treatment 
(Figure 16A). In this instance, long-term exposure to Thiostrepton may actually lead 
to a loss in the effect of FOXM1 inhibition on the cells. This could be what is 
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allowing expression levels of Foxm1 to increase, because FOXM1 is no longer 
being subjected to inhibition, and this may also enhance its auto-regulatory function 
[199]. FOXM1 may now be regulating the HR genes to increase their expression 
levels, for basal DNA repair pathways. 
 
Overall, our RT-qPCR data suggested that short-term exposure to Thiostrepton in 
breast cancer cells offers the most appropriate therapeutic window for our combined 
therapy. This is because Foxm1 and HR gene expression levels are lower at our 
earliest time-point, and therefore breast cancer cells may have increased 
sensitisation to Olaparib after exposure to Thiostrepton. It seems that longer-term 
exposure to Thiostrepton causes Foxm1 and HR expression levels to recover to 
higher levels that may render our combination therapy less effective. 
 
To further investigate the effect of FOXM1 inhibition over time, we next determined 
how FOXM1 and RAD51 protein expression levels changed at different time-points, 
post-treatment with Thiostrepton. Interestingly, the most significant change in 
FOXM1 protein expression occurred at our earliest time-point, 24-hours post-
treatment with Thiostrepton (Figure 16B-C). As with Foxm1 mRNA data, FOXM1 
protein expression is recovered over time, at 72- and more so at 120-hours post-
treatment with Thiostrepton. Surprisingly, Figure 16B-C shows that Thiostrepton 
treatment over time caused protein expression of RAD51 to change in a different 
way to mRNA expression. There was an initial increase in RAD51 expression at 24-
hours, and this was reduced by 120-hours, post-treatment with Thiostrepton. This 
could be explained by the large increase in Rad51 mRNA expression that we 
observed between 4- and 24-hours treatment with Thiostrepton (Figure 16A), which 
seems to be subsequently translated into RAD51 protein at 24-hours treatment with 
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Thiostrepton (Figure 16B-C). By 120-hours exposure to Thiostrepton, breast cancer 
cells may be adjusting back to normal basal expression levels, which may not 
require high translation rates of Rad51 mRNA. Alternatively, FOXM1 inhibition may 
cause a reduction in the proteins it regulates, such as RAD51, at this later time-
point.  
 
Taken together, short-term exposure to Thiostrepton also caused reduced FOXM1 
protein expression, and this was increased over time, as we observed with Foxm1 
mRNA expression. As our 24-hour Thiostrepton treatment time-point showed a 
large increase in RAD51 protein expression, this could be based on increased 
Rad51 mRNA expression between 4- and 24-hours of Thiostrepton treatment. Since 
the effect of FOXM1 inhibition seemed to be lost after long-term exposure to 
Thiostrepton, at mRNA and protein levels, the reduction in Rad51 mRNA 
expression observed at 4-hours post-treatment seems a more viable therapeutic 
window to exploit with sensitisation to Olaparib in breast cancer cells.  
 
5.2 Thiostrepton treatment changes expression levels 
of FOXM1 and homologous recombination proteins 
over time in non-tumourigenic breast epithelial cells 
Our data so far suggested that the therapeutic window of our combination therapy 
would be based on short-term Thiostrepton exposure, with a subsequent 
sensitisation of breast cancer cells to Olaparib, through reduced expression of 
FOXM1 and HR proteins. We next investigated the response of non-tumourigenic 
breast epithelial MCF10A cells to Thiostrepton treatment over time, by analysing 
expression levels of FOXM1 and HR genes. Using this approach, we explored how 
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we could potentially increase the therapeutic window of our combination therapy, in 
order to spare the normal cells of breast cancer patients. 
 
We first performed RT-qPCR on MCF10A cells that had been treated with 
Thiostrepton over time (Figure 17A). Interestingly, we only observed a decrease in 
Foxm1 mRNA expression levels at our latest time-point of 120-hours post-treatment 
with Thiostrepton. This result is different to current literature, and to what we 
observed in HCC1954 breast cancer cells. In a previous study, Thiostrepton 
treatment has been shown to have no effect on protein expression levels of FOXM1 
in MCF10A cells, up to 72-hours exposure [183]. In HCC1954 cells, Foxm1 mRNA 
expression was reduced much earlier, at 4-hours post-treatment with Thiostrepton, 
and this was then recovered by 120-hours post-treatment with Thiostrepton (Figure 
16A).  
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Figure 17. FOXM1 inhibition reduces expression levels of homologous 
recombination proteins, at later time-points in the non-tumourigenic breast 
epithelial cell line MCF10A, compared to breast cancer cells. 
A) RNA collected 24-, 72- and 120-hours post-treatment with 50nM Thiostrepton 
and RT-qPCR performed. β-actin was used as a control and mRNA levels of 
BRCA2, BRIP1, NBS1, FOXM1 and RAD51 were normalised to vehicle control, 
DMSO. N=1 and error bars represent SD. B) Bi) Whole cell lysates collected 24-, 
72- and 120-hours post-treatment with 50nM Thiostrepton were analysed on 
Western blot and probed with the FOXM1 antibody. β-tubulin was used as a loading 
control. N=1. Image J was used to quantify Western blots. 
 
Our MCF10A cell line data also differed to what we observed in HCC1954 breast 
cancer cells, where HR genes were up-regulated over time, post-treatment with 
Thiostrepton (Figure 16A). FOXM1 is not the sole regulator of homologous 
recombination gene transcription; therefore, it could be other transcriptional 
regulators that have caused the observed reduction in HR gene expression before 
FOXM1 expression levels were reduced. This could be because the damage 
caused by Thiostrepton treatment was being repaired by other DNA repair 
pathways.  
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When we investigated FOXM1 protein expression levels over time in MCF10A cells 
treated with Thiostrepton (Figure 17B, Bi), we observed a similar trend to our mRNA 
data for MCF10A cells treated with Thiostrepton (Figure 17A). At both mRNA and 
protein level, FOXM1 expression levels were not reduced with short-term exposure 
to Thiostrepton. It was only after long-term exposure to Thiostrepton that we 
observed decreased FOXM1 expression levels. Based on this data in MCF10A 
cells, our therapeutic window seemed to be further supported, where short-term 
Thiostrepton exposure with subsequent Olaparib sensitisation could be the most 
effective way to treat breast cancer patients, and to spare their normal cells. 
 
It must be noted that in Figure 16 and Figure 17, experiments were carried out in 
different cell lines at different times, which limits comparison. The time-points also 
fluctuate, which makes interpretation less conclusive and so this also limits 
comparison. 
 
6.0 DNA damage is increased in cells treated with 
Thiostrepton and Olaprib in combination  
6.1 Breast cancer cells treated in combination with 
Thiostrepton and Olaparib have significantly 
increased levels of DNA damage, compared to 
treatment with either agent alone 
We have now shown that our combination therapy of Thiostrepton and Olaparib 
causes a more greatly reduced cell viability and colony formation, compared to 
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either agent alone, in breast cancer cells (Figure 12A-D; Figure 13A-D), and that the 
reduced expression levels of HR genes, upon a shorter exposure to Thiostrepton, 
could be involved in mediating the sensitisation of breast cancer cells to Olaparib 
(Figure 16A-C). We have also investigated the therapeutic window of our 
combination therapy, by comparing the response of breast cancer cells and non-
tumourigenic breast epithelial cells to Thiostrepton treatment over time (Figure 17A-
B). Our data suggested that our combination therapy may be more effective at 
treating breast cancer patients with a short-term exposure to Thiostrepton, so that 
the cells can be sensitised to Olaparib, and the patient’s normal cells can be 
spared.  
 
To further investigate the mechanistic basis of our combination therapy, we next 
determined whether levels of DNA damage differed between our treatment 
conditions. It has been shown previously that FOXM1-deficient cells exhibit 
increased DNA breaks [115, 118]. Since a number of HR genes have been shown 
to be under the regulation of FOXM1 in breast cancer cells [115, 117, 118], and we 
have also shown for the first time that Rad51 is regulated by FOXM1 in breast 
cancer cells (Figure 15A-D), we decided to investigate how this role of FOXM1 may 
be affected in breast cancer cells treated with our combination therapy. 
 
We therefore determined whether Thiostrepton and Olaparib in combination caused 
increased DNA double-strand breaks in our cells, compared to either agent alone. 
To this end, we treated HCC1954 cells with 50nM Thiostrepton, 5µM Olaparib, 
50nM Thiostrepton + 5µM Olaparib, or vehicle control. 
 
146 
 
50nM Thiostrepton and 5µM Olaparib were selected, because these concentrations 
were used for HCC1954 in Figure 12. 
 
 
 
Figure 18. γH2AX foci in breast cancer cells upon treatment with Thiostrepton 
alone, Olaparib alone and Thiostrepton and Olaparib in combination. 
Percentage of total number of cells containing more than 5 foci were measured 
using confocal microscopy, 24-hours post-treatment of cells on coverslips in a 24-
well plate. The treatments used were 50nM Thiostrepton (white), 5µM Olaparib 
(white), 50nM Thiostrepton + 5µM Olaparib (red) and vehicle control, DMSO (grey). 
N=3 and error bars represent SEM. T-tests were used (p-value of: <0.05*). 
 
We analysed γH2AX foci, a marker of DNA double-strand breaks, after 24-hours 
and determined that DNA double-strand breaks were significantly increased upon 
treatment with Thiostrepton and Olaparib, compared to either agent alone (Figure 
18). Our results therefore suggest that increased DNA double-strand breaks may 
provide a mechanistic explanation for our combination therapy in breast cancer 
cells. 
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Taken together, we have shown that the role of FOXM1 in regulating DNA repair 
genes can be exploited therapeutically, using Thiostrepton and Olaparib in 
combination. Our data suggests that Olaparib sensitisation upon treatment with 
Thiostrepton is mediated through the HR proteins RAD51 and BRIP1, and that 
short-term Thiostrepton treatment may benefit patients to spare normal cells. We 
also showed that increased DNA DSBs may be exerting a role in the mechanism of 
action of our combination therapy, compared to Thiostrepton alone and Olaparib 
alone. 
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Chapter 4 - Investigating the role of FOXM1 in the 
oxidative stress response and its therapeutic 
implications 
 
 
1.0 Foxm1 silencing alters expression levels of 
oxidative stress pathway proteins 
1.1 FOXM1 regulates the expression levels of a 
number of genes involved in the response to 
oxidative stress in breast cancer cells 
Previous studies have shown that FOXM1 has been involved in a number of ways 
to regulate the response to oxidative stress. FOXM1 has been shown to counteract 
oxidative stress-induced premature senescence, by regulating Bmi-1 expression 
[120]. FOXM1 has also been shown to protect cells from oxidative stress by forming 
a negative feedback loop, stimulating the expression of antioxidant enzyme genes, 
and therefore counteracting increased intracellular ROS levels [119]. Using siRNA 
targeted against Foxm1, the authors demonstrated that the expression levels of the 
antioxidant genes MnSOD, catalase and PRDX3 were subsequently reduced [119]. 
They also showed that FOXM1-deficiency caused elevated ROS levels, compared 
to the control, further establishing a role for FOXM1 in ROS regulation [119]. In this 
study, we aimed to further investigate the role of FOXM1 in the oxidative stress 
response and whether we can exploit this therapeutically.  
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To identify which other genes involved in the oxidative stress response may be 
regulated by changes in FOXM1 expression, we performed RT-qPCR on the 
HCC1954, MCF7 and HS578T breast cancer cell lines that had been transfected 
with two different siRNAs targeting FOXM1 (siFoxm1(5) and siFoxm1(pool)) or a 
non-targeting siRNA control (siCon; Figure 19A-C). We measured the expression 
levels of a range of genes previously shown to be involved in the response to 
oxidative stress. These included MTCO1, NFR1, PPARGC1 and NFE2L2 (also 
known as NRF2). Our results suggest that upon Foxm1 silencing, we observed a 
significant change in expression of Mtco1; one of the three cytochrome c oxidase 
subunit mitochondrial genes, Nrf1; a regulator of genes involved in oxidative stress, 
and Ppargc1; involved in mitochondrial biogenesis, but these changes were not 
consistent across all cell lines. However, our results did show that silencing Foxm1 
resulted in a significant decrease in Nrf2 expression in all three breast cancer cell 
lines; HCC1954, MCF7 and HS578T. This validated previous work which reported 
that Nrf2 is transcriptionally activated by FOXM1, and that Foxm1 silencing causes 
reduced NRF2 expression, in hepatocellular carcinoma cells and bladder cancer 
cells [302, 303]. However, they reported that Nrf2 silencing did not affect FOXM1 
expression [302]. 
 
To determine whether this change in Nrf2 mRNA expression was also translated 
into changes in protein expression, we immunoblotted protein lysates that had been 
isolated from HCC1954, MCF7 and HS578T breast cancer cell lines that had been 
transfected with either siRNA against FOXM1 (siFoxm1(5) and siFoxm1(pool)) or a 
non-targeting siRNA control (siCon). As the NRF2-KEAP1 cytoplasmic interaction is 
regulated by protein kinase C phosphorylation, to enable NRF2 nuclear 
translocation in response to oxidative stress [313, 314], we analysed the expression 
of both phosphorylated NRF2 and total NRF2 (Figure 19D-E), upon Foxm1 
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silencing. Our data showed that phosphorylated NRF2 and total NRF2 expression 
levels were decreased, confirming our RT-qPCR data and suggesting that both 
forms of NRF2 are affected by Foxm1 silencing. The consequence of decreased 
phosphorylated NRF2 and total NRF2 could lead to a reduced activity of the 
antioxidant response. This may also result in additional effects on proteins 
downstream of NRF2. We next investigated NQO1, an enzyme that is regulated by 
NRF2, through binding to the antioxidant response element (ARE) consensus 
sequence in NQO1 [315]. Roles of NQO1 include the reduction of quinones to 
hydroquinones, by-passing the generation of highly reactive semiquinones [316]. 
This role has been exploited by using bioactive drugs, such as β-lapachone, that 
require NQO1 activity, and subsequently leads to harmful cellular events including 
ROS formation, DNA damage and apoptosis, in pancreatic cancer cells as well as 
head and neck cancer cells [317, 318]. Other roles include the direct scavenging of 
reactive oxygen species [141]. Surprisingly, we observed an increase in NQO1 
expression, upon Foxm1 silencing in the HCC1954 and MCF7 breast cancer cell 
lines (Figure 19E). As we observed that Foxm1 silencing reduced NRF2 expression, 
it could be expected that Foxm1 silencing would also cause a corresponding 
reduction in the expression of NQO1. Therefore, this increased NQO1 expression 
may be a compensatory action of the cells to Foxm1 silencing, and this may not be 
mediated by the NRF2 pathway. 
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Figure 19. FOXM1 regulates the expression levels of a number of genes 
involved in the response to oxidative stress in breast cancer cells. 
A) B) C) RNA collected 48-hours post-transfection with siFoxm1(5) and 
siFoxm1(pool) and RT-qPCR performed. β-actin was used as a control and mRNA 
levels of MTCO1, NRF1, PPARGC1, FOXM1 and NFE2L2 were normalised to 
siCon. N=3 and error bars represent SEM. T-tests were used (p-value of: <0.05*, 
<0.01**, <0.001***, <0.0001****). D) Di) E) Ei) Whole cell lysates collected 72-hours 
post-transfection with siFoxm1(5) and siFoxm1(pool) were analysed on Western 
blot and probed with FOXM1, phospho-NRF2, NRF2 total and NQO1 antibodies. β-
actin and -tubulin were used as loading controls. N=1. Image J was used to quantify 
Western blots. The controls used for these transfections were siCon (negative 
control) and siPLK1 (positive control).  
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2.0 Chemotherapy resistance causes upregulation of 
FOXM1 and the oxidative stress protein NQO1  
2.1 FOXM1 and NQO1 have increased expression 
levels in platinum-resistant ovarian cancer cells 
Our data thus far suggested that FOXM1 can regulate NRF2 and NQO1 expression. 
Previous studies have shown evidence that all three of these proteins play a role in 
chemoresistance [188, 319, 320]. Therefore, we next aimed to explore this further in 
our study. FOXM1 has been suggested to mediate acquired Cisplatin resistance in 
breast cancer cells, through a proposed mechanism involving the DNA repair 
pathway [188]. Other studies have linked FOXM1 to chemoresistance in ovarian 
cancer [174, 190], lung cancer [321], and there have also been additional studies in 
breast cancer [191, 322]. Another study investigated NRF2, and subsequently 
NQO1, in lung carcinoma, breast adenocarcinoma and neuroblastoma, and 
suggested that these proteins were involved in mediating chemoresistance [319]. 
Other studies have linked NRF2 to chemoresistance in pancreatic cancer [323], and 
NQO1 to chemoresistance in cholangiocarcinoma [320]. 
 
Since FOXM1, NRF2, NQO1 expression levels have been implicated in 
chemoresistance in different cancer types, we used an established model of ovarian 
cancer cells that are chemosensitive and chemoresistant to further investigate these 
proteins in our chosen model. The parental ovarian cancer cell line Ovcar4, the 
Cisplatin-resistant ovarian cancer cell line Ov4cis and the Carboplatin-resistant cell 
line Ov4carbo were kindly provided to us by the Lockley lab, BCI.  
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We first validated chemotherapy sensitivity in our cell lines. We treated our cells 
with increasing concentrations of Cisplatin (Figure 20A) or increasing 
concentrations of Carboplatin (Figure 20B) and analysed cell viability after 72-hours. 
A range of chemotherapy concentrations were tested in order to observe 
differences in sensitivity between chemo-sensitive and -resistant ovarian cancer cell 
lines. The IC50 of Cisplatin for Ovcar4 and Ov4cis were around 3µM and around 
16µM, respectively (Lockley lab, BCI, personal communication). Therefore, we 
selected concentrations either side of these values. Our data confirmed that the 
Ov4cis cells were resistant to Cisplatin (IC50 14.9µM, Table 7), compared to 
Ovcar4 (IC50 3.0µM, Table 7), and the Ov4carbo cells were resistant to Carboplatin 
(IC50 out of range, Table 7), compared to Ovcar4 (IC50 44.4µM, Table 7), as 
expected.  
 
Figure 20. Validating chemotherapy sensitivity in our ovarian cancer cells. 
A) Dose response curves for Cisplatin in ovarian cancer cells, after 72-hours 
treatment in a 96-well plate. N=2 and error bars represent SE. B) Dose response 
curves for Carboplatin in ovarian cancer cells, after 72-hours treatment in a 96-well 
plate. N=1 and error bars represent SD.  
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Table 7. IC50 values for ovarian cancer cell lines treated with Cisplatin and 
Carboplatin. 
 
Once our cell lines had been validated, we next immunoblotted protein lysates that 
had been isolated from Ovcar4, Ov4cis and Ov4carbo ovarian cancer cell lines for 
basal protein expression levels of FOXM1 and NQO1. Since NRF2 is upstream of 
NQO1, and FOXM1 directly regulates NRF2 expression, we decided to focus the 
rest of our study on FOXM1, and a downstream protein, NQO1, and their roles in 
chemoresistance. Our results showed that FOXM1 expression levels were 
increased in platinum-resistant ovarian cancer cells, compared to parental ovarian 
cancer cells (Figure 21A-B).  
 
 
Figure 21. FOXM1 expression levels are increased in platinum-resistant 
ovarian cancer cells. 
A) Whole cell lysates were analysed on a Western blot and probed with FOXM1 and 
NQO1 antibodies. β-tubulin was used as a loading control. B) C) FOXM1 and NQO1 
blots were quantified. ImageJ analysis was used, and normalisation was to the 
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parental cell line Ovcar4. N=3 and error bars represent SEM. T-tests were used (p-
value of: <0.05*, <0.001***). 
 
This confirmed published data that FOXM1 is upregulated in chemoresistant cancer 
cells. We now have a model to further investigate the mechanistic and therapeutic 
implications of targeting FOXM1 and the oxidative stress response pathway in 
cancer cells. We next wanted to determine if these proteins play roles separately, or 
together, in driving cancer cells to chemoresistance. 
 
3.0 Investigating chemoresistance in ovarian cancer 
cells, and whether this is mediated by FOXM1 and 
NQO1 
3.1 Foxm1 silencing results in increased NQO1 
expression, and Nqo1 silencing results in decreased 
FOXM1 expression  
Our data suggests that upon Foxm1 silencing in breast cancer cells, NQO1 
expression is increased (Figure 19E). To determine whether this data was a specific 
feature of breast cancer cells, we immunoblotted protein lysates that had been 
isolated from the Ovcar4, Ov4cis and Ov4carbo ovarian cancer cell lines that had 
been transfected with either siRNA against FOXM1 (siFoxm1(5)) or a non-targeting 
siRNA control (siCon). We subsequently analysed the expression of NQO1 (Figure 
22A, C) upon Foxm1 silencing. As observed in breast cancer cells (Figure 19E), we 
also observed an increase in NQO1 expression when Foxm1 had been silenced. To 
investigate this further, we transfected the ovarian cancer cells with either siRNA 
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against NQO1 (siNqo1(pool)) or a non-targeting siRNA control (siCon) and after 72-
hours isolated protein lysates. Significantly, we observed a decrease in FOXM1 
expression upon Nqo1 silencing (Figure 22A-B).  
 
 
 
Figure 22. Foxm1 silencing results in increased NQO1 expression and Nqo1 
silencing results in decreased FOXM1 expression, in ovarian cancer cells. 
A) Whole cell lysates collected 48-hours post-transfection with siFoxm1(5) and 
siNqo1(pool) were analysed on a Western blot and probed with FOXM1 and NQO1 
antibodies. β-tubulin was used as a loading control. The controls used for this 
transfection were siCon (negative control) and siPLK1 (positive control). B) C) 
FOXM1 and NQO1 blots were quantified. ImageJ analysis was used, and 
normalisation was to siCon. N=3 (Ovcar4 and Ov4cis), N=1 (Ov4carbo), and error 
bars represent SEM. T-tests were used (p-value of: <0.01**, <0.001***, 
<0.0001****). 
 
These data suggest that FOXM1 and NQO1 expression are potentially regulated by 
each other and may have compensatory functional roles in the cell. 
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siFoxm1(5) only was tested in ovarian cancer cell lines, and it showed the greatest, 
reproducible knock-down of Foxm1 across multiple experiments. Another siRNA 
targeted to Foxm1, as well as another siRNA targeted to Nqo1, will also need to be 
tested to validate data with siFoxm1(5) and siNqo1(pool). 
 
It must also be noted that there is a caveat to this experiment, and the following 
experiments, where using a single siRNA targeted to Foxm1/Nqo1 does not allow 
full interpretation. Therefore, future experiments should test a second siRNA 
targeted to Foxm1, and a second siRNA targeted to Nqo1. 
 
3.2 Thiostrepton treatment significantly increases 
expression levels of NQO1  
After having observed increased expression of NQO1 upon Foxm1 silencing in 
breast cancer cells and ovarian cancer cells (Figure 19E; Figure 22A, C), we next 
used the FOXM1 inhibitor Thiostrepton as another means to inhibit FOXM1 activity 
and to determine its effect of NQO1 expression. At this stage, we also investigated 
the expression of another downstream enzyme of the NRF2 pathway, SOD1, which 
is involved in catalysis of the potentially toxic superoxide to a less toxic substance 
hydrogen peroxide. SOD1 is a superoxide dismutase, and in mammals there are 
three SOD isoforms (the cytoplasmic Cu/ZnSOD (SOD1), the mitochondrial MnSOD 
(SOD2), and the extracellular Cu/ZnSOD (SOD3)) [324]. Interestingly, MnSOD 
(SOD2) expression levels have already been shown to be reduced upon Foxm1 
silencing [119].  
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We treated Ovcar4, Ov4cis and Ov4carbo cells with either a vehicle control 
(DMSO), 1M Thiostrepton or 2M Thiostrepton, and isolated total protein lysates. 
Our results suggested that inhibition of FOXM1 increased expression of NQO1 
(Figure 23A, C), as was observed upon siRNA-mediated Foxm1 silencing (Figure 
19E; Figure 22A, C).  
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Figure 23. FOXM1 inhibition does affect protein expression levels of the 
oxidative stress proteins NQO1 and SOD1, in ovarian cancer cells. 
A) Whole cell lysates collected 48-hours post-treatment with 1µM Thiostrepton, 2µM 
Thiostrepton or vehicle control were analysed on a Western blot and probed with 
FOXM1, NQO1 and SOD1 antibodies. β-tubulin was used as a loading control. B) 
C) D) FOXM1, NQO1 and SOD1 blots were quantified. ImageJ analysis was used, 
and normalisation was to vehicle control sample, DMSO. N=2 (Ovcar4 and Ov4cis 
for FOXM1 and NQO1), N=1 (Ov4carbo for FOXM1 and NQO1), N=1 (Ovcar4, 
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Ov4cis and Ov4carbo for SOD1), and error bars represent SEM. T-tests were used 
(p-value of: <0.01**). 
 
Furthermore, Thiostrepton is an allosteric regulator of FOXM1 and prevents the 
interaction of the transcription factor FOXM1 with several gene promoters, but not 
necessarily to its own [203].  While siRNA-mediated silencing is through mRNA 
degradation. This difference may explain why FOXM1 expression levels are not 
always decreased upon treatment with Thiostrepton. Interestingly, we observed 
increased expression of SOD1 in the chemotherapy-resistant cell lines, independent 
of siRNA transfection, as we have observed for FOXM1 and NQO1. 
 
3.3 Cisplatin treatment significantly increases 
expression levels of FOXM1 and NQO1  
Our data suggests that FOXM1 and NQO1 expression is increased in platinum-
resistant ovarian cancer cells (Figure 21A-B). Previously, Cisplatin has been shown 
to induce FOXM1 expression in ovarian cancer cells [308]. Furthermore, kidney 
adenocarcinoma cells treated with Cisplatin were shown to have increased ROS 
production and increased NQO1 expression [325]. Therefore, we next investigated 
whether short-term treatment with Cisplatin could regulate the expression levels of 
FOXM1 and NQO1 and whether increasing concentrations of Cisplatin caused a 
parallel increase in FOXM1 and NQO1 expression, in our cells. To this end, we 
immunoblotted protein lysates that had been isolated from Ovcar4 and Ov4cis 
ovarian cancer cell lines treated with either 1M Cisplatin, 2M Cisplatin, 3M 
Cisplatin, 4M Cisplatin or a vehicle control for 24-hours. Our data suggested that 
FOXM1 and NQO1 expression was increased upon Cisplatin treatment, but this 
was not dependent of the chemoresistance of the cells (Figure 24A-B).  
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Cisplatin concentrations were used based on Figure 20 to ensure low toxicity, 
where increasing concentrations were tested to determine whether this caused 
changes in FOXM1 and or NQO1 expression levels.  
 
 
 
Figure 24. Cisplatin treatment significantly increases protein expression 
levels of FOXM1 and NQO1 in ovarian cancer cells. 
A) Ai) B) Bi) Whole cell lysates collected 24-hours post-treatment with 1µM 
Cisplatin, 2µM Cisplatin, 3µM Cisplatin, 4µM Cisplatin or vehicle control were 
analysed on a Western blot and probed with FOXM1 and NQO1 antibodies. β-
tubulin was used as a loading control. N=1. Image J was used to quantify Western 
blots. 
 
This result therefore suggests that FOXM1 and NQO1 may play a role in generating 
chemoresistance to Cisplatin in ovarian cancer cells.  
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3.4 Cisplatin-resistant cells are not re-sensitised to 
Cisplatin upon Foxm1 or Nqo1 silencing 
Our data suggests a relationship between the proteins FOXM1 and NQO1, and 
chemoresistance in platinum-resistant ovarian cancer cells, as we observed 
increased expression of both proteins in platinum-resistant cells (Figure 21A-B), and 
upon short-term Cisplatin treatment (Figure 24A-B). We have also observed that 
when FOXM1 or NQO1 are individually silenced, this caused a corresponding 
change in the expression of the other protein (Figure 22A-C). We therefore next 
determined the role FOXM1 and NQO1, alone or together, in the re-sensitisation of 
platinum-resistant cells to Cisplatin. To this end, we transfected with either siRNA 
against FOXM1 (siFoxm1(5)), siRNA against NQO1 (siNqo1(pool)) or a non-
targeting siRNA control (siCon) for 24-hours, and this was followed by treating the 
cells with either 5M Cisplatin or 10M Cisplatin or vehicle control. We analysed cell 
viability after 120-hours Cisplatin treatment. Our results suggest that in the Ov4cis 
cells, there was no re-sensitisation to Cisplatin with Foxm1 silencing or Nqo1 
silencing alone at the concentrations tested (Figure 25B). Interestingly, there was a 
trend for increased resistance to Cisplatin when Nqo1 was silenced in the parental 
Ovcar4 cells (Figure 25A), which was not observed in the Ov4cis cells. Previously, 
we observed that FOXM1 expression was decreased upon Nqo1 silencing (Figure 
22A-B) therefore this resistance to Cisplatin in NQO1-depleted cells may be due to 
the combined reduction in FOXM1 and NQO1 expression. Therefore, we 
hypothesise that NQO1 and FOXM1 may play a role together in causing 
chemoresistance in Ovcar4 cells.  
 
When Foxm1 was silenced, there were no changes to the trend in cell viability in 
chemoresistant Ov4cis cells (Figure 25B). This result indicates that FOXM1 does 
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not appear to play a role in resistance in ovarian cancer. The same can be said for 
NQO1, because Nqo1 was silenced, there were no changes to the trend in cell 
viability in Ov4cis cells (Figure 25B). 
 
Cisplatin concentrations were used based on Figure 20 to ensure low toxicity, 
where increasing concentrations were tested to determine whether this caused 
changes in cell viability when Foxm1 or Nqo1 were silenced. This also applied to 
Figure 28, when Foxm1 and Nqo1 were silenced together. 
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Figure 25. Cisplatin-resistant cells are not re-sensitised to Cisplatin upon 
Foxm1 or Nqo1 silencing. 
A) Ai, ii) B) Bi, ii) Cisplatin sensitisation was measured using CTG, post-treatment 
with Cisplatin, after Foxm1 silencing or Nqo1 silencing in a 96-well plate. Three 
experiments shown for each cell line. C) Ci, ii) Cell viability was also measured 
without drug treatment using CTG, post-transfection with siFoxm1(5) or 
siNqo1(pool) in a 96-well plate. Three experiments shown for both cell lines. The 
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controls used for this transfection were siCon (negative control) and siPLK1 
(positive control), data not shown for siPLK1.  
 
Furthermore, the reduction in cell viability upon silencing of Nqo1 was greater in 
Ovcar4 cells (Figure 25C), and interestingly these cells have lower expression of 
NQO1, in comparison to the platinum-resistant cells. Therefore, perhaps Ovcar4 
cells have a threshold of expression of NQO1 required for viability, and loss of 
NQO1 results in a reduction in cell viability, independent of Cisplatin treatment.  
 
4.0 Do FOXM1 and NQO1 act together to mediate 
resistance in Cisplatin-resistant ovarian cancer cells? 
4.1 Foxm1 + Nqo1 silencing causes reduced cell 
viability compared to alone in ovarian cancer cells 
Our data suggests that FOXM1 and NQO1 individually do not mediate resistance to 
Cisplatin in Ovcar4 cells, but may act together in these cells to cause 
chemotherapy-resistance. To investigate this further, we silenced Foxm1 and Nqo1 
alone or together. We determined the effect on cell viability of silencing Foxm1 and 
Nqo1 alone or together, by transfecting Ovcar4, Ov4cis and Ov4carbo cells with 
either siRNA against FOXM1 (siFoxm1(5)), siRNA against NQO1 (siNqo1(pool)) or 
together and a non-targeting siRNA control (siCon) for 144-hours and then 
measured cell viability. Our results suggest that loss of both FOXM1 and NQO1 
together resulted in a trend for reduced cell viability in all cell lines, in comparison to 
silencing either FOXM1 or NQO1 alone (Figure 26). These experiments were 
controlled for the amount of siRNA used to ensure this increased toxicity upon loss 
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of FOXM1 and NQO1 together was not due to an increase in siRNA concentration 
(Materials and Methods, Section 4.2.2).  
 
 
Figure 26. Cell viability without drug treatment upon Foxm1 silencing and 
Nqo1 silencing, alone or together, in ovarian cancer cells. 
Cell viability was measured using CTG, post-transfection with siFoxm1(5) and 
siNqo1(pool), alone or together, in a 96-well plate. The controls used for this 
transfection were siCon (negative control) and siPLK1 (positive control). Repeats 
are displayed, and error bars represent SD.  
 
The reduction in cell viability upon silencing of Foxm1 and Nqo1 together was also 
greater in Ovcar4 cells. These cells have lower expression of both NQO1 and 
FOXM1, in comparison to the platinum-resistant cells, so Ovcar4 cells may have a 
threshold of expression of both FOXM1 and NQO1 required for viability, and loss of 
both results in a reduction in cell viability. 
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4.2 Foxm1 + Nqo1 silencing causes additional 
reduced colony formation compared to alone in 
ovarian cancer cells 
To validate our results suggesting that loss of both FOXM1 and NQO1 causes a 
greater reduction in cell viability, compared to either alone, we also analysed loss of 
both proteins by clonogenic assay. To this end, we transfected with either siRNA 
against FOXM1 (siFoxm1(5)), siRNA against NQO1 (siNqo1(pool)), siRNA against 
FOXM1 (siFoxm1(5)) + siRNA against NQO1 (siNqo1(pool)) or a non-targeting 
siRNA control (siCon) for 6 days, when we subsequently stained, dissolved and 
measured absorbencies of remaining colonies on day 8. Significantly, we also 
observed a reduction in colony formation upon depletion of Foxm1 and Nqo1 
together, in comparison to either gene alone, across all cell lines (Figure 27A-C).  
 
 
Figure 27. Colony formation without drug treatment upon Foxm1 silencing 
and Nqo1 silencing, alone or together, in the ovarian cancer cells. 
A) B) C) Colony formation was measured using SRB staining and dissolving 
colonies, on day 8 post-transfection with siFoxm1(5) and siNqo1(pool), alone (grey) 
or together (white), in a 6-well plate. The controls used for this transfection were 
siCon (negative control) (blue) and siPLK1 (positive control) (red), and data was 
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normalised to siCon. N=3 and error bars represent SEM. T-tests were used (p-value 
of: <0.05*, <0.01**, <0.001***, <0.0001****). 
 
This effect was also the greatest in Ovcar4 cells compared to the platinum-resistant 
cells, so this confirmed our cell viability data and further suggested that Ovcar4 cells 
may have a threshold of expression of both FOXM1 and NQO1 required for viability, 
and loss of both results in a reduction in cell viability and colony formation. 
 
4.3 Cisplatin-resistant cells are not re-sensitised to 
Cisplatin upon Foxm1 + Nqo1 silencing 
Our data thus far suggests that loss of both FOXM1 and NQO1 causes a reduction 
in cell viability (Figure 26) and colony formation (Figure 27A-C). We next wanted to 
determine whether this loss of expression could re-sensitise platinum-resistant cells 
to Cisplatin. We transfected the Ovcar4 and Ov4cis cells with either siRNA against 
FOXM1 and NQO1, alone or together, or a non-targeting siRNA control (siCon), 
followed by treating the cells with increasing concentrations of Cisplatin, or vehicle 
control. We analysed cell viability after 96-hours post-treatment with Cisplatin. 
Figure 28B shows that there was no re-sensitisation to Cisplatin with Foxm1 
silencing + Nqo1 silencing at the concentrations tested, as observed for single 
transfections in Figure 25B. Consistent with data in Figure 25A, there was increased 
resistance to Cisplatin when Nqo1 was silenced alone in the Ovcar4 cells, and this 
was not observed in the Ov4cis cells.  
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Figure 28. Cisplatin-resistant cells are not re-sensitised to Cisplatin upon 
Foxm1 + Nqo1 silencing. 
A) Ai) B) Bi) Cisplatin sensitisation was measured using CTG, post-treatment with 
Cisplatin after Foxm1 silencing and Nqo1 silencing, alone or together, in a 96-well 
plate. The controls used for this transfection were siCon (negative control) and 
siPLK1 (positive control), and data was normalised to siCon. Two repeats are 
shown for each cell line, and error bars represent SD.  
 
Ov4cis cells had a reduced cell viability when Nqo1 alone was silenced, and this 
appears to be the opposite of Ovcar4 cells, however it must also be noted that there 
was toxicity observed for siCon in Ov4cis cells (Figure 28). Therefore, it would be 
difficult to conclude that this effect is the opposite of Ovcar4 cells without optimising 
the experiment to ensure that there was no experimental toxicity due to siRNA 
transfection. 
 
4.4 The FOXM1 inhibitor Thiostrepton sensitises 
ovarian cancer cells to Cisplatin 
To further understand the role of FOXM1 and NQO1 in Cisplatin resistance, we next 
used the FOXM1 inhibitor Thiostrepton to see whether an alternate means of 
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inhibiting FOXM1 may influence the sensitivity to Cisplatin. To this end, we 
transfected with either siRNA against NQO1 or a non-targeting siRNA control 
(siCon) and treated the cells with 1M Thiostrepton +/- 3M Cisplatin or vehicle 
control. We analysed cell viability after 96-hours drug treatment. Cisplatin 
concentrations were again based on previous experiments in this project, and 
Thiostrepton concentrations were based on literature in ovarian cancer cells to 
ensure FOXM1 inhibition and low toxicity [173]. This also supported Thiostrepton 
concentrations used in Figure 23. 
 
Our previous data was confirmed, where Nqo1 silencing caused resistance to 
Cisplatin in the Ovcar4 cells. Treatment with Thiostrepton confirmed previously 
published data, and Thiostrepton caused sensitisation to Cisplatin in Ovcar4 and 
Ov4cis cells, compared to treatment with either agent alone (Figure 29A-B) [188, 
308, 309]. Data was not combined because of Thiostrepton toxicity in second 
repeat. 
 
 
 
 
171 
 
 
 
Figure 29. Thiostrepton sensitises ovarian cancer cells to Cisplatin. 
A) B) Cisplatin sensitisation was measured using CTG, post-treatment with 1µM 
Thiostrepton +/- 3µM Cisplatin, or vehicle control, after Nqo1 silencing in a 96-well 
plate. Data was normalised to its vehicle control sample, H2O control. Two repeats 
are shown for each cell line, and error bars represent SD.  
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4.5 The effect of Foxm1 + Nqo1 silencing is not 
additional to Nqo1 silencing, where the antioxidant 
enzymes SOD1 and Gpx1 have increased protein 
expression 
Our previous data has suggested that SOD1 expression was also increased in the 
platinum-resistant ovarian cancer cells, therefore we analysed whether expression 
of SOD1 and a further enzyme in the NRF2-antioxidant response pathway, Gpx1, 
were influenced by changes in FOXM1 or NQO1 expression. We immunoblotted 
protein lysates that had been isolated from Ovcar4, Ov4cis and Ov4carbo ovarian 
cancer cell lines that had been transfected with either siRNA against FOXM1 or 
NQO1, alone or together, or a non-targeting siRNA control (siCon).  
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Figure 30. SOD1 and Gpx1 protein expression levels upon Foxm1 and Nqo1 
double silencing in the ovarian cancer cell lines Ovcar4, Ov4cis and 
Ov4carbo. 
A) Ai-iii) B) Bi-iii) Whole cell lysates collected 72-hours post-transfection with 
siFoxm1(5) and siNqo1(pool), alone or together, were analysed on Western blot 
and probed with FOXM1, NQO1, SOD1 and Gpx1 antibodies. β-tubulin was used as 
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a loading control. The controls used for this transfection were siCon (negative 
control) and siPLK1 (positive control). N=1. Image J was used to quantify Western 
blots. 
 
Interestingly, in the all cell lines, we observed an increase in the expression of 
SOD1, upon Nqo1 silencing and this was maintained upon Foxm1 + Nqo1 silencing 
(Figure 30A). We also observed an increase in the expression of Gpx1, upon 
Foxm1/Nqo1 silencing and upon Foxm1 + Nqo1 silencing, in Ov4carbo cells (Figure 
30B), suggesting FOXM1 and NQO1 may be regulating the NRF2-antioxidant 
pathway in general. 
 
5.0 Analysing the sensitivity of ovarian cancer cells 
to Thiostrepton and to Diminutol 
5.1 Treatment with the FOXM1 inhibitor Thiostrepton 
and the NQO1 inhibitor Diminutol reduce cell viability  
Based on our data demonstrating that silencing of Foxm1 and Nqo1 together 
reduced cell viability (Figure 26) and colony formation (Figure 27A-C) in our ovarian 
cancer cells, and the greatest in the Ovcar4 cells, we next wanted to understand the 
therapeutic implications of this and whether this could be exploited with clinical 
inhibitors of FOXM1 (Thiostrepton) and NQO1 (Diminutol). To this end, we first 
determined whether these drugs alone caused any effect on cell viability in our cells 
by treating cells with either increasing concentrations of the FOXM1 inhibitor 
Thiostrepton (Figure 31A) or the NQO1 inhibitor Diminutol (Figure 31B) for 72-
hours, and analysed cell viability.  
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A range of Thiostrepton and Diminutol concentrations were tested to support further 
selection of concentrations in combination strategy experiments for Figures 32-34. 
Diminutol has a reported Ki of 1.72μM, as a competitive inhibitor of NQO1 [152]. 
Therefore, concentrations selected were also based on what is already known 
about the compound. 
 
 
Figure 31. Sensitivity of ovarian cancer cells to Thiostrepton treatment and 
Diminutol treatment. 
A) Dose response curves for Thiostrepton in ovarian cancer cells, after 72-hours 
treatment in a 96-well plate. Data was normalised to vehicle control. N=1 and error 
bars represent SD. B) Dose response curves for Diminutol in ovarian cancer cells, 
after 72-hours treatment in a 96-well plate. N=1 and error bars represent SD. 
 
Table 8. IC50 values for ovarian cancer cells treated with Thiostrepton and 
Diminutol. 
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Our results suggest that there was no difference in sensitivity to either Thiostrepton 
or Diminutol alone in the Ov4cis cells, in comparison to the parental Ovcar4 cells 
(Table 8). 
 
6.0 A combined treatment of Thiostrepton and 
Diminutol show they more greatly reduce viability in 
ovarian cancer cells 
6.1 Thiostrepton and Diminutol treatment in 
combination cause significantly reduced cell viability, 
compared to either agent alone  
Previous investigations have shown that when Thiostrepton or Bortezomib were 
used in combination with ROS inducers, this caused apoptosis [187]. There is 
currently no published data on FOXM1 inhibitors being used in combination with 
NQO1 inhibitors. To investigate this, we treated Ovcar4 and Ov4cis cells with 2M 
Thiostrepton, 10M Diminutol, 2M Thiostrepton + 10M Diminutol or vehicle 
control and analysed cell viability after 96-hours. Our results suggested that 
treatment with Thiostrepton and Diminutol in combination caused a greater 
reduction in cell viability, compared to either agent alone (Figure 32A-B).  
 
178 
 
 
Figure 32. Treatment with Thiostrepton and Diminutol in combination cause a 
greater reduction in cell viability, compared to either agent alone, in ovarian 
cancer cells. 
A) B) Cell viability was measured using CTG, at 96-hours post-treatment in a 96-
well plate. The treatments used were 2µM Thiostrepton alone (white), 10µM 
Diminutol alone (white), 2µM Thiostrepton + 10µM Diminutol (red) and vehicle 
control, DMSO (grey). Data was normalised to its vehicle control sample, DMSO. 
N=3 and error bars represent SEM. T-tests were used (p-value of: <0.05*, 
<0.0001****). 
 
Since both the Ovcar4 cells and the Cisplatin-resistant cells had reduced cell 
viability upon treatment with our combination therapy, this suggests that this 
treatment is independent of chemosensitivity as well as expression levels of FOXM1 
and NQO1. Given the role of FOXM1 in regulating DNA repair and the antioxidant 
response pathway protein NRF2 [115, 302], reduced levels of this protein could be 
detrimental to cells by causing increased DNA damage and/or increased oxidative 
stress. Then, given the role of NQO1 as a ROS scavenger [141], reduced levels of 
this protein could also be detrimental to cells by causing increased oxidative stress. 
Taken together, this result suggests that targeting FOXM1 and NQO1 in cancer 
cells could have translational relevance, and that Thiostrepton and Diminutol could 
be an effective treatment option for cancer patients. 
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7.0 Investigating the mechanistic basis for 
Thiostrepton and Diminutol as a combination therapy 
7.1 There are increased DNA double-strand breaks 
upon treatment with Thiostrepton and Diminutol, 
compared to either agent alone, in Cisplatin-resistant 
ovarian cancer cells  
Having observed an increased reduction in cell viability upon treatment with 
Thiostrepton and Diminutol in combination (Figure 32A-B), we next investigated the 
mechanism for our treatment combination. The action of Thiostrepton is firstly on 
FOXM1, through inhibition, and subsequently on expression of various downstream 
proteins, including DNA repair protein expression [115]. So this led us to investigate 
the amount of DNA double-strand breaks in our cells, under our different treatment 
conditions. Previously, FOXM1-deficient cells have been shown to exhibit increased 
DNA breaks [115, 118]. We have also shown a significant increase in DNA double-
strand breaks upon treatment with Thiostrepton and Olaparib, compared to either 
agent alone, in breast cancer cells (Results, Chapter 3). 
 
We therefore determined whether Thiostrepton and Diminutol in combination 
caused enhanced DNA double-strand breaks in our cells, compared to either agent 
alone. To this end, we treated Ovcar4, Ov4cis and Ov4carbo cells with 2M 
Thiostrepton, 5M Diminutol, 2M Thiostrepton + 5M Diminutol or vehicle control. 
We analysed γH2AX foci, a marker of DNA double-strand breaks, after 48-hours 
and determined that DNA double-strand breaks were increased upon treatment with 
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Thiostrepton and Diminutol, compared to either agent alone, in the Ov4cis cells 
(Figure 33B).  
 
In Ov4cis cells only, we observed an increase in DNA double-strand breaks in cells 
treated with Thiostrepton and Diminutol in combination, compared to either agent 
alone. Whereas, in Ov4carbo cells, there was a significant increase in DNA double-
strand breaks upon treatment with Thiostrepton alone, but not in combination with 
Diminutol. This result could suggest that this mechanism of increase DNA double-
strand breaks may be playing a lesser role in Ov4carbo cells, and needs to be 
further investigated. In Ovcar4 cells, the error bars are too large to make any 
conclusions about the response, and therefore needs to be repeated. 
 
 
Figure 33. γH2AX foci in ovarian cancer cells upon treatment with 
Thiostrepton alone, Diminutol alone and Thiostrepton and Diminutol in 
combination. 
A) B) C) Percentage of total number of cells containing more than 5 foci were 
measured using confocal microscopy, 48-hours post-treatment of cells on coverslips 
in a 24-well plate. The treatments used were 2µM Thiostrepton (white), 5µM 
Diminutol (white), 2µM Thiostrepton + 5µM Diminutol (red) and vehicle control, 
DMSO (grey). N=2 and error bars represent SEM. T-tests were used (p-value of: 
<0.05*). 
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Our results suggest that increased DNA double-strand breaks may be contributing 
to the mechanism of action of our combination therapy. This does not exclude the 
possibility that other mechanisms may also be acting in cells treated with 
Thiostrepton and Diminutol in combination. 
 
7.2 There is a significant increase in reactive oxygen 
species upon treatment with Thiostrepton and 
Diminutol, compared to either agent alone, in 
Cisplatin-resistant ovarian cancer cells  
To further investigate the mechanism for our treatment combination, we next 
considered reactive oxygen species production in our cells, under our different 
treatment conditions. Previously, melanoma cells were examined for upregulation of 
cellular oxidative stress in response to 10μM Thiostrepton, for 1- to 6-hour 
exposure, where there was around five-fold increase in ROS within an hour of 
exposure to Thiostrepton [326]. FOXM1-deficiency has also been shown to cause 
elevated ROS levels [119]. Whilst lung adenocarcinoma cells examined after NQO1 
depletion showed increased endogenous ROS [327], and pancreatic cancer cells 
treated with the NQO1 inhibitor Dicoumarol induced growth inhibition through 
increased ROS production [328]. Conversely, prostate cancer cells examined after 
inhibition of NQO1 showed decreased endogenous ROS [329], and 
cholangiocarcinoma cells treated with the NQO1 inhibitor Dicoumarol showed no 
increase in ROS formation [158]. These differences in ROS generation could be 
cell-specific, and NQO1 inhibition could exert different cell killing mechanisms. 
Furthermore, regulation through the ROS response may be selective. 
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Therefore, given the extensive literature linking FOXM1 and NQO1 inhibition to 
ROS generation, we determined whether Thiostrepton and Diminutol in combination 
caused enhanced reactive oxygen species production in our cells, compared to 
either agent alone. To this end, we treated Ovcar4 and Ov4cis cells with 10M 
Thiostrepton, 10M Diminutol, 10M Thiostrepton + 10M Diminutol or vehicle 
control. We analysed production of reactive oxygen species, a marker of oxidative 
stress, after 3-hours and determined that there was a trend for increased ROS 
generation upon treatment with Thiostrepton and Diminutol, compared to either 
agent alone, in the Ov4cis cells (Figure 34B). Our results therefore suggest our 
combination therapy may also affect ROS generation. 
 
Figure 34. ROS production in the ovarian cancer cells upon treatment with 
Thiostrepton alone, Diminutol alone and Thiostrepton and Diminutol in 
combination. 
A) B) ROS levels (fluorescence), normalised to cell viability (luminescence), were 
measured 3-hours post-treatment in a 96-well plate. The treatments used were 
10µM Thiostrepton (white), 10µM Diminutol (white), 10µM Thiostrepton + 10µM 
Diminutol (red) and vehicle control, DMSO (grey). Data was normalised to its 
vehicle control sample, DMSO. N=1 and error bars represent SD.  
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8.0 Investigating the therapeutic implications of 
combining Thiostrepton and ROS-inducing agents  
8.1 A combined treatment of Thiostrepton and ROS-
inducing agents show they cause a more greatly 
reduced cell viability in breast cancer cells 
Alongside our investigation of FOXM1, NQO1 and chemoresistance, we also 
investigated the therapeutic implications of combining the FOXM1 inhibitor 
Thiostrepton and ROS-inducing agents in breast cancer cells. Using this approach, 
we were able to explore other combination treatment options. We could also confirm 
previously published data for Thiostrepton or Bortezomib used in combination with 
ROS inducers to cause apoptosis [187]. 
 
We began by treating cells with the ROS-inducing agents, Menadione and 
Podophyllotoxin in dose responses, and determined if our cells responded 
differently to each ROS-inducing agent. To this end, we treated our cells with 
increasing concentrations of Menadione (Figure 35A) and Podophyllotoxin (Figure 
35B). A range of Menadione and Podophyllotoxin concentrations were tested to 
support further selection of concentrations in combination strategy experiments for 
Figures 36-37. Menadione has been shown to induce ROS in breast cancer cells at 
5μM [330]. Furthermore, a Podophyllotoxin derivative has been shown to induce 
ROS in breast cancer cells at 10μM [331]. The literature also guided our decision 
about which concentrations to test. This was considered alongside compound 
toxicity. 
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We analysed cell viability after 72-hours, and determined that HCC1954 and MCF7 
were more sensitive to the ROS-inducing agent Podophyllotoxin than Menadione 
(Table 9). 
 
 
Figure 35. Sensitivity of breast cancer cells to the ROS-inducing agents, 
Menadione and Podophyllotoxin. 
A) Dose response curves for Menadione in breast cancer cells, after 72-hours 
treatment in 96-well plate. Data was normalised to its vehicle control. N=2 and error 
bars represent SE. B) Dose response curves for Podophyllotoxin in breast cancer 
cells, after 72-hours treatment in 96-well plate. N=3 and error bars represent SE.  
 
Table 9. IC50 values for breast cancer cells treated with Menadione and 
Podophyllotoxin. 
 
We then tested ROS-inducing agents in combination with Thiostrepton to explore 
other potential combination therapy options for patients. In the first instance, we 
used the FOXM1 inhibitor Thiostrepton and the ROS-inducing agent Menadione. To 
this end, we treated HCC1954 with 50nM Thiostrepton, MCF7 with 500nM 
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Thiostrepton, both cell lines with 8M or 5M Menadione, combination options or 
vehicle control, on day 2 and day 7. We analysed cell viability on day 10, and 
determined that Thiostrepton and Menadione in combination caused a greater 
reduction in cell viability, compared to either agent alone (Figure 36A-B). 
 
 
 
Figure 36. Treatment with Thiostrepton and Menadione in combination cause 
greater reduction in cell viability, compared to either agent alone, in breast 
cancer cells. 
A) Ai) B) Cell viability was measured using CTG, on day 10 post-treatment in a 96-
well plate. The treatments used were Thiostrepton alone (white), Menadione alone 
(white), Thiostrepton and Menadione in combination (red), and DMSO-vehicle 
control (grey). For HCC1954, the treatments were 50nM Thiostrepton alone, 8µM 
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Menadione alone, 5µM Menadione alone, 50nM Thiostrepton + 8µM Menadione, 
50nM Thiostrepton + 5µM Menadione and vehicle control. The treatments used for 
MCF7 were 500nM Thiostrepton alone, 8µM Menadione alone, 5µM Menadione 
alone, 500nM Thiostrepton + 8µM Menadione, 500nM Thiostrepton + 5µM 
Menadione and vehicle control. Data was normalised to its vehicle control sample, 
DMSO. Two repeats shown (HCC1954) and N=1 (MCF7) is shown and error bars 
represent SD. 
 
The FOXM1 inhibitor Thiostrepton was also combined with the ROS-inducing agent 
Podophyllotoxin. To this end, we treated HCC1954 with 40nM Thiostrepton, MCF7 
with 50nM Thiostrepton, both cell lines with 10nM Podophyllotoxin, combination 
options or vehicle control, on day 2, day 5 and day 8. We analysed colony formation 
on day 11 and determined that Thiostrepton and Podophyllotoxin in combination 
caused a more significantly reduced colony formation, compared to either agent 
alone (Figure 37A-B). 
 
 
Figure 37. Treatment with Thiostrepton and Podophyllotoxin in combination 
cause a greater reduction in colony formation, compared to either agent 
alone, in breast cancer cells. 
A) B) Colony formation was measured using SRB staining and counting colonies, 
on day 11 post-treatment in a 6-well plate. The treatments used were Thiostrepton 
alone (white), Podophyllotoxin alone (white), Thiostrepton and Podophyllotoxin in 
combination (red), and ethanol-vehicle control (grey). For HCC1954, the treatments 
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were 50nM Thiostrepton alone, 10nM Podophyllotoxin alone, 50nM Thiostrepton + 
10nM Podophyllotoxin and vehicle control. The treatments used for MCF7 were 
40nM Thiostrepton alone, 10nM Podophyllotoxin alone, 40nM Thiostrepton + 10nM 
Podophyllotoxin and vehicle control. Data was normalised to its vehicle control 
sample, ethanol.  N=3 and error bars represent SEM. T-tests were used (p-value of: 
<0.01**, <0.0001****). 
 
Our data suggests that Thiostrepton and the ROS-inducing agents, Menadione and 
Podophyllotoxin, can be used in combination in a therapeutic context. These 
combinations could be used as an alternative treatment option for cancer patients. 
 
Taken together, we have confirmed that FOXM1 plays a role in the oxidative stress 
response, and that this role can be exploited therapeutically. Our data suggests that 
there may be a regulatory relationship between FOXM1 and NQO1, and upon 
depletion of these proteins together, we observed a greater reduction in cell viability 
and colony formation in ovarian cancer cells. Furthermore, we have suggested that 
FOXM1 and NQO1 may be involved in driving Cisplatin resistance in ovarian cancer 
cells. Therapeutically, we have shown that the FOXM1 inhibitor Thiostrepton and 
the NQO1 inhibitor Diminutol could be offered as a potential combination therapy to 
help treat cancer patients. 
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1.0 Thiostrepton and Olaparib are synthetically lethal 
in breast cancer 
1.1 FOXM1 in normal cells and cancer cells 
FOXM1 plays an extensive number of roles in the cell. These roles are essential to 
many fundamental cellular pathways, including cell cycle regulation, DNA damage 
response regulation and oxidative stress response regulation, where FOXM1 is 
itself regulated through auto-regulation and post-translational modifications [98, 
105, 115, 199]. Therefore, FOXM1 has functional significance in normal cells, and it 
is these activities have been harnessed by cancer cells by increasing expression of 
this transcription factor [180].  
 
Overexpression of FOXM1 has been identified in several solid tumours, and it has 
been subsequently recognised as a tumour biomarker [180]. Poor prognosis has 
also been linked to patients with higher expression of FOXM1 [169]. In studies of 
specific cancer types, such as breast cancer, HER2 status was found to be 
correlated with FOXM1, where FOXM1 could be used as a potential target in 
resistant breast cancer tumours [168]. Not only have cancer cells been shown to 
have higher FOXM1 expression, this increased FOXM1 expression has also been 
implicated in chemoresistance [191]. 
 
Taken together, FOXM1 represents a novel candidate in cancer therapy, and its 
role in chemoresistance emphasises a greater need for developing novel treatment 
strategies for cancer patients. It is also important that a patient’s normal cells may 
be spared in this treatment approach, so that only the cancer cells are susceptible 
to the cancer therapy. 
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1.2 FOXM1 and homologous recombination 
This project first proposed to exploit the role of FOXM1 in homologous 
recombination, using a combination therapy to achieve a synthetic lethal approach, 
with translational application [116-118]. The success demonstrated by existing 
clinically relevant synthetic lethal approaches, such as those of PARP inhibitors in 
Brca1/2-deficient cancers, as well as several other studies that have identified 
synthetic lethal combinations, such as MMR-deficiency and Methotrexate, led us to 
apply a similar approach in the context of targeting FOXM1 and reduced 
homologous recombination [40, 299].  
 
To expand on the topic of synthetic lethal approaches, in view of other successes 
and possible limitations, another example includes the identification of 3′-
phosphoadenosine 5′-phosphosulfate (PAPS) synthase 1 (PAPSS1) as a novel 
platinum-sensitising target in non-small cell lung cancer [332]. The clinical potential 
of this study is that it addresses an existing treatment problem in advanced non-
small cell lung cancer patients, where the standard platinum-based chemotherapy 
response rate is only 30–33% [332]. A limitation of this current study, however, is 
that an siRNA approach to targeting PAPSS1 was used, and this would be difficult 
to deliver in therapeutically relevant doses [332]. Therefore, validating potent 
PAPSS1 inhibitors for use as a therapeutic agent would be required as the next 
step [332]. Overall, this study is also relevant to our project, such that it shows how 
we can use siRNA and compounds as two experimental approaches, to 
demonstrate and validate synthetic lethality in cancer cells. 
 
Since FOXM1 has been shown to directly regulate HR genes, including Rad51, 
Brip1 and Nbs1, we were first of all interested to determine whether we could 
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correlate FOXM1 with HR proteins in different panels of cancer cell lines [116-118]. 
Since RAD51 is a central enzymatic component of HR, we decided to correlate 
expression levels of FOXM1 with expression levels of RAD51. In one study, the role 
of RAD51 in tumourigenesis was investigated [333]. The authors found that cells 
expressing a dominant-negative form of RAD51 generated more tumours, with 
faster growth, compared to control and wild-type mammalian RAD51 cells [333]. 
That said, overexpression of RAD51 stimulated HR, and induced strong 
chromosome instability, and this showed that there are risks of excess HR [334]. 
Altogether, this data has indicated the importance of tight control of the level of HR. 
 
As our later mechanistic data also showed, where Foxm1 silencing reduced 
expression levels of HR genes, alongside this initial Western blot correlation, we 
were able to confirm current findings that have been previously discussed, which 
have demonstrated FOXM1 as a transcriptional regulator of genes involved in HR. 
Then, going further, our data showed for the first time that Rad51 is regulated by 
FOXM1 in breast cancer cells, having only previously been shown in glioblastoma 
cells [116]. Our data also revealed the potential extent at which FOXM1 regulates 
members of the HR pathway in breast cancer cells, where Rad51 and Brip1 mRNA 
levels seemed more reduced upon Foxm1 silencing, compared to our other 
investigated genes, Brca2 and Nbs1. This data will be further considered later on in 
our discussion, once our combination therapy has been discussed.  
 
To investigate the relationship between FOXM1 and RAD51 in a more clinically 
relevant setting, we used patient data and observed that higher FOXM1 expression 
and higher RAD51 expression both, individually, correlated with a reduced survival 
probability. Again, our data validated the earlier findings in glioblastoma patients 
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[116], this time in breast cancer patients. It may be of added benefit to explore the 
relationship between FOXM1 and RAD51 together to add to what we have 
investigated here, which was individually, in patients with reduced survival 
probability. Furthermore, it may also be of benefit to investigate the correlation of 
FOXM1 and RAD51 in breast cancer samples using immunohistochemical 
analyses, as carried out in recurrent glioblastoma samples [116]. Overall, we could 
use additional patient data to supplement the in vitro data that we have obtained. 
 
1.3 Selecting compounds for our combination 
therapy 
After our initial investigations showed a relationship between FOXM1 and RAD51 in 
breast cancer cells that could be further explored, this prompted us to next test a 
combination treatment strategy in these cells. This would be on the basis of 
exploiting targeting FOXM1 and HR, in cancer cells, whilst sparing a patient’s 
normal cells. Our combination strategy was first on our experimental priorities so 
that we could develop a therapy that would have translational benefit to cancer 
patients. Once established, we then intended to go on and investigate the possible 
mechanistic implications of our combination therapy. 
 
This combination therapy was in fact very much a case of applying what has been 
successfully, and clinically, achieved with PARP inhibitors. Instead of exploiting a 
germline Brca1/2 mutation or “BRCAness” in tumours, which causes ineffective HR 
and therefore leads to increased sensitivity to PARP inhibitors and ultimately 
selective cell death, our approach was almost to mimic this effect upstream of this 
pathway, by targeting an upstream regulator of HR genes [277]. So, by targeting 
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FOXM1, this would in turn reduce expression levels of its downstream targets, 
including HR genes, and then FOXM1-targeted cancer cells could be sensitised to 
PARP inhibition, and induce selective cell death. 
 
As alluded to previously, the concept of targeting FOXM1 as part of a combination 
therapy is not entirely new. In fact, at the time of our study, there were other groups 
working on similar concepts to us. In particular, the authors of one of the most 
recent of these studies were able to show that targeting FOXM1 with Thiostrepton 
induced “BRCAness” and enhanced sensitivity to Olaparib, in ovarian cancer cells 
[310]. We have shown for the first time that this synthetic lethality approach can 
occur in breast cancer cells. It is also important to note that this work provided some 
insight into the adaptive response of ovarian cancer cells to PARP inhibition, 
relating to the emergence of chemotherapy resistance that is often observed in 
ovarian cancer patients [310]. The adaptive cellular response has been suggested 
to provide a transitional state for cells to acquire fitness-conferring genetic 
mutations, after several rounds of treatment with chemotherapeutic agents, and the 
authors have implicated FOXM1-mediated adaptive pathways to be involved in this 
response [310]. Furthermore, regarding the mechanism of action of PARP 
inhibitors, as previously discussed, the authors observed that Thiostrepton caused 
an enhanced amount of DNA damage and PARP1 trapping in cells treated with 
Olaparib [310]. This was referred to as being a further mechanistic explanation for 
increased sensitivity to Olaparib, as PARP trapping has been considered to be 
more cytotoxic than inhibition of the enzymatic activity of PARP [289, 310]. Upon 
PARP trapping, PARP1 is trapped on DNA by the PARP inhibitor, and PARP1-DNA 
complexes could then interfere with DNA replication, and this mechanism therefore 
explains why despite similar potencies to inhibit PARP catalytic activity, PARP 
trapping can affect the toxicity of different PARP inhibitors [289]. 
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Other studies demonstrated that targeting FOXM1 induced Cisplatin sensitivity in 
ovarian cancer cells [308]. This study is clinically relevant to ovarian cancer patients 
because chemotherapy represents a standard of care treatment option for these 
patients, and emergence of chemoresistance to Cisplatin is a problem for 
successful treatment [308]. FOXM1 was shown to be higher in patient samples that 
were Cisplatin-resistant, compared to Cisplatin-sensitive, and when FOXM1 was 
targeted this increased sensitivity to Cisplatin [308]. As EXO1 was identified to be 
regulated by FOXM1 and DNA repair was promoted upon Cisplatin treatment, it was 
suggested that targeting FOXM1 and EXO1 could improve Cisplatin sensitivity in 
patients [308]. This study provides a potential parallel with our data. While EXO1 is 
the only DNA repair protein implicated in this study of Cisplatin sensitivity, other 
DNA repair proteins, such as those included in our project, may also contribute to 
Cisplatin resistance. Therefore, FOXM1 inhibition in combination with PARP 
inhibition may provide a potential therapeutic opportunity to overcome Cisplatin 
resistance in cancer cells. 
 
The choice of FOXM1 inhibitors and PARP inhibitors are extensively covered in the 
Introduction, and indeed many of those listed represent suitable candidates to be 
used in our combination treatment strategy. As our study had a principle focus on 
identifying a novel treatment combination with translational benefit in breast cancer 
patients, it was certainly of consideration to select two compounds that are already 
FDA-approved so that they could therefore enter clinical trials at a more advanced 
stage of the drug discovery process.  
 
Of the FOXM1 inhibitors previously discussed, a number of studies that have been 
conducted using these compounds to inhibit FOXM1, yet there are differing insights 
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into the mechanistic activity of these compounds. Then, it is also worth considering 
that the thiazole antibiotics Siomycin A and Thiostrepton were the first chemical 
inhibitors of FOXM1 to be identified [183, 194, 198]. While proteasome inhibitors, 
such as Bortezomib, and small molecule inhibitors were next identified [195]. 
 
When the mechanism of action of these FOXM1 inhibitors was explored, 
Thiostrepton has been subjected to a more in-depth understanding, compared to 
the other compounds. In an early study, Siomycin A was suggested to act by at 
least two mechanisms when antagonising FOXM1 [194]. This included blocking its 
phosphorylation, thereby causing reduced transactivation ability, and down-
regulation of FOXM1 mRNA and protein levels [194]. However, this was later 
subjected to a certain level of scrutiny in a correspondence which indicated that a 
complete model for the mechanism of action of thiazole antibiotics was still lacking, 
at that time [335]. In particular, the correspondence mentioned how the effect of 
Siomycin A treatment on non-transformed cells had not yet been investigated, and 
that this may have important implications for the mechanism of action of Siomycin A 
[335]. 
  
Studies have shown that Thiostrepton specifically inhibited proliferation of MCF7 
breast cancer cells, but not MCF10A breast epithelial cells, suggesting that 
Thiostrepton does not promote a general cytotoxic phenotype [183]. It also showed 
that Thiostrepton inhibited FOXM1 protein and mRNA expression, and that FOXM1 
expression was inhibited predominantly at the gene promoter level [183]. Therefore, 
these authors have suggested that FOXM1 may be a target of Thiostrepton 
because of decreased FOXM1 mRNA levels upon Thiostrepton treatment, which 
may also be supported by the proposed auto-regulatory mechanism of FOXM1 itself 
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[183, 199]. In a later study, Thiostrepton was shown to directly bind to the FOXM1 
protein, thus preventing its interaction with several gene promoters, but not 
necessarily to its own [203].  
 
In another study, Thiostrepton’s suggested activity of inhibiting transcriptional 
activity and FOXM1 expression via proteasome inhibition was considered [204]. As 
proteasome inhibitors act to stabilise cellular proteins, this seemingly 
counterintuitive model was further investigated [205]. Therefore, in this model, 
proteasome inhibitors were suggested to increase expression of a putative negative 
regulator of FOXM1, and this putative negative regulator was later identified as 
HSP70 [204, 205].  
 
The proteasome inhibitor Bortezomib has also been identified as a FOXM1 inhibitor, 
and it has been shown to inhibit FOXM1 transcriptional activity and FOXM1 
expression [195]. The selectivity of Bortezomib has not yet been discussed in the 
context of studies that have investigated its role as a FOXM1 inhibitor. That said, 
Bortezomib is a 26S proteasome inhibitor that is used in the treatment of 
relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM), and a 
study has demonstrated that Bortezomib significantly down-regulated IκBα 
expression and triggered NF-κB activation in MM cell lines and primary tumour cells 
from MM patients [336]. Furthermore, as mentioned in the introduction, Bortezomib 
was the first proteasome inhibitor to enter clinical practice [206]. Bortezomib has 
also been used in a study as a potential inhibitor of oestrogen receptor‐positive 
breast cancer, where FOXM1 was among a list of genes down-regulated by this 
compound [337]. It was also suggested that FOXM1 may mediate the effects of 
Bortezomib on multiple genes [337]. Despite the potential benefits of using this 
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compound in our studies, it may be more challenging to introduce this clinically 
because of the previously discussed restrictions on Bortezomib, such as dose 
limiting toxicity [206]. 
 
Collectively, based on the studies discussed, Thiostrepton has received more 
coverage in the current literature, compared to other FOXM1 inhibitors. This can be 
further emphasised by the extensive use of Thiostrepton in studies of different 
cancer types including, human cancer cells testing different lines [198], 
nasopharyngeal carcinoma cells [338], medulloblastoma cells [201], and ovarian 
cancer cells [310]. So, together with the mechanistic studies of Thiostrepton that 
showed selectivity for MCF7 breast cancer cells, compared to MCF10A breast 
epithelial cells, as well as the model for direct interaction of Thiostrepton with 
FOXM1, and the use of Thiostrepton in different cancer types, made this the 
compound of choice for our study. 
 
Whilst the studies previously discussed highlight the several benefits to using 
Thiostrepton as a FOXM1 inhibitor, there still exist potential limitations when 
translating this to human treatment. This was referred to by Fang and colleagues, 
where they mentioned that whilst it has current use as a topical antibiotic, human 
use could be limited by the low solubility and bioavailability [310]. A study has 
shown that micelle-formulated Thiostrepton had better solubility and 
pharmacodynamic effect on the tumour in xenograft models [310, 339]. Therefore, 
Thiostrepton may still represent a highly suited compound for treatment of human 
cancer, when formulated into nanoparticles [339]. 
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Of the PARP inhibitors discussed, the selection was more straightforward than that 
of the FOXM1 inhibitors. This was more to do with the fact that PARP inhibitors 
currently offer huge clinical benefits to cancer patients. Several PARP inhibitors 
have been identified, and Olaparib represents the first PARP inhibitor to become 
available in clinical practice [40]. It has consequently been used in a number of 
studies and clinical trials, and its use has not been restricted to ovarian cancer 
patients, as it has also been shown to benefit breast cancer patients [39]. Olaparib 
has been used to treat patients with platinum-sensitive, relapsed, high-grade serous 
ovarian cancer, and has shown to significantly improve progression-free survival 
when used as a maintenance treatment [340]. Among patients with HER2-negative 
metastatic breast cancer and a germline Brca mutation, Olaparib monotherapy was 
demonstrated to have a significant benefit over standard therapy [39]. In another 
study, Olaparib as a monotherapy was evaluated in patients with Brca1/2-
associated cancers, and encouraging data was shown across different cancer types 
which could be followed up in phase III trials [341]. Therefore, PARP inhibitors as a 
treatment option for patients may not only be limited to breast cancers and ovarian 
cancers associated with germline Brca1/2 mutations, but may also be offered to 
other cancer patients [341]. 
 
In the FDA approval summary of Olaparib, treatment with Olaparib is indicated to 
give a better response rate and a favourable safety profile, compared to single 
agent chemotherapies that are available [40]. It is also stated that this compound 
has a relatively mild safety profile, rather than facing the cumulative toxicity from 
other treatment options [40]. Additionally, Olaparib is orally available, providing ease 
of administration, and has rapid absorption [40]. Clinical management of patients 
receiving Olaparib has also been investigated, and this is important to understand 
so that more supportive care can be offered to patients, caregivers, and health care 
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providers [342]. The provision of such documentation details some of the adverse 
effects associated with Olaparib treatment, and how dose modification may be an 
important consideration during therapy [342]. For example, fatigue may be 
experienced because of baseline disease-related fatigue, and gastrointestinal 
symptoms from disease burden, so awareness of these adverse effects can be 
effectively managed to allow therapy to continue [342]. Therefore, as a result of the 
extensive investigations of Olaparib, this compound was selected to be used in 
combination with Thiostrepton in our study. 
 
We were able to show for the first time that Thiostrepton and Olaparib caused 
greater reduction in cell viability and colony formation, compared to either agent 
alone, in breast cancer cells, using respective assays. Our results indicated that 
FOXM1 inhibition using Thiostrepton enhanced sensitivity to the PARP inhibitor 
Olaparib, as shown by two different experimental approaches.  
 
In terms of the benefits of our combination therapy compared to current standard of 
care treatments, the main aim of our research was to develop a novel combination 
therapy that can be offered as a treatment option to breast cancer patients. In the 
case of the study where Thiostrepton and Olaparib as a combination treatment 
strategy in ovarian cancer cells had been investigated, this was to overcome the 
adaptive cellular response and acquired resistance to chemotherapy [310]. 
Therefore, further investigation would be required to determine whether our 
combination therapy in breast cancer cells would offer the same outcome for 
patients who have chemoresistance. Nevertheless, our combination therapy was 
above all developed for the purpose of having translational benefit to breast cancer 
patients. 
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To be pursued clinically, the first major considerations would need to be reflective of 
current clinical data collected on patients who have already received treatment with 
Olaparib, and then how Thiostrepton may be used in a combination setting with this 
PARP inhibitor. Other major considerations would need to be inclusive of time- and 
dose-specific factors, to be tailored to individual patients. 
 
1.4 Mechanistic implications of Thiostrepton and 
Olaparib as a treatment, and sparing normal cells 
Once our combination therapy had been established we then decided to explore the 
mechanism of selectivity in cancer cells, compared to normal cells. By conducting 
Foxm1 silencing assays and time course assays, this enabled us to gain a more 
detailed understanding of how FOXM1 inhibition was mediating sensitisation to 
Olaparib. 
 
As previously mentioned, Foxm1 silencing reduced expression levels of HR genes, 
as measured by RT-qPCR, and this allowed us to determine the extent at which HR 
gene expression was affected in FOXM1-depleted breast cancer cells. This data 
may in turn provide insight into how Thiostrepton mediates sensitisation to Olaparib, 
so that the therapeutic implications of this treatment combination can be evaluated 
for clinical benefit to cancer patients.  
 
Whilst our Foxm1 silencing data showed significantly decreased mRNA expression 
of all HR genes tested, we observed that Rad51 and Brip1 were reduced more 
consistently than Brca2 and Nbs1, across our breast cancer cell lines. This result 
therefore suggested that RAD51 and BRIP1 could be under greater influence of 
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FOXM1. Since siRNA-mediated silencing is through mRNA degradation, while the 
mechanism of action of Thiostrepton is suggested to be through binding FOXM1 
and preventing the regulation of other gene promoters [203], we used this data to 
guide our mechanistic understanding of how breast cancer cells may become 
sensitised to Olaparib, after Thiostrepton treatment. 
 
In accordance with the previously discussed importance of testing Thiostrepton’s 
selectivity in breast cancer cells, compared to normal breast epithelial cells, we too 
assessed the selectivity of the response in our breast cancer cell lines, and our 
normal breast epithelial cell line [183].  
 
Firstly, regarding expression levels of FOXM1, we observed that FOXM1 
expression levels, mRNA and protein, decreased at an earlier time-point of 
Thiostrepton treatment in HCC1954 breast cancer cells, compared to MCF10A 
normal breast epithelial cells. This observation was somewhat different to what had 
been previously shown by Kwok and colleagues, where they suggested that 
Thiostrepton had no effect on FOXM1 expression in untransformed MCF10A cells 
[183]. Interestingly, this group had treated MCF10A cells with 10μmol/L 
Thiostrepton for up to and including, 72-hours [183]. So whilst they did not treat for 
the same duration of time as our assay, 120-hours, they had also used a 
considerably higher concentration of Thiostrepton, as we used 50nM Thiostrepton. 
Overall, this differing response to Thiostrepton treatment observed between our 
work and that of Kwok and colleagues could be attributed to different basal levels of 
FOXM1 to begin with in the MCF10A cell lines [183]. This could in turn be an 
important consideration for patients receiving our combination therapy, to spare 
their normal cells.  
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Since our HCC1954 breast cancer cells responded earlier to Thiostrepton 
treatment, through decreased FOXM1 expression levels, compared to our MCF10A 
normal breast epithelial cells, this could open up a therapeutic window in a clinical 
setting. This early response of HCC1954 breast cancer cells suggests that 
treatment would need to be tailored to the patient, in a time-specific manner, so that 
Thiostrepton would only cause FOXM1 inhibition in cancer cells, thus sparing 
normal cells.  
 
Referring back to the work of Kwok and colleagues, they observed a decrease in 
FOXM1 expression over the course of their time-points in MCF7 breast cancer cells, 
whilst we observed an initial decrease in FOXM1 expression in HCC1954 breast 
cancer cells, which was subsequently rescued over time [183]. These differences 
have therefore further illustrated the greater need for time- and dose-specific 
considerations, in a clinical setting. Then, as this is a combination therapy, the 
additional benefits of this strategy would be to use lower doses to reduce compound 
toxicity in patients. 
 
In further view of the mechanistic implications relating to the involvement of HR 
genes in mediating Olaparib sensitisation after Thiostrepton treatment, the 
expression changes observed over time with Thiostrepton treatment were not 
completely aligned with our Foxm1 silencing data. Notably, Brip1 expression 
remained higher than other HR genes at the time-point where Foxm1 expression 
was at its lowest. Yet, Rad51 expression was reduced to a similar level as the other 
HR genes tested, Brca2 and Nbs1.  
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Indeed, RAD51 could therefore play a more central role in mediating Olaparib 
sensitisation, after Thiostrepton treatment. This does not, however, exclude the 
possibility that other HR genes may also contribute to this sensitisation, albeit to a 
potentially lesser extent than RAD51. The implications of this could be viewed in 
different ways. In one instance, as RAD51 is fundamental to orchestrating the HR 
pathway, reducing expression levels of this particular protein with Thiostrepton 
treatment could assume a potentially greater sensitisation to Olaparib. This 
comparing to other less important proteins involved in the HR pathway, such that if 
their expression levels were reduced by treatment with Thiostrepton, the 
sensitisation to Olaparib may be lesser. In another instance, the repair mechanism 
choice during HR may also be considered, as this is critical in ensuring repair is as 
efficient and risk-free as possible [343]. In a study conducted in yeast cells, the 
authors described a model explaining how different repair mechanisms are able to 
compensate for each other during DSB repair [343]. They also referred to a balance 
between potentially competing DSB repair pathways [343]. Based on this study, it 
could be conceivable to suggest that cancer cells may exploit this kind of 
compensation and balance between repair mechanisms to their advantage, both in 
normal survival, and in overcoming treatment pressures such as our proposed 
combination therapy. Interestingly, another study has shown that upregulation of the 
HR pathway is capable of rescuing the growth and DNA repair defects associated 
with loss of BRCA1 function [344]. In particular, RAD51 was found to be 
upregulated, and shown to be a feature of BRCA1-deficient breast tumours [344]. 
This study therefore demonstrates that the expression levels of other proteins 
involved in HR can be altered when one protein becomes deficient in cells. Overall, 
these studies show how there may be changes in pathways and expression levels 
of other proteins to compensate for other changes in cells, such as the observed 
reduction in expression levels of HR proteins upon treatment with our combination 
therapy, Thiostrepton and Olaparib. Therefore, the implications here suggest that 
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cancer cells may have an enhanced sensitisation to Olaparib through reduced 
expression levels of RAD51, compared to other HR proteins. That said, cancer cells 
may adapt over time to our combination therapy, by employing compensatory 
mechanisms, and this could ultimately lead to the emergence of treatment 
resistance.  
 
1.5 Significance of increased DNA damage in 
combination therapy 
1.5.1 Decreased RAD51 may be mediating sensitisation to 
Olaparib 
Having evaluated which HR genes may be involved in mediating sensitisation to 
Olaparib, after Thiostrepton treatment, our studies of DNA damage, specifically 
DNA breaks, enabled us to gain even more insight of the mechanistic action of the 
compounds together, compared to either agent alone. As mentioned in the 
introduction, FOXM1’s role in the DNA damage response was not only illustrated by 
demonstrating that it transcriptional regulates a number of DNA repair genes, but 
that in cells transfected with siRNA targeted to FOXM1 had increased DNA breaks, 
too [115]. In their study, Tan and colleagues also showed that these FOXM1-
deficient cells increased activation of the tumour suppressor, p53, thus identifying a 
role for FOXM1 in the transcriptional response during DNA damage/checkpoint 
signalling [115]. 
 
As discussed earlier, Fang and colleagues observed that Thiostrepton enhanced 
DNA damage and PARP1 trapping in cells treated with Olaparib [310]. In their 
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study, they observed an increased level of γH2AX with Thiostrepton treatment, and 
this increase was enhanced when combined with Olaparib [310]. The data 
presented by Fang and colleagues in ovarian cancer cells corroborates our data in 
breast cancer cells, as we also observed an increased level of γH2AX in cells 
treated with Thiostrepton and Olaparib [310]. This significant increase in γH2AX foci 
in our study again implicates FOXM1 as playing an important role in regulating DNA 
repair genes and maintaining DNA repair efficacy. 
 
Furthermore, as γH2AX were observed in cells treated after 24-hours with our 
agents, this could account for the increased RAD51 protein expression initially 
observed in our Thiostrepton time course treatment Western blot, and could explain 
why this trend was not observed at the mRNA expression level. Thus still 
implicating RAD51 as playing a more prominent role in mediating sensitisation to 
Olaparib, after Thiostrepton treatment. 
 
Measuring γH2AX has clinical applications such as assessing DSBs levels induced 
by radio- and chemotherapy as a marker of treatment efficacy [345]. It is also used 
in dose/scheduling estimation, as well as in determining the efficiency of DNA repair 
to predict potential tumour sensitivity or resistance to DNA damaging anticancer 
agents [345]. Furthermore, by determining DSB levels induced by anticancer 
treatment in normal cells, this may help in predicting toxicity of anticancer treatment 
[345]. The main advantage of this as an approach, compared to other DNA damage 
markers, is the high sensitivity of the technique [345]. That said, other 
considerations include background levels of foci, and could make this difficult in 
predicting the toxicity of anticancer treatments in patients, when comparing DSBs in 
tumour cells and normal cells [345]. 
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1.6 What about other combination therapies?  
Our research has clearly demonstrated that Thiostrepton and Olaparib as a 
combination therapy could be further pursued clinically, and could subsequently 
offer breast cancer patients an alternative treatment option. That said, this by no 
means excludes the exploration of other potential treatment avenues, which may 
ultimately build on our study. 
 
Interestingly, a recent study has uncovered that PARP inhibitors not only cause 
tumour cell death by damaging their DNA, these cells are also subjected to attack 
by immune cells that are attracted to them [346]. PARP inhibitors seemingly 
unmask cancer cells from evasion of immune cells, and could help make 
immunotherapy work in this patient population [346]. The authors also discuss how 
there are clinical trials combining PARP inhibitors with anti-PD-L1 in Brca1/2-mutant 
breast and ovarian cancer, and that other histologies may also benefit, such as 
ERCC1-deficient non–small cell lung cancer [346]. Therefore, in the context of our 
study it could be possible to further enhance the response of breast cancer cells to 
Thiostrepton and Olaparib by combining this with anti-PD-L1 therapy. 
 
Recent advances suggest that targeting both the tumour cell and its interaction with 
the immune microenvironment may significantly improve patient benefit. To this 
end, inhibitors of the immune checkpoint molecules PD-1, CTLA-4, and PD-L1 have 
recently shown great clinical promise and represent a novel way of treating cancer 
[347]. To date, one of the few genetic determinants of response to immune 
checkpoint blockade identified is the presence of mutations in DNA repair genes 
[348, 349]. It was hypothesised that this was due to the increased amount of 
somatic mutations in DNA repair-deficient tumours, which can encode “non-self” 
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immunogenic antigens [348]. A number of clinical studies have identified the 
presence of mutations in DNA repair genes in patients who have responded to 
checkpoint inhibitors. A recent study indicated that MMR status predicted clinical 
benefit with the PD-1 inhibitor, Pembrolizumab [349]. In addition, mutations in the 
DNA repair and replication genes POLD1, POLE, Lig3, RAD17, and BRCA2, were 
identified in melanoma and lung cancer patients that had a better clinical response 
to PD-1 inhibition [350]. Given that we have observed a decrease in a range of DNA 
repair genes and an increase in DNA double-strand breaks upon FOXM1 inhibition, 
it would be interesting to understand whether a combination therapy of Thiostrepton 
with an immune checkpoint inhibitor may have clinical benefit.  
 
As DNA damage has represented a backbone of cancer treatment, other 
combinations may also be considered. Tumours with HR deficiencies would be 
synthetically lethal with other DNA repair inhibitors, not just PARP inhibitors. As 
Minchom and colleagues discuss, there are ATM, ATR and CHK1 inhibitors, and 
these are being tested in clinical trials [351]. The benefit of such alternative options 
could be used, for example, in patients who may become resistant to PARP 
inhibitors. In one study, when compared with BRCA1-proficient cells, PARP 
inhibitor-resistant BRCA1-deficient cells were shown to be increasingly dependent 
on ATR for survival [352]. So, the authors suggest that ATR inhibition can be used 
to overcome PARP inhibitor resistance in BRCA-deficient cancers [352]. In the case 
of our study, the implication of this is that Thiostrepton may ultimately synergise to 
cause synthetic lethality with other inhibitors targeted against DNA damage 
response defects in the cells. Furthermore, if resistance to PARP inhibitors occurred 
in patients treated with our combination therapy, other inhibitors such as ATR 
inhibitors may become more relevant in this particular clinical setting. 
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Taken together, we have shown for the first time that Thiostrepton and Olaparib in 
combination caused greater reduction in cell viability and colony formation, 
compared to either agent alone, in breast cancer cells. Furthermore, this response 
was not FOXM1- or RAD51-expression level dependent. As Olaparib has already 
been approved for clinical use, Thiostrepton would be the focus to accelerate this 
combination therapy into the clinic. This would require development of Thiostrepton 
for use in humans, and then for use in combination with Olaparib.  We have also 
investigated the mechanistic implications of our combination therapy in breast 
cancer cells. Our data has suggested that the HR proteins RAD51 and BRIP1 may 
be playing an important role in mediating Olaparib sensitisation, upon treatment with 
Thiostrepton. Furthermore, our data using non-tumourigenic breast epithelial cells 
has suggested a possible therapeutic window, where short-term Thiostrepton 
exposure with subsequent Olaparib sensitisation could be the most effective way to 
treat breast cancer patients, and to spare their normal cells. Finally, increased DNA 
damage was observed in breast cancer cells treated with our combination therapy, 
compared to either agent alone, suggesting that this may be a mechanistic basis for 
these compounds acting together. We also discussed how a combination therapy of 
Thiostrepton with an immune checkpoint inhibitor may benefit patients, given our 
data showing how Thiostrepton treatment caused decreased DNA repair genes and 
increased DNA damage. Overall, Thiostrepton and Olaparib may be considered as 
a combination therapy with clinical relevance for treating cancer patients. 
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2.0 Thiostrepton and Diminutol are synthetically 
lethal in ovarian cancer 
2.1 FOXM1 and oxidative stress 
FOXM1 also plays a role in regulating the oxidative stress response [119, 120]. 
Cancer cells that overexpress FOXM1 can harness this role during initiation and 
progression of the tumour. Whilst we have already discussed a potentially viable 
treatment strategy for targeting FOXM1 and homologous recombination, we also 
wanted to explore the possibility of developing another combination therapy option, 
by exploiting a different pathway regulated by FOXM1. Given the emergence of 
resistance to treatment is common for cancer patients, this emphasises the need to 
investigate novel therapies in a range of different strategies. This project therefore 
next proposed to exploit the role of FOXM1 in oxidative stress, by initially 
determining the relationship between FOXM1 and members of the oxidative stress 
response.  
 
The role of FOXM1 in regulating oxidative stress has been outlined in the 
introduction, such as transcriptional regulation of antioxidant genes MnSOD and 
catalase [119]. Furthermore, ROS levels have been shown to be elevated in 
FOXM1-deficient cells, compared to normal cells, emphasising FOXM1’s role as an 
important regulator of intracellular ROS [119]. Therefore, based on the current data, 
this led us to further explore the role of FOXM1 in regulating the oxidative stress 
response. 
 
We began by determining how expression levels of proteins involved in the 
oxidative stress response changed upon Foxm1 silencing, in breast cancer cell 
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lines. This data subsequently formed the basis for the rest of our study. We were 
able to observe a consistent decrease in Nrf2 mRNA expression upon Foxm1 
silencing, which validated previous work that FOXM1 regulates NRF2 expression 
[302, 303]. Notably, we also observed an increase in the expression of NQO1, 
which is downstream of NRF2, upon Foxm1 silencing, and this expression change 
became the focus of our later investigations, because the relationship between 
FOXM1 and NQO1 had also not yet been fully evaluated. 
 
2.2 Potential role for FOXM1 and NQO1 in mediating 
chemoresistance  
Since chemoresistance plays a large role in hindering a patient’s response to 
treatment, it is essential to assess which mechanisms cancer cells may be using to 
cause chemoresistance, and to in turn discover new ways to target this in cancer 
cells. As previously mentioned, both FOXM1 and NQO1 have been implicated in 
chemoresistance [188, 320].  
 
Given that we observed an increase in NQO1 expression upon FOXM1 loss, we 
aimed to understand whether FOXM1 and NQO1 were involved in a co-ordinated 
response to chemotherapy. To investigate this further, we used a model of chemo-
sensitivity and –resistance, and this was in the form of platinum-sensitive and –
resistant ovarian cancer cell lines. Once platinum sensitivity had been validated, we 
indeed observed that our platinum-resistant ovarian cancer cell lines had higher 
expression levels of both FOXM1 and NQO1, compared to our platinum-sensitive 
cell line. This confirmed published data that these proteins are often upregulated in 
chemoresistant cancer cells. In Docetaxel-resistant human lung adenocarcinoma 
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A549 cells FOXM1 has been shown to be upregulated, compared to the parental 
cells [321]. Furthermore, in Cisplatin-resistant A2780cp cells, NRF2 and NQO1 
have both been shown to be upregulated, compared to the parental cells [353]. 
 
Significantly, when Nqo1 was silenced, we saw a corresponding decrease in 
FOXM1 expression levels. We also confirmed what we initially observed in breast 
cancer cells, that when Foxm1 was silenced, we saw a corresponding increase in 
NQO1 expression levels. This result was further confirmed using a different 
approach to siRNA, where treatment with the FOXM1 inhibitor Thiostrepton also 
showed an increase in NQO1 expression. These data suggest that FOXM1 and 
NQO1 expression are potentially regulated by each other, and may have 
compensatory functional roles in the cell. Whilst there seems to be no evidence in 
the literature suggesting a direct link between FOXM1 and NQO1, these changes in 
protein expression could be occurring indirectly. Since NRF2 is a transcriptional 
target of FOXM1, and NQO1 is expressed by NRF2 regulation, this indicates that 
there could be a link between FOXM1 and NQO1 through the NRF2 pathway [302, 
303].  
 
Since our data thus far has suggested that FOXM1 and NQO1 may be acting 
together in cells, we next investigated this relationship in a Cisplatin-treatment 
setting. In this instance, both FOXM1 and NQO1 expression levels were shown to 
be upregulated after cells were exposed to Cisplatin, and this was independent of 
chemoresistance of the cells (Figure 24). It is also important to note that when Kwok 
and colleagues investigated acquired Cisplatin resistance in breast cancer cells, 
they assessed the contribution of FOXM1 and downstream targets BRCA2 and 
XRCC1, and discussed how FOXM1 is not the sole regulator of these genes, and 
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that additional roles of FOXM1 may add to causing Cisplatin resistance [188]. Our 
data showed that silencing Nqo1 did not re-sensitize platinum-resistant cells to 
Cisplatin, therefore suggesting that NQO1 is not the sole mediator of 
chemoresistance in these cells and may have a co-ordinated role with other 
FOXM1-target proteins such as BRCA2 and XRCC1 in maintaining resistance to 
these drugs. We did, however, observe increased resistance to Cisplatin when 
Nqo1 was silenced in Cisplatin-sensitive cells only. Therefore, this led us to 
hypothesise that FOXM1 and NQO1 may play a role together in causing 
chemoresistance in chemosensitive cells.  
 
Whilst our data so far had evaluated the roles of FOXM1 and NQO1 individually in 
chemoresistance, we also wanted to assess whether these proteins acted together 
in chemoresistance. In one study, a link between FOXM1 and the antiapoptotic 
genes, XIAP and Survivin, in the modulation of chemoresistance in breast cancer 
cells was established [191]. The authors were able to show that FOXM1 
transcriptionally activated XIAP and Survivin expression [191]. This type of study 
shows that different pathways can converge on generating a chemoresistant 
phenotype and our study may show a different mechanism of how two proteins may 
act together to mediate chemoresistance, where the downstream effector is not 
necessarily a direct target of the upstream regulator.  
 
Our data suggested that silencing Foxm1 and Nqo1 silencing together caused the 
greatest reduction in cell viability, and this was again in platinum-sensitive cells, 
rather than platinum-resistant cells. The implications of this could be that FOXM1 
and NQO1 have a threshold of expression for cell viability, and because platinum-
sensitive cells have lower expression levels of these proteins they are increasingly 
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sensitive to their inhibition. This suggests that upon silencing of Foxm1 and Nqo1 in 
platinum-resistant cells, where their expression is higher, that the remaining levels 
of FOXM1 and NQO1 are sufficient for viability.  
 
When Foxm1 and Nqo1 were individually silenced, re-sensitisation to Cisplatin was 
not observed so we next addressed whether Foxm1 and Nqo1 silencing together 
would lead to Cisplatin re-sensitisation. This approach has been similarly 
investigated in studies where FOXM1 and downstream targets of FOXM1 have 
been implicated in chemoresistance [116, 308]. In recurrent glioblastoma cells, 
Zhang and colleagues showed that targeting FOXM1 was shown to sensitise 
resistant cells to Temozolomide, by downregulating RAD51 expression [116]. 
Furthermore, in ovarian cancer cells, Zhou and colleagues showed that targeting 
FOXM1 and its target gene EXO1 could increase sensitivity to Cisplatin [308]. 
These studies have illustrated that FOXM1 is not acting alone in chemoresistance, 
and that other proteins may be playing a role in generating a chemoresistant 
phenotype. However, we did not observe re-sensitisation to Cisplatin when Foxm1 
and Nqo1 were silenced together. 
 
Interestingly, whilst NRF2 has been regarded as the main transcriptional regulator 
of NQO1, there are studies showing there are other regulators of NQO1 
transcription. In a study where ROS and the pathogenesis of Dox-induced 
cardiomyopathy were investigated, an NRF2-independent activation of NQO1 was 
identified, where Progesterone was shown to induce NQO1 [354]. This study 
therefore indicates that other pathways could be involved in regulating NQO1 
expression, in relation to changes in FOXM1 expression, when considering their 
relationship and their roles in chemoresistance.  
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Having assessed the response of our cells to Cisplatin when Foxm1 and Nqo1 were 
silenced together, we next treated our cells with the FOXM1 inhibitor Thiostrepton, 
so that an alternate approach to using siRNA was tested. Our data supported 
previously published data that had shown synergy between Thiostrepton and 
Cisplatin, and we observed a combined action that was greater in both Cisplatin-
sensitive and -resistant cells [188, 308, 309]. In the study by Kwok and colleagues, 
they discussed how Thiostrepton synergised with Cisplatin and reversed acquired 
Cisplatin-resistance in breast cancer cells, and caused increased Cisplatin-induced 
cell death [188].  
 
Whilst the main focus of our study was on FOXM1 and NQO1, we did also 
investigate other members of the NRF2 pathway, to gain a more detailed 
understanding of the role of these proteins and potentially other expression changes 
upon chemoresistance. In particular, we observed that the antioxidant response 
protein, SOD1 was upregulated in platinum-resistant ovarian cancer cells, 
compared to the platinum-sensitive parental ovarian cancer cells (Figure 30). We 
also observed an increased expression of Gpx1, upon Nqo1 silencing and upon 
Foxm1 + Nqo1 silencing, in Carboplatin-resistant cells. We therefore suggested that 
FOXM1 and NQO1 may be regulating the NRF2-antioxidant pathway in general. 
Interestingly, overexpression of SOD1 has already been implicated in causing 
Cisplatin resistance in ovarian cancer cells, thus supporting SOD1 as another 
potential target for a novel anticancer chemosensitiser [355]. Furthermore, in a 
study of pancreatic ductal adenocarcinoma, Gpx1 silencing resulted in the 
epithelial–mesenchymal transition and Gemcitabine resistance [356]. It was also 
shown that Gpx1 expression negatively correlated with pancreatic ductal 
adenocarcinoma prognosis [356].  
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2.3 Selecting compounds for our combination 
therapy 
Our novel data accumulated so far suggests that both FOXM1 and NQO1 may be 
playing a role in mediating chemoresistance, because they are upregulated in 
chemoresistant cells, their expression levels change when the other changes, and 
there seems to be a threshold of expression in platinum-sensitive cells. This next 
raised the possibility of developing a combination treatment strategy to target these 
proteins, in cancer cells. This strategy could also hold further implications; such that 
is could potentially reduce the risk of cancer cells becoming chemoresistant.   
 
From the outset, we wanted to investigate the relationship between FOXM1 and 
members of the oxidative stress response. We consequently found that a 
relationship existed between FOXM1 and NQO1, and that this could be playing a 
role in mediating chemoresistance of cancer cells. We next investigated a synthetic 
lethal approach, through exploiting the role of FOXM1 in oxidative stress. We 
discovered that it may be possible to target FOXM1 and the antioxidant protein 
NQO1, in cancer cells. 
 
NQO1 inhibitors may represent ideal candidates to be used alongside the FOXM1 
inhibitor, Thiostrepton. Notably, the NQO1 inhibitor Dicoumarol could be argued as 
the best candidate for our study, because of it being the most commonly used 
NQO1 inhibitor and it has a high potency. That said, as previously highlighted, there 
have been a number of studies that have revealed problems with using Dicoumarol 
as an NQO1 inhibitor, including mitochondrial uncoupling [160]. 
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Other Coumarin-based compounds that were reviewed in the introduction, as well 
as another competitive inhibitor of NQO1, Diminutol, could have offered the 
potential to be used in our combination therapy treatment strategy. Since we were 
not evaluating the activating or detoxifying properties of NQO1, we did not use 
irreversible inhibitors for our study. Furthermore, in the case of Coumarin-based 
compounds, whilst they seemingly showed greater potency than Dicoumarol, they 
were not without their limitations [162, 164, 165]. In particular, a problem that was 
also identified with Dicoumarol is that protein binding could compromise the activity 
of these compounds [162]. This was tested in the presence and absence of BSA, 
and was found to be variable between compounds [162]. Therefore, we selected 
Diminutol due to the novelty of this compound as an inhibitor of NQO1, as there has 
been limited investigation of this compound in current literature. So, we were 
therefore keen to assess the mechanistic implications of this compound in our 
combination therapy, when treating cancer cells.   
 
We were able to show that Thiostrepton and Diminutol acted in combination in 
ovarian cancer cells, using cell viability assays. Our results indicated that FOXM1 
inhibition using Thiostrepton enhanced sensitivity to the NQO1 inhibitor Diminutol, 
as shown by our experimental approach. This also seemed to be independent of 
having lower FOXM1 and/or NQO1 expression levels, therefore having the potential 
to be used to treat more patients. Taken together, our combination therapy data has 
revealed a novel strategy for targeting FOXM1 and the oxidative stress response in 
cancer cells, through targeting NQO1. This is the first time that targeting NQO1 has 
been used in a synthetic lethal approach with targeting FOXM1, as previous studies 
have shown that synergy could be achieved in cancer cells treated with FOXM1 
inhibitors in combination with ROS inducers [187]. 
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The benefits of our combination therapy, of Thiostrepton and Diminutol, compared 
to current standard of care treatments, is that we have developed a novel treatment 
option that may perturb the emergence of chemoresistance which has delayed 
successful responses to therapy. This type of approach may be appropriate for 
platinum-resistant patients, those who have relapsed within six months of 
completing first-line therapy and may have less than 15% response rates to 
subsequent chemotherapy [357]. In these cases, their progression-free survival 
could be 3-4 months and their median survival less than a year [357]. 
 
To be pursued clinically, there may be more obstacles to overcome, compared to 
those outlined in the case of our Thiostrepton and Olaparib combination therapy. 
Whilst we have initially viewed Diminutol as an ideal compound to be used in 
combination with Thiostrepton, because of the novelty aspect, this may in fact 
hinder clinical progression. A lack of clinical data for Diminutol would make this 
more of a priority in the first instance so that an assessment of how this compound 
may be used in the treatment of cancer patients could then be investigated in a 
clinical setting. Once this has been established, other factors regarding time- and 
dose-specific considerations can be evaluated in cancer cells and patients. Safety 
and efficacy of Diminutol include some of the main profiles that will need to be 
assessed before this compound can be used in human cancer treatment [358]. 
 
2.4 Exploring the mechanism of Thiostrepton and 
Diminutol as a combination therapy 
Once our combination therapy had been established we then decided to explore the 
mechanistic implications of this, by assessing γH2AX and ROS levels in cells 
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treated with single agents and our agents in combination. A study has shown that 
cells transfected with siRNA targeted to FOXM1 had increased DNA breaks [115]. 
Furthermore, we showed an increased level of γH2AX with Thiostrepton treatment, 
and this increase was enhanced when combined with Olaparib, in breast cancer 
cells. Based on this, we therefore first investigated γH2AX foci in ovarian cancer 
cells treated with agents alone and agents in combination. 
 
Our results showed that our Cisplatin-resistant cells had increased γH2AX foci 
when treated with Thiostrepton and Diminutol in combination, compared to either 
agent alone. As suggested in our results, it could be that increased DSBs may be 
contributing to the mechanism of action of our combination therapy, where other 
actions may also be contributing to the overall mechanism. In a study which 
included the investigation of the response of breast cancer cells to ROS-inducing β-
lapachone treatment, the observed cellular changes were the generation of NQO1-
dependent ROS, DNA breaks, Ca2+-dependent γH2AX formation and PARP-1 
hyperactivation [359]. Such studies demonstrate that further mechanistic 
implications may be involved in mediating the combined activity between FOXM1 
inhibition and NQO1 inhibition.    
 
Subsequently, we next investigated ROS levels in our cells treated with 
Thiostrepton alone, Diminutol alone, and the agents in combination. Our Cisplatin-
resistant cells had increased ROS levels when treated with Thiostrepton and 
Diminutol in combination, compared to either agent alone. This was not observed in 
our platinum-sensitive cells. Previously, FOXM1-deficiency has shown elevated 
ROS in the human primary fibroblasts IMR90, while Thiostrepton treatment has 
shown increased ROS in melanoma cells [119, 326]. Furthermore, in lung 
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adenocarcinoma cells depleted of NQO1, there was increased endogenous ROS 
[327], and pancreatic cancer cells treated with the NQO1 inhibitor, Dicoumarol, 
induced growth inhibition through increased ROS production [328]. Conversely, 
prostate cancer cells had decreased endogenous ROS after inhibition of NQO1 
[329], and cholangiocarcinoma cells treated with the NQO1 inhibitor Dicoumarol 
showed no increase in ROS formation [158]. These differences in ROS generation 
were suggested to be cell-specific, such that NQO1 inhibition could exert different 
cell killing mechanisms. Furthermore, regulation through the ROS response may be 
selective. Therefore, in the context of our results, it may be suggested that 
Cisplatin-resistant cells are sensitised to our combination therapy, through 
increased ROS generation, compared to platinum-sensitive cells. 
 
2.5 Other combination therapy options, FOXM1 
inhibitors and ROS inducers 
In the final part of our project we were able to corroborate the findings by Halasi and 
colleagues, who successfully showed that oxidative stress and FOXM1 inhibitors 
could be combined to induce cell death in cancer cells [187]. Halasi and colleagues 
used ROS inducers including β-phenylethyl isothiocyanate (PEITC) and 2-
methoxyestradiaol (2-ME) in different human cancer cells [187]. Both of these 
compounds were tested in this study because they are being used in clinical trials, 
where 2-ME was used to confirm the effects of PEITC [187]. Therefore, the authors 
were able to show that suppression of FOXM1 further sensitised cancer cells to 
oxidative stress–mediated apoptosis induced by different types of ROS inducers 
[187].  
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Using the FOXM1 inhibitor Thiostrepton in combination with the ROS inducer 
Menadione, or Podophyllotoxin, we validated what was observed in the study by 
Halasi and colleagues, using different ROS inducers to those used in their study 
[187]. Therefore, we have shown for the first time that Menadione and 
Podophyllotoxin with Thiostrepton caused a greater reduction in cell viability and 
colony formation, respectively, than either agent alone, in breast cancer cells. 
 
Notably, Halasi and colleagues also included in vivo work to further support their 
findings. They showed that the FOXM1 inhibitior Bortezomib in combination with the 
ROS inducer β-phenylethyl isothiocyanate efficiently inhibited the growth of breast 
tumour xenografts in nude mice [187]. The authors discussed how this combination 
therapy may be less toxic to normal cells because of a generally lower expression 
of FOXM1 and less dependence of their antioxidant system, compared to tumour 
cells [187]. It would be beneficial, especially in consideration of our novel 
combination therapy of Thiostrepton and Diminutol, to test this combination in in 
vivo studies, to further develop and support in vitro investigations that we have 
already carried out in our project. 
 
Taken together, our data shows that FOXM1 and NQO1 may play a role in 
chemoresistance in ovarian cancer cells. We have suggested that NQO1 is not the 
sole mediator of chemoresistance in these cells and may have a co-ordinated role 
with other FOXM1-target proteins such as BRCA2 and XRCC1 in maintaining 
resistance to these drugs. Loss of FOXM1 and NQO1, using siRNA, resulted in a 
greater reduction in cell viability in chemosensitive ovarian cancer cells, suggesting 
that these cells may have a threshold of expression of these proteins that is 
required for viability. We have also shown for the first time that Thiostrepton and 
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Diminutol in combination caused a greater reduction in cell viability, compared to 
either agent alone, in ovarian cancer cells. Furthermore, this response was not 
FOXM1- or NQO1-expression level dependent. Interestingly, the novelty of 
Diminutol as an NQO1 inhibitor is what made it an attractive compound to use in our 
studies, however to be pursued clinically this compound would require further study. 
We have also investigated the mechanistic implications of our combination therapy 
in ovarian cancer cells. Our data suggested that increased DNA damage in ovarian 
cancer cells treated with our combination therapy, compared to either agent alone, 
and increased levels of ROS may both contribute to a mechanistic basis for the 
cellular response. Overall, Thiostrepton and Diminutol may be considered as a 
combination therapy with clinical relevance for treating cancer patients. 
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